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ABSTRACT 
 
Alzheimer’s disease (AD) is the most common form of dementia in elderly 
population. Unfortunately, the current treatment approaches for AD are symptomatic and 
do not interfere with the disease progression at any stage. The risk of AD increases with 
age; from 12 %, above 70 years of age, to 50 % beyond 80 years of age. Due to an 
improvement in average life span in many regions across the globe, AD is being 
recognized as a major socio-economic health problem that is expected to worsen in the 
near future. Also, with 99.6 % of current clinical trials failing in AD due to insufficient 
knowledge of the disease targets and lack of early diagnostic methods; detailed 
investigations into AD pathogenesis is critically important. 
Development of amyloid beta (Aβ) plaques in the brain is one of the primary 
pathological hallmarks of AD. Impaired clearance and not overproduction of toxic Aβ 
proteins leads to their accumulation and subsequent plaque formation in sporadic AD that 
accounts for more than 90 % of total AD cases. Blood brain barrier (BBB) is expected to 
be the primary clearance portal of Aβ from the brain. Being at the interface between brain 
and plasma, the BBB also maintains the dynamic equilibrium of brain and plasma Aβ 
pools. This equilibrium is believed to be perturbed in AD due to BBB dysfunction. 
However, the manifestations of BBB dysfunction and the precise mechanisms that may 
trigger it, are not clearly understood.  
Two major Aβ isoforms, Aβ40 and Aβ42, play a predominant role in AD 
pathogenesis. Aβ42 is believed to be pathological whereas Aβ40 is constitutively 
expressed and believed to have protective properties against neurological anomalies. 
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Also, Aβ40 expression is 10- and 1.5- fold higher than Aβ42 in cerebral spinal fluid 
(CSF) and plasma, respectively. This ratio of Aβ42:Aβ40 increases in brain and 
decreases in plasma, respectively, during disease progression. However, the 
pathophysiological mechanisms driving this clinical observation is not known yet.  
In my thesis, I demonstrate distinct age dependent changes in the BBB 
permeability and plasma exposure of Aβ40 and Aβ42 at the BBB endothelium in wild 
type (WT) and AD-transgenic (APP,PS1) mice. Further, to investigate the 
pathophysiological mechanisms driving these observations, I conducted in-vitro studies 
in polarized hCMEC/D3 monolayers, a widely used BBB model, and demonstrated that 
Aβ40 and Aβ42 are internalized at the BBB endothelium via clathrin- and lipid raft-
mediated endocytosis, respectively. This mechanistic difference offers an opportunity to 
the BBB to independently handle and modulate the clearances of Aβ40 and Aβ42. Also, 
in-vivo investigations coupled with quantitative modeling, have indicated that Aβ40 may 
accumulate more than Aβ42 at the BBB endothelium. This may decrease Aβ40 
transcytosis at the BBB and increase the exposure of the BBB endothelium to the 
vasculotropic Aβ40. To investigate the mechanisms driving this observation, I tested the 
hypothesis published by our lab previously that the impaired transcytosis of Aβ40 at the 
BBB endothelium is due to the perturbed vesicular exocytosis. Also, synaptic 
transmission involving SNARE exocytosis machinery is known to be impaired in AD. 
Thus, I investigated the ability of Aβ40 and Aβ42 to perturb the SNARE exocytosis 
machinery at the BBB endothelium and in neurons, in comparison with tetanus 
neurotoxin, a well-established disruptor of the VAMP-2 mediated exocytosis. My 
findings reveal that Aβ40 and Aβ42 isoforms use VAMP-2 (vesicular SNARE) to 
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exocytose at the BBB endothelium and neurons. Further, using fluorescence resonance 
energy transfer (FRET) and lifetime microscopy (FLIM), I have demonstrated that Aβ40 
and Aβ42 interfere with the functioning of SNARE fusion between VAMP-2 and SNAP-
25. Moreover, my findings suggest that Aβ40 may be more efficient than Aβ42 in 
perturbing this process, and consequently may interfere with its own exocytosis.   
  In summary, my work provides evidence for the presence of distinct clearance 
mechanisms of Aβ40 and Aβ42 isoforms at the BBB endothelium. This novel assertion 
provides a framework to explain the disrupted clearance of Aβ, perturbed Aβ42:Aβ40 
ratios and dysregulated transport of Aβ and other endogenous proteins at the BBB 
endothelium observed in AD patients. These findings could be applied to identify new 
drug targets to ameliorate BBB dysfunction in AD. 
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CHAPTER ONE 
1. INTRODUCTION 
1.1. Global epidemic of Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia in the elderly 
population (> 65 years). Currently, it affects nearly 5 million Americans. As per World 
Health Organization (WHO), there will be a global epidemic of AD by 2050. (Hebert et 
al., 2013) Apart from progressive decline in memory and cognition, other clinical 
symptoms of AD include depression, disorientation, agitation, anxiety and other 
behavioral anomalies that restrict the patient’s ability to learn and in later stages perform 
routine everyday tasks. As a result, these patients become dependent on the families and 
caregivers for their social and economic needs. This multifaceted societal burden was 
estimated to be more than 2.5 billion dollars in 2012. Furthermore, due to lack of 
effective treatment options beyond symptomatic relief, AD has become the 6th leading 
cause of death, and the only one among top ten diseases that cannot be cured, prevented 
or even slowed. Needless to say, this complex situation indicates an urgent need towards 
meticulous and comprehensive understanding of the basic disease pathogenesis.   
1.2. Alzheimer’s disease: “graveyard for drug developers” 
To address this unmet medical need, several drug companies are working towards 
discovering drugs to interfere with AD pathology. However, with 99 % of clinical trials 
failed or discontinued in just 2013-14, AD is increasingly being regarded as the 
“graveyard for drug developers”. One possible reason for this situation is the recruitment 
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of patients who are in the lateral stages of the disease, well beyond the onset of mild 
cognitive impairment (MCI). The proposed cascade of pathological biomarkers (Figure 
1.1), are manifested in the AD patient, several years before any symptomatic changes in 
the cognition are noted. It is now believed that the therapeutic inventions are effective 
only during the early stages when the level of some biomarkers, particularly Ab, show 
predominant alterations.  
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Figure 1.1 Proposed cascade of biomarker profiles in Alzheimer’s disease (AD) 
pathology. Changes in amyloid beta (Ab) protein and tau levels are evident many years 
before the onset of Mild Cognitive Impairment (MCI). Reused by acquiring license and 
permission (Jack et al., 2010).  
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1.3. Hallmarks of Alzheimer’s disease 
Since the time of Alois Alzheimer, the eminent scientist who diagnosed the first AD 
case (Stelzmann et al., 1995), the two characteristic hallmarks of AD brain have been 
identified: (1) amyloid plaques, composed of amyloid beta (Ab) proteins, in the brain 
parenchyma, and (2) neurofibrillary tangles (NFT) in the neurons, composed of the tau 
protein (Figure 1.2). These are known to initiate the synaptic neuronal dysfunction that 
leads to clinical symptoms of memory loss and dementia. Although, both Ab or/and tau 
proteins competed for the spot of key trigger to AD pathogenesis, it was shown that Ab 
peptides are capable of modulating taupathy (formation of NFT) and therefore work 
upstream of tau in AD pathogenesis (Figure 1.2).  
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Figure 1.2 Hallmarks of Alzheimer’s disease (AD). Comparing the brain of healthy 
individuals (normal brain) to that of AD patients, two characteristic hallmarks of AD 
have been identified: (1) Extracellular plaques of amyloid beta (Ab) protein and (2) 
Neurofibrillary tangles (NFT) of tau protein. Image modified and reused from National 
Institute on aging and National Institute of Health (National Institute on Aging, 2015).  
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1.4. Production and clearance of amyloid beta (Ab) protein 
The accumulation of mass is imminent, if there is an imbalance between its 
production and/or clearance. Increased burden of Ab in brain with AD progression is no 
exception. Production of Ab has been well investigated (Figure 1.3) and is known to be 
generated from the proteolytic processing of parent precursor protein- Amyloid Precursor 
Protein (APP), expressed primarily in the brain. The APP, which is a transmembrane 
protein, can be cleaved sequentially by either of the two pathways:  
(1) Normogenic or non-amyloid genic pathway. In this pathway, a-secretase cleaves the 
Aβ domain of APP and releases the non-toxic fragment sAPPα. This sAPPα is further 
cleaved by ¡-secretase to generate small soluble peptide p3, another non-toxic 
peptide. 
(2) Amyloidgenic or AD pathway. APP is first cleaved by b-secretase outside the Ab 
domain to release soluble sAPPb extracellularly. Finally, this sAPPb is cleaved by ¡-
secretase to form the ~ 4 kD toxic protein Ab.  
Depending upon the cleavage site of ¡-secretase, it can form either the short Ab40 or 
slightly longer Ab42 (Blennow et al., 2006; LaFerla et al., 2007; Selkoe and Podlisny, 
2002) (Figure 1.5). These two isoforms will be discussed in parallel in the subsequent 
sections. More than 90 % of the APP is processed in the normogenic pathway, and only 
10 % is expected to participate in the amyloidogenic pathway. Furthermore, there are 
reports indicating that a negative feedback loop may exist to regulate the processing of 
APP via the amyloidogenic pathway by modulating the transcription and expression of 
either secretases. 
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Figure 1.3 Generation of Amyloid beta (Ab) peptides. Ab is produced from the 
sequential cleavage of transmembrane, amyloid precursor protein (APP), by proteases b-
secretase and g-secretase. The Ab peptide thus released extracellularly, forms oligomers 
followed by fibrils that eventually form plaque in combination with metals and other 
cellular debris. The soluble Ab peptides and even more Ab oligomers have been 
proposed to trigger neuronal loss leading to dementia. The increase in brain Ab levels is 
believed to be due to impaired clearance and not due to the overproduction of Ab. Image 
modified and reused from National Institute on Aging and National Institute of Health 
(National Institute on Aging, 2015).   
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1.5. Ab is both physiological and pathological 
Before we move onto the intricate details of Ab clearance, the processing of APP 
will be discussed. Firstly, the production of Ab has been shown to be important for the 
viability of neurons in the brain (Plant et al., 2003). Ab was also found in the CSF of 
non-demented individuals (Mehta et al., 2000; Shoji et al., 1997) as well as in the 
medium of neuronal cell cultures (Haass et al., 1992). The systemic clearance of Ab is 
fast with a short half-life of 2.5-3 minutes after primarily getting metabolized in liver and 
kidneys (Ghiso et al., 2004). Ab is also a constituent of normal urine (Ghiso et al., 2004, 
1997). In physiology, APP catabolism to form Ab has been shown to modulate synaptic 
activity by several mechanisms. For example, a negative feedback loop has been 
proposed to inhibit APP transcription when Ab is in excess (Kamenetz et al., 2003). 
Further, APP has also been demonstrated to have neuroprotective properties (Giuffrida et 
al., 2009) by triggering neuronal cell survival (Plant et al., 2003) and excitability (Parihar 
and Brewer, 2010; Plant et al., 2006). The proposed physiological roles of Ab are 
reviewed in (Castellani et al., 2009; Pearson and Peers, 2006).  
The idea that Ab is toxic and gets accumulated as plaques in the brain and 
perpetrates AD pathophysiology has been long proposed. After the two isoforms were 
identified and characterized, it was established that Ab42 is the more toxic and 
pathological form, whereas Ab40 may have a physiological function that is not well 
understood. Studies in mice that overexpress Aβ40 or Aβ42 (BRI-mice), crossed with 
Tg2576 mouse model, which harbor Swedish mutation on APP showed that the overall 
higher levels of Aβ40 inhibited amyloid deposition by 60–90 % (McGowan et al., 2005). 
The ratio of Ab42:Ab40 in patient brain has been shown to increase with AD 
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progression. However, it is interesting that in familial AD cases, the change in ratio is due 
to a decrease in Ab40 and not always due to an increase in Ab42 (Tanzi, 2012). 
However, no such trend is yet clear in sporadic AD cases. Whether, it is the same or 
opposite rationale in sporadic AD cases as well is not known. An excellent review is put 
together in (Castellani et al., 2009; Tanzi, 2012) . The toxicity of Ab is believed to be 
perpetrated by triggering apoptosis, promoting inflammation and enhancing oxidative 
stress. This ultimately results in disrupted synaptic neurotransmission and neuronal death. 
However, it is also noted that not all individuals manifesting increasing Ab burden 
correlate with cognitive decline, and that large amounts of Ab is also seen in cognitively 
normal elderly individuals. These ideas probably suggest that Ab should be considered 
toxic only when there is an imbalance between its production and clearance. Further, 
there is evidence that Ab interferes with exocytosis mechanisms in neurons (Uemura and 
Greenlee, 2001). Apart from neuronal synapses, this idea of Ab directly modulating 
vesicular exocytosis becomes even more interesting when we consider that exocytosis is 
one of the basic components of simple cellular trafficking physiology and function 
(intracellular uptake or endocytosis, transit and exocytosis). More so, because Ab, being 
a protein itself, would have to be transported via vesicular trafficking, and therefore, may 
impact its own transit. This idea would be elaborated in a separate section.  
Along with Ab, APP has also been ubiquitously expressed in neuronal as well as 
non-neuronal cells (Niederwolfsgruber et al., 1998) to promote cell growth, 
differentiation and carcinogenesis (Nalivaeva and Turner, 2013). Some studies suggest 
that the membrane localization and processing of APP may differ from neuronal and 
peripheral cells; and so, specific function and transducer properties of APP (or Ab) might 
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be unique to its production site (Jung et al., 1996). Interestingly, abnormal APP 
metabolism in pancreas has been also seen in AD, such that it is referred as type 3 
Diabetes by several investigators (de la Monte and Wands, 2008; Miklossy et al., 2010). 
Insulin degrading enzyme or IDE, one of the primary proteases involved in the 
catabolism of insulin, has been shown to directly regulate the activity of not just insulin 
but also of Ab, and APP (Farris et al., 2003). Further, interleukin 1, estrogen hormone 
and GSK-3 alpha have been also shown to regulate Ab metabolism. (Jaeger et al., 2009; 
Jaffe et al., 1994; Phiel et al., 2003) Further, whether this central insulin resistance is a 
cause or consequence of Ab triggered AD pathology is not totally understood yet. 
Moreover, there is evidence that APP is involved in several normal brain functions 
including cell-cell interactions (Coulson et al., 2000), cell-surface adhesion (Soba et al., 
2005), neuronal cell migration (Rice et al., 2012) and development (Joo et al., 2010) and 
maturation (Kirazov et al., 2001) of adult brain development and neuromuscular 
junctions (Akaaboune et al., 2000). It has also been shown to regulate calcium 
homeostasis (Octave et al., 2013) and have a functional role in neuronal network 
formation, synaptic vesicular exocytosis, finally affecting learning and memory.  
1.6. Ab clearance mechanisms- Blood Brain Barrier as the primary clearance portal  
Predominantly, there are three ways by which excess Ab can be removed or cleared 
from the brain parenchyma: (1) proteolytic degradation by enzymes such as neprilysin, 
insulin degrading enzyme, and angiotensin converting enzyme (ACE); (2) receptor 
mediated transport across the blood-brain barriers- that comprise of both: Blood-Brain 
Barrier (BBB) and Blood-Cerebral Spinal Fluid Barrier (BCSFB); (3) bulk flow or 
perivascular drainage from the brain interstitial fluid (ISF) to CSF and into the blood 
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stream via either the choroid plexus (CP) or via the ‘glymphatic pathway’ (Nedergaard, 
2013). Once into the blood stream, Ab is cleared almost instantaneously (within minutes) 
by liver and kidneys (Figure 1.4).   
1.6.1. Proteolytic degradation of Ab 
Depending upon the amino acid site of cleavage, several proteases are implicated 
in the degradation of Ab (Saido and Leissring, 2012) peptides. Two among them, 
neprilysin (NEP) and insulin degrading enzyme (IDE), appear to have the maximum 
contribution towards the degradation (Marr et al., 2003; Maruyama et al., 2005). Both 
have been independently shown to be inversely correlated with Ab load in the brain and 
with disease progression. Particular links with the vascular deposits of Ab in Cerebral 
Amyloid Angiopathy (CAA) have also been established where the expression of NEP has 
been shown to decline in the vasculature of AD patients with CAA (Carpentier et al., 
2002). The levels of these enzymes have also been shown to decrease with age, thus 
substantiating that proteolytic degradation contributes to AD pathology. Recently, it was 
shown that APP-intracellular domain (AICD), one of the proteolytic cleaved products of 
APP, epigenetically upregulates the expression of NEP, as well as another enzyme that 
aids in Ab clearance- transthyretin (Kerridge et al., 2014). Other proteases contributing to 
Ab degradation include matrix metalloproteinases (Lorenzl et al., 2003; Yoshiyama et al., 
2000), angiotensin converting enzyme (ACE) (Kugaevskaya, 2012), endothelin 
converting enzymes (ECEs) (Pacheco-Quinto, 2013; Tayler, 2013), plasmin and 
cathepsins (Baranello et al., 2015).  
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1.6.2. Bulk flow or perivascular glymphatic drainage of Ab 
 Despite the high metabolic activity and the extreme sensitivity of neuronal 
function to its immediate milieu, brain lacks the lymphatic vasculature that is expected to 
clear out the byproducts of metabolism like in the rest of the body. This role is 
supposedly taken over the by the bulk flow of CSF that is formed in choroid plexus and 
flows through the ventricles and subarachnoid space. The solutes (or waste byproducts) 
are finally reabsorbed into the blood stream via arachnoid villi of the dural sinuses, 
cranial nerve sheaths or nasal lymphatics. The interstitial fluid (ISF) diffuses through the 
brain tissue without any discrete anatomical flow path. This convective bulk flow of ISF 
is instrumental in removing most interstitial solutes including Aβ (Iliff et al., 2012; 
Weller et al., 2008).  
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Figure 1.4 Clearance processes of amyloid beta (Ab) protein. Predominantly, brain 
Ab can be cleared by (1) enzymatic degradation by neprilysin (NEP), insulin degrading 
enzyme (IDE), etc.; (2) phagocytosis by microglia; (3) perivascular glymphatic drainage- 
that is via interstitial fluid (ISF) into the cerebral spinal fluid (CSF) or (4) transport across 
the BBB endothelium. Once in the plasma, it is cleared by catabolic processes in liver 
and kidney. The soluble Ab is stabilized by chaperones a2M and apoE. BBB maintains 
this dynamic equilibrium of plasma and brain Ab pools. Receptors such as RAGE 
(influx) and LRP (efflux) have been proposed to be involved in Ab transcytosis. 
However, the precise vesicular transport machinery (endocytosis, cellular transit and 
exocytosis) of Ab at the BBB endothelium is not known yet.  
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1.6.3. Ab clearance across the brain barriers  
There are two well-defined barriers between the brain and plasma milieu: (1) 
Blood-Brain Barrier (BBB) and (2) Blood-CSF Barrier (BCSFB). Transport across the 
BBB has been proposed to be one of the primary clearance portals for brain Aβ clearance. 
In fact, the large surface area of the BBB (20 m2), along with BCSFB, are critical to 
maintaining the brain homeostasis (Marques et al., 2013). This clearly indicates that brain 
barriers directly hold the communication channel between plasma and brain homeostasis 
and respond to peripheral or brain parenchymal events with specific responses that are 
not independent of each other.  
1.7. Blood-brain barrier: an integral component of the neurovascular unit 
The Blood-Brain Barrier was first discovered in 1885 when Paul Ehrlich injected a 
water soluble dye in the periphery that could not enter and stain the brain. Subsequent 
follow up experiment by his student Edwin Goldmann in 1904, who injected trypan blue 
directly into the cerebrospinal fluid (CSF) stained all cell types in the brain but failed to 
penetrate into the periphery. These studies clearly demonstrated that a physical barrier 
exists between the brain and periphery that prevented the entry of even small molecules. 
However, it was not until 1990, that Lewandowsky formally used the term 
bluthirnschranke (Blood-Brain Barrier) to describe this barrier (Hawkins and Davis, 
2005).  
The sophistication in describing BBB characteristics has evolved over the years. 
Anatomically, it is represented as a single layer of endothelial cells that line the 
circumference of the brain capillary walls. These endothelial cells are distinguished from 
those in the periphery by increased mitochondrial content (Olden-dorf et al., 1977), a lack 
33	
	
of fenestrations (Fenstermacher et al., 1988), minimal pinocytotic activity (Sedlakova et 
al., 1999), and the presence of tight junction (TJ) (Kniesel and Wolburg, 2000). More 
recently, it is being realized that the abovementioned BBB endothelium is an integral part 
of the neurovascular unit (NVU) that consists of: (1) endothelium lining the cerebral 
vascular tree, pericytes covering the vascular capillaries, and vascular smooth muscle 
cells (VSMCs) enwrapping the cerebral arterioles and arteries; (2) glial cells such as 
astrocytes, microglia and oligodendrocytes; and (3) neurons. This close proximity of 
neurons with the NVU enables an effective functioning of the central nervous system to 
regulate cerebral blood flow, transport of oxygen and energy, and clearance of toxic and 
metabolic waste. It was shown that for Aβ40 (Shibata et al., 2000), about 75 % of the 
total clearance is via the BBB, 10 % is by ISF bulk flow and 15 % is retained due to 
enzymatic degradation or by macrophages (Lai and McLaurin, 2012). Using two-photon 
microscopy it was shown that neurons are usually within 13 µm of a capillary (Zhang and 
Murphy, 2007), and the neuronal cells are considerably away from CSF (Smith et al., 
2004). Therefore, BBB, being relatively closer to the neurons, have an edge to control the 
brain solutes composition. This BBB is therefore expected to maintain the dynamic 
equilibrium between plasma and brain Aβ pools, as is discussed in the next section.  
1.8. Plasma and brain Ab pools 
Theoretically, there are two distinguishable Ab pools- (1) Brain Ab pool, that is the 
combination of ISF and CSF Ab pools; and (2) plasma or peripheral Ab pool, also called 
as circulating Ab pool. However, more emphasis has been placed on the changes in brain 
Ab pool, because of the manifestation of characteristic plaques in the brain and 
consciously or unconsciously disregarded the contribution of circulating plasma or 
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peripheral Ab pools that are not immediately apparent. The brain Ab concentration 
increases from 0.3 nM (normal) to ~ 12 nM (AD) during the course of the disease (Deane 
et al., 2004). Interestingly, the same 40 fold increase in also seen in the plasma Ab 
concentration that rises from 0.05 nM (normal) to ~ 2 nM (AD) (Deane et al., 2004). 
Also, the brain Ab concentration is noted to be about 6 fold higher than the plasma Ab 
concentration, in both physiological (normal) and pathological (AD) conditions (Cirrito 
et al., 2003; Deane et al., 2004). This circulating plasma Ab reflects the contribution of 
Ab from the peripheral tissues that produce Ab constitutively, as well as Ab that gets 
transported across the blood brain barriers from the CNS. The increase in plasma Ab pool 
will probably expose BBB on the luminal side, which may affect the luminal signaling 
and functioning.  
1.9. Ab isoforms and the critical Ab42:Ab40 ratios 
The ratio of Ab42:Ab40 has been noted to be perturbed in AD patients with the 
disease progression. Among the two isoforms, at physiological conditions, Ab40 levels 
are 10- and 1.5- fold greater than that of Ab42 in CSF and in plasma, respectively (Fagan 
et al., 2006). As the disease progresses from mild cognitive impairment (MCI) to 
cognitive decline, Ab42:Ab40 ratio decreases in plasma and increases in brain (Toledo et 
al., 2013). In familial AD, the increase in the ratio is due to overproduction of Ab. 
However, in sporadic AD, it is attributed not to overproduction but impaired clearance 
(Mawuenyega et al., 2010). Also, interestingly, it is known that there are distinct sites of 
production for Ab40 and Ab42; Ab40 is primarily produced in trans golgi network 
(TGN), whereas Ab42 is primarily produced in endoplasmic reticulum (ER) (Hartmann 
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et al., 1997). Can the Ab40 and Ab42 clearance pathways also be any different? If they 
are different, then both Ab40 and Ab42 clearance pathways may have to be investigated 
separately to understand inefficient Ab clearance in the AD brain.  
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Figure 1.5 Critical ratio of Ab isoforms is perturbed in AD. Amyloid beta (Ab) 
peptide is formed from APP due to cleavage by protease b- and g- secretases. In the non-
amyloidogenic or normogenic pathway, a-secretase cleaves at the regions that are within 
the Ab peptide sequence. Depending upon the site of g- secretase, Ab can be formed as 
long (Ab42) or short (Ab40). Moreover, physiological ratio of Ab42:Ab40 is changed 
during the course of disease progression in both CSF and plasma. Ab42 is the primary 
component of most parenchymal plaques and is supposed to be more fibrillogenic and 
neurotoxic. Therefore, this isoform, is expected to be more toxic and is studied 
extensively. Whereas, Ab40 is present in larger amounts and predominates 
cerebrovascular amyloid deposits. Further, there is evidence that Ab40 is actually 
neuroprotective against Ab42. Therefore, our hypothesis is that the impaired Ab 
clearance, could mean the impairment of toxic Ab42 clearance out of the brain, as well as 
impaired clearance (uptake) of relatively protective Ab40 into the brain.  
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The association between the plasma Ab levels and brain Ab accumulation along with 
cognitive decline in familial AD or Down Syndrome patients have been well established 
(Matsuoka et al.; Schupf et al., 2001). The reports from the sporadic AD cases have been 
rather inconsistent. For example, cross sectional studies in sporadic AD patients have 
reported a decrease (Lui et al., 2010), or an increase (Mayeux et al., 2003, 1999) in Ab42 
or an increase (Mehta et al., 2000) in Ab40 levels with no significant change in their 
ratios (Figurski et al., 2012; Fukumoto et al., 2003; Toledo et al., 2011). Similarly, 
longitudinal studies have been associated with an increased risk conversion to AD having 
a high baseline of Ab40 (Hansson et al., 2012; van Oijen et al., 2006), or Ab42 (Blasko et 
al., 2010; Mayeux et al., 2003; Schupf et al., 2008). Interestingly, there is consistency in 
the lower plasma levels of Ab42:Ab40 ratio in studies that accounted for them (Graff-
Radford et al., 2007; Okereke et al., 2009; Schupf et al., 2008; van Oijen et al., 2006). 
These ideas further substantiate that Ab should be considered toxic only when there is an 
imbalance between its production and clearance.  
In plasma and CSF, Ab peptides can exist as soluble free unbound forms or are 
bound to chaperones. There are several receptors that can play this role of chaperones 
including apoE, apoJ, transthyretin, and LRP (sLRP). (Deane et al., 2009) Ab40 binds to 
LRP with a higher affinity (Kd = 0.6 - 1.2 nM) compared to Ab42 (Deane et al., 2004). 
Interestingly, no differential effect of Ab isoforms was seen on LRP internalization or 
synthesis, but just proteasome dependent LRP degradation was promoted at pathological 
levels of Ab.   
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1.10. Impaired clearance, and not overproduction triggers Ab accumulation  
After several years of debate on what impacts AD pathology most, over production 
or impaired clearance, it was clarified that impaired clearance and not overproduction is 
responsible for the accumulation of Ab in the brain (Mawuenyega et al., 2010). In this 
seminal study, the authors conducted stable isotope labeling kinetics (SILK) study of Ab 
production versus clearance. Participants were infused with a stable isotope of 13C6-
leucine and cerebrospinal fluid samples were collected before, during and after labeling. 
Stable isotope labeling tandem mass spectrometry (SILT-MS) method was used to 
analyze samples. Finally, the increase in labeled Ab during the production phase and the 
removal of labeled Ab during the clearance phase reflected the relative production and 
clearance of Ab in the CNS (Mawuenyega et al., 2010).   
1.11. Amyloid as prions 
A new dimension suggests AD progression may be similar to that of the infectious 
prion (or prionoids/ prion like) disease. As per this concept, amyloid state of protein 
refers to that state where proteins elongates to form fibers and spines consisting of many 
b sheets (Eisenberg and Jucker, 2012). As infectious prions in the microbial world, these 
self-aggregating prionoids or amyloids transmit or propagate the disease from one cell to 
another. However, several unanswered questions pertaining to this theory arise. For 
example, (1) what triggers these proteins to transition into amyloid state; (2) how do they 
transmit from one cell to another; and (3) does that mean extracellular amyloids have 
access to intracellular amyloids, and vice versa? Several theories have been proposed to 
support or oppose this ideology. However, overall, they all direct the rational 
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investigations to intracellular and transcellular trafficking and protein sorting in the cell 
(Aguzzi and Rajendran, 2009; Benilova et al., 2012).  
1.12. BBB dysfunction in Alzheimer’s disease: Are we still missing something?  
1.12.1. Why do we have to investigate the vesicular transport of amyloid beta (Aβ) 
protein at the BBB?  
(1) Alzheimer’s disease is characterized by amyloid plaque deposition in the brain.  
(2) Impaired clearance and not over production of Aβ likely drives the amyloid 
accumulation in AD brain.  
(3) Blood brain barrier (BBB) is one of the primary clearance portals of Aβ from 
brain.  
(4) A 40-fold increase in the total amount of Ab is seen in both plasma and brain 
pools. Also, ratio of Ab42:Ab40 is disrupted in AD patients, both in brain 
(increases) and plasma (decreases).  
(5) Plasma Ab may contribute to the brain Ab load by so far unclear mechanisms.  
Therefore, the key question is: How is Ab being cleared across the BBB? Owing 
to the existence of dynamic equilibrium between plasma and brain Ab pools, does the 
problem (impaired clearance) lie in one or both directions, because the transport in 
either direction is not independent of each other (DeMattos et al., 2001; Eisele et al., 
2014; Schupf et al., 2008; Sutcliffe et al., 2011)? Further, what causes the BBB to be 
‘dysfunctional’- a concept that will be elaborated more in the subsequent section? In 
AD, it is known that not just Ab, but transport of other biomolecules such as insulin, 
transferrin, glucose, etc. is also disrupted. So the next question is, are these impaired 
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trafficking processes linked in any way? And finally, how can they be rectified?  
1.13. Thesis proposal  
My thesis work attempts to address the abovementioned questions. It is known that 
BBB plays a key role in brain homeostasis. Therefore, its dysfunction, will contribute to 
multiple diseases, including AD. The BBB dysfunction has been characterized in several 
reviews (Erickson and Banks, 2013) as (1) BBB disruption, which results in the leakage 
of peripherally circulating substances into the CNS that can be neurotoxic (Alafuzoff et 
al., 1983; Wada, 1998); (2) transporter dysfunction leading to consequences such as 
inadequate nutrient supply, buildup of toxic substances in the CNS, and increased 
presence of compounds that are normally prevented from entering the brain (De Reuck, 
2012; Slemmon et al., 1994); and (3) altered protein expression and secretions by 
endothelial cells and other cell types of the NVU that can result in inflammatory 
activation, oxidative stress, and neuronal damage (Owen et al., 2010; Sultana et al., 
2013). All three of these perturbations have been reported in AD. Consequently, BBB 
dysfunction has been postulated as a cause and consequence of AD (Erickson and Banks, 
2013). Moreover, almost all AD cases, associated with vascular defects (such as high 
cholesterol, blood pressure, or cardiovascular disorders) have been shown to be directly 
correlating with BBB impairment (Erickson and Banks, 2013; Sagare et al., 2013).   
Defects in the BBB transporters that influx or efflux Aβ has been an active field 
of research. It has been shown that Aβ in the brain parenchyma is primarily cleared 
across the BBB via the low-density lipoprotein receptor-related protein-1 (LRP-1), whose 
expression is reduced in the microvasculature of AD brain (Shibata et al., 2000). This 
assertion of decreased Aβ efflux has been validated by several other groups (Deane et al., 
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2009, 2004; Jaeger et al., 2009; Pascale et al., 2011; Sagare et al., 2007, 2013). Other 
efflux transporters such as PGP are also implicated in Aβ efflux. It was postulated that 
both LRP and PGP may act together to efflux Aβ. However, it has now been shown that 
LRP can function independently as well (Deane et al., 2004; Shibata et al., 2000). Once 
in the plasma, Aβ is rapidly cleared by the liver, and to a lesser extent by the kidney and 
spleen. It’s very short half-life (in minutes) further suggests the physiological necessity of 
maintaining low levels of circulating Aβ around the cerebrovascular milieu to prevent its 
influx into the brain, which can contribute to the plaque deposition, as has been shown 
recently. The influx transporter, receptor for advanced glycation end products (RAGE) 
has been identified as the primary transporter mediating luminal-to-abluminal Aβ 
transcytosis at the BBB endothelium (Candela et al., 2010; Deane et al., 2009; Fang et al., 
2010; Mackic et al., 1998; Shi et al., 2009; Takuma et al., 2009). This assertion has been 
validated in several transgenic rodent AD models.  
Another transporter that has been described in relation to AD is the glucose 
uptake transporter GLUT-1. Brain glucose consumption is known to be reduced in AD. A 
corresponding decrease in the expression of GLUT-1 on BBB has also been observed in 
AD patients (Harik, 2011; Horwood and Davies, 1994; Kalaria and Harik, 1989) 
However, whether the reduced glucose consumption is the cause or consequence of 
decreased transporter expression is yet to be deciphered. Although transporters provide 
critical information about Aβ transcytosis process, the rationale behind why the 
transporters become dysfunctional in the first place remain unresolved.  
In addition to pathological changes at the receptor level, there may also be 
alterations in intracellular trafficking at the BBB. For example, changes in transport of 
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free and bound iron-transferrin (Deane et al., 2004; Qian and Wang, 1998), cholesterol 
(Chen et al., 2014) insulin (Mooradian, 1997), among others have been shown as a part of 
AD pathology. The vesicular trafficking disruptions could be manifested as: (1) 
perturbation in molecular pathways, and (2) alterations in vesicular trafficking. The 
occurrence and the impact of both these defects are addressed in my thesis.   
1.14. Vesicular transcytosis of Aβ 
Primary pathway by which Aβ can get across cellular plasma membrane is via the 
transcellular pathway. After binding to cell surface receptor, Aβ is endocytosed into the 
cell. There are several sub-steps that assist this vesicle formation and subsequent entry or 
endocytosis into the cell. It starts by the attachment or binding of Aβ to its receptor. This 
binding can result in either of the following effects (a) Aβ is taken up into the endothelial 
cell by endocytosis, sorted to the other end of the cell, and exocytosed. In other words, it 
is trafficked or transported across the BBB endothelium (Figure 1.6). (b) Aβ is bound to 
the receptor (say efflux transporter in this case PGP from the luminal side or LRP from 
the abluminal side) and is effluxed out into the plasma without entering the endothelium, 
and so does not reach the opposite side; or (c) it enters the BBB endothelium 
(endocytosis), but fails to exocytose on the opposite side and accumulate in the 
endothelial cell.  
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Figure 1.6 General vesicular transcytosis apparatus at the BBB endothelial cell. (1) 
Aβ cargo binds the receptor on the luminal side. (2) The membrane around the cargo-
receptor complex begins to bud and form a vesicle by recruiting the coat proteins as well 
as targeting peptides (SNAREs). (3) The vesicle is now cleaved from the membrane by 
other proteins in a process called as scission. (4) The free vesicle in the cytosol is 
uncoated to expose the targeting peptide. (5) The uncoated vesicle is then translocated 
onto the other side of the cell or the acceptor organelle by microtubular cytoskeletal 
elements. (6) The vesicle is attached or tethered to the abluminal membrane by a 
tethering factor. This process usually employs Rab GTPases. (7) The tethered vesicle 
docks at the abluminal side of the membrane and the v-SNARE (targeting peptide on the 
vesicle) comes close to the t-SNARE (targeting peptide on the target membrane) by a 
process called as docking. (8) Finally, the two SNARE peptides, coil around each other to 
form the SNARE complex and bring the two membrane close to each other and 
eventually fuse, to release the transported cargo. As shown, this entire vesicular transport 
apparatus is divided into endocytosis or uptake, cellular transit and exocytosis.  
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Despite large amount of work conducted to understand the receptors-mediated 
endocytosis, the vesicular transport apparatus: comprising the endocytosis, intracellular 
transit and exocytosis still remains to be de-convoluted. In my thesis project, I 
specifically focused on the segments of this process occurring at the two plasma 
membrane extremities of the cell: endocytosis (uptake) and exocytosis (fusion, release). 
Interestingly, synaptic transmission processes, that involves the fusion or release of the 
neurotransmitters at the synaptic cleft is also impaired in AD (Figure 1.7). However, 
little is known about the mechanistic players that are responsible for this loss. In our 
work, we investigated the contribution of the commonly employed SNARE exocytosis 
machinery in AD.  
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Figure 1.7 Synaptic neurotransmission is impaired in Alzheimer’s disease (AD). 
Healthy neurons communicate with each other via synaptic neurotransmission involving 
the release of neurotransmitters in vesicles by presynaptic neurons into the synapse that 
are further taken up by the receptors on the post synaptic neuron. In damaged neuronal 
network in AD, extracellular Aβ plaques and neurofibrillary tangles may disrupt this 
synaptic neurotransmission. SNARE machinery is also involved in synaptic 
neurotransmitter release, as well as the vesicular trafficking at the BBB endothelium. 
Image modified and reused from National Institute on aging and National Institute of 
Health (National Institute on Aging, 2015).  
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1.14.1. Can AD be a trafficking disorder?  
Now, as receptors cannot explain the problem completely, and we are aware that 
clearance or the transport of Aβ across the BBB endothelium may be the problem-nexus, 
finally leading to its accumulation as plaques; is there a possibility that AD is a 
trafficking disorder? It is difficult to provide a clear cut answer to this question, but that 
is certainly a possibility.  
Interestingly, several disorders are known in literature where impaired trafficking is 
the issue. Very recently, a mutation in COPA genes disable the coat proteins to assemble 
and form the complex needed for the intracellular transport in hereditary auto-immune 
mediated lung disease and arthritis (Watkin et al., 2015). Earlier, chloride channel disease 
have been shown to result from impaired vesicular function (Jentsch et al., 2005). 
Clathrin mediated endocytosis has been shown to be impaired in multiple diseases 
including Type A-B Niemann-Pick disease. In AD as well, there is evidence that 
understanding trafficking might provide some critical clues. For example, the neuronal 
sortilin-related receptor (SORL1) that has roles in sorting and trafficking has been found 
to be associated with AD (Caglayan et al., 2014; Rogaeva et al., 2007). Disorders in 
trafficking of APP had already been suggested in the field earlier (Kim et al., 2015; 
Suzuki, 2006). However, the trafficking apparatus and possible issues in Aβ itself need 
further investigation. Trafficking disorders have been specifically common in 
neuropathological disorders: dynein dysfunction has been shown to synaptic vesicle 
docking and impair cognitive function (Kimura et al., 2012), impaired receptor mediated 
endocytosis contributes to alcohol-induced apoptosis (Casey et al., 2008), lysosomal 
dysfunction leading to Alzheimer-like neuritic dystrophy (Lee et al., 2011), lysosomal 
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and SNARE function are impaired in lysosomal storage disorders (Fraldi et al., 2010); as 
well as some rare ailments such as Hermansky-Pudlak Syndrome and Chediak-Higashi 
syndrome (Huizing et al., 2001). 
What we do not know is how this cargo, Aβ is trafficked across the BBB 
endothelium. Is it the same or different process in either direction of luminal to abluminal 
(plasma to brain) or abluminal to luminal (brain to plasma)? What are the molecular 
players that are involved? Is there an impairment in the function of these molecular 
players that prevents them to shuttle Aβ normally? These are some of the questions that 
need critical investigation to discover the nexus of the impaired clearance of Aβ at BBB 
endothelium.  
1.15. Thesis project  
1.15.1. Objective 
The primary objective of my thesis project was to identify key molecular and 
kinetic processes that are critical to Ab transport at the BBB endothelium in Alzheimer’s 
disease (AD). 
This objective was built upon three simple ideas (Figure 1.8): 
(1) Detecting early is the key and changes in Ab are earliest changed biomarker seen in 
AD.  
(2) BBB maintains the equilibrium between plasma and brain Ab pools. Although Ab 
plaques are seen in brain, both plasma and brain Ab levels increase 40-fold 
proportionately. Therefore, luminal exposure could affect the brain Ab buildup as well.  
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 (3) Characteristic ratio of Ab42:Ab40 increase in brain and decrease in plasma. This 
switch may be due to alterations in either isoform. So, investigations in parallel are 
critical.  
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Figure 1.8 The three simple ideas used to build the thesis project objective.  
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1.15.2. Hypothesis 
The primary hypothesis of my work is that over time, Ab isoforms are 
accumulating at the BBB endothelium; thereby (1) impacting their transit or permeability 
across BBB; (2) perturbing the dynamic equilibrium of brain and plasma Ab pools; and 
finally (3) triggering BBB dysfunction and worsening Ab burden to transform into 
plaques.  
This hypothesis is built upon earlier published work from our group 
demonstrating that mutant form Dutch-Aβ40 is accumulating in the BBB endothelium by 
interfering with its own exocytosis in cerebral amyloid angiopathy (CAA) (Agyare et al., 
2013). Dutch-Aβ40, a vasculotropic mutant form, accumulated more than the regular 
Aβ40 isoform. Interestingly, more than 80 % of sporadic AD cases have CAA. Here, we 
hypothesize, that over several years, like the mutant form, Aβ isoforms are also 
accumulating at the BBB endothelium, probably to varying extents, and thereby 
impacting their clinical ratios, as well as clearance transport processes. 
1.15.3. Specific Aims  
1. Evaluate age dependent changes in luminal exposure of Aβ isoforms at the BBB 
endothelium (Chapter TWO) 
2. Investigate key molecular players in the uptake or endocytosis of Aβ isoforms at 
the BBB endothelium (Chapter THREE) 
3. Evaluate the initial kinetic interactions of Aβ isoforms with the BBB endothelium 
(Chapter FOUR) 
4. Investigate the role of SNARE exocytosis machinery in the exocytosis of Aβ 
isoforms at the BBB endothelium and in the neurons in AD (Chapter FIVE) 
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1.15.4. Rationale 
The rationale for this work is that differential interactions of Aβ isoforms with the 
BBB endothelium could resolve mechanistic reasons behind the perturbed ratio seen in 
AD and explain the dysregulated transcytosis leading to the impaired Aβ clearance.   
1.15.5. Novelty 
 Our approach was novel as we investigated (1) early changes at BBB 
endothelium, rather than brain parenchyma, where the plaques are observed. We believe 
that changes at BBB endothelium could probably be the ‘cause’ to lead to the ‘effect’ of 
brain Ab plaques; suggesting a possible paradigm shift in field. (2) We investigated not 
just pathological Ab42, but both Ab isoforms in parallel. (3) We employed sophisticated 
research tools for mechanistic (such as FLIM-FRET) and kinetic (such as SPECT-CT) 
techniques to elucidate initial Ab interactions with BBB endothelium.  
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CHAPTER TWO 
2. AGE DEPENDENT CHANGES IN AMYLOID BETA KINETICS IN WILD 
TYPE AND ALZHEIMER’S DISEASE TRANSGENIC MICE 
 
2.1. SUMMARY 
Age is the most common risk factor for Alzheimer’s disease (AD). Amyloid beta 
(Aβ) proteins accumulate in the AD brain most likely due to their impaired clearance. 
The manner in which age causes BBB dysfunction, perturbs Aβ trafficking at the BBB, 
and brings dynamic changes in plasma and brain Aβ concentrations is not well 
understood. In this chapter, changes in plasma pharmacokinetics as well as luminal to 
abluminal (L-A) permeability of 125I-Aβ with age in WT and AD transgenic (APP,PS1) 
mice are presented. We demonstrate that luminal exposure of BBB endothelium to Aβ40 
isoform increases with age whereas Aβ42 isoform decreases in WT animals. This trend is 
lost in APP,PS1 animals. Surprisingly, the increased exposure of protective Aβ40 
isoform is not translated into its higher BBB permeability; where, BBB permeability of 
Aβ40 decreases with age and is apparent in as early as 8 week WT animal, when 
compared to APP,PS1 mice. On the other hand, BBB permeability of Aβ42 increases 
with age in WT animal and is not significantly different from APP,PS1 animal even at 52 
weeks. These findings suggest that over age, unknown mechanisms triggering BBB 
dysfunction prevent the protective isoform Aβ40 to reach the brain whereas toxic Aβ42 
can permeate regardless. In the subsequent chapters, we discuss some of these 
mechanisms that might be implicated in triggering this BBB dysfunction.   
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2.2. INTRODUCTION 
Age is the most common risk factor associated with Alzheimer’s disease (AD). 
(Karran et al., 2011; Tanzi, 2012) Many of the common AD symptoms such as dementia 
or memory loss, confusion, apathy, depression and delusion are often misinterpreted as 
the consequences of normal aging (Selkoe, 1991; Selkoe and Podlisny, 2002; Selkoe and 
Schenk, 2003). However, there is a distinction between AD symptoms and physiological 
changes observed in normal aging. Typically, there are basic differences between normal 
aging, pathological aging and AD. For example, it has been demonstrated that brains of 
normal aging and AD have different numbers and volume of neurons, particularly in 
hippocampus region that is majorly affected in AD (Simić et al., 1997).  
Moreover, the pathological hallmarks of AD, amyloid plaques and intraneuronal 
tangles are not consistently expressed during normal or pathological aging. Further, the 
extents of soluble and insoluble Aβ in circulation, may also distinguish AD, normal 
aging, and pathological aging (J Wang et al., 1999). It was shown that the increasing 
amount of insoluble Aβ40 is believed to shift the trend from normal aging, to 
pathological aging, to AD (Jun Wang et al., 1999). 
Moreover, age dependent changes seen in the Aβ transporter expression at the BBB 
and blood-CSF-Barrier or Choroid plexus (CP) could contribute to BBB dysfunction 
leading to disequilibrium of plasma and brain Aβ pools. For example, at CP, there was an 
increase in the transcription of the Aβ efflux transporters, LRP-1 and PGP, no change in 
RAGE expression and a decrease in LRP-2, the CP epithelium influx transporter, with 
aging (Pascale et al., 2011). These changes are the reverse of that seen at the BBB, where 
the transcription of LRP-1 and PGP decreases and the expression of RAGE increases. 
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This indicates a compensatory mechanism for Aβ transporters at the brain barriers. 
However, what exactly drives this change or switch in the transcriptional expression of 
the transporters is not known yet. 
The convenience and necessity of plasma biomarkers in AD have been very well 
accepted (Lui et al., 2010; Toledo et al., 2013; Yaffe et al., 2011). Although some 
controversies still exist, there is a reasonable acceptance that the two Aβ pools do not 
work independently of each other. That is to say, plasma Aβ levels might be able to 
directly or indirectly contribute to the brain Aβ load, leading to its accumulation. 
However, what role does age play in this orchestrated event is poorly understood.  
The purpose of the following study was to precisely address some of these questions. 
Plasma pharmacokinetics and BBB permeability of Aβ isoforms in three different age 
groups (8 week, 24 week, and 52 week) of wild type and AD transgenic (APP,PS1) mice 
were compared and trends assessed. We propose that there are age dependent changes in 
the luminal exposure of BBB endothelium that may be able to define or provide clues to 
explain the alterations in clinical ratios of Aβ isoforms as well as the Aβ accumulation 
trends in AD. We hypothesize that age could trigger and accelerate several pathological 
features observed in AD.  
 
2.3. MATERIALS AND METHODS  
2.3.1. Aβ proteins 
 Aβ40 and Aβ42 were synthesized as described earlier (Kandimalla et al., 2005). 
The Aβ monomers were prepared according to the procedure described by Klein (Klein et 
al., 2004). Briefly, Aβ peptides were accurately weighed, dissolved in ice cold 1,1,1,3,3,3 
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hexafluoroisopropanol (HFIP) (MP Biomedicals, Santa Ana, CA), and incubated at room 
temperature for 60 min. The resultant solutions were chilled on ice, aliquoted 
appropriately, and allowed to dry overnight. The HFIP traces were further removed by 
vacuum evaporation, and the dried films were stored at -20 °C. Before each experiment, 
the Aβ films were dissolved in anhydrous dimethyl sulfoxide (DMSO), diluted in Hams 
F-12 medium (Mediatech, Manassas, VA), and centrifuged at 18,000 rpm to remove any 
insoluble Aβ aggregates.  
2.3.2. Radio iodination of proteins 
 Carrier-free Na125I and Na131I were obtained from PerkinElmer Life and Analytical 
Sciences (Boston, MA). Human Aβ40 (500 µg), Aβ42 (500 µg) or BSA (500 µg) was 
labeled with either 125I or 131I, using the chloramine-T procedure (Kandimalla et al., 2005; 
Poduslo et al., 1997). Free radioactive iodine was separated from the radiolabeled protein 
by dialysis against 0.01 M phosphate-buffered saline at pH 7.4 (Sigma-Aldrich, St. Louis, 
MO). Purity of the radiolabeled proteins was determined by trichloroacetic acid (TCA) 
precipitation. The radioiodinated Aβ was deemed to be acceptable if the TCA perceptible 
counts were greater than 95 % of the total counts. The final radioactivity associated with 
125I labeled Aβ40 or Aβ42 was determined to be 4 mCi/mg protein. 
2.3.3. Animals 
All experiments conducted on animals were as per the National Institutes of Health 
Guide for Care and Use of Laboratory animals and approved by the Institution’s Animal 
Care and Use Committee of the Mayo Clinic, Rochester, MN. The wild-type (WT) mice 
(B6/SJL strain) were housed in virus free barrier facility with 12-h light and dark cycle, 
and were provided with pellet food and purified water ad libitum.  
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2.3.4. Plasma pharmacokinetic studies 
The plasma pharmacokinetic studies were conducted as explained schematically in 
Figure 2.1. Briefly, 8-, 24-, and 52- wild type or WT (C57B6/SJL) and AD transgenic 
(APP,PS1) mice weighing 25-30 g were anesthetized. The genetic background of these 
APP,PS1 mice was the C57B6/SJL mice. Femoral vein and femoral artery were 
catheterized under general anesthesia using 1.5 % isofluorane in oxygen at 4 L/min. 100 
µCi/100µL single intravenous bolus dose of 125I-Aβ40 or 125I-Aβ42 was administered via 
the femoral vein and blood samples (20 µL) were collected from the femoral artery. 
Samples were collected at 0.25, 1, 3, 5, 10 and 15 minutes. At the end of the experiment, 
at 15th minute, an aliquot of 131I-BSA (100 µCi, 100 µL) was injected to serve as a 
measure of residual plasma volume (Vp). One minute after the 131I-BSA injection, the 
final blood sample was collected, and the animal was sacrificed. Blood samples were 
made up to a volume of 100 µL using saline, centrifuged, and the blood cells were 
separated. The resultant plasma, thus obtained, was subjected to TCA precipitation and 
radioactivity of both 125I and 131I in precipitate and supernatant was assayed using two 
channel gamma counter (Cobra II; PerkinElmer Life and Analytical Sciences, Boston, 
MA).  
The plasma concentrations of 125I-Aβ40 and 125I-Aβ42 were described by bi-
exponential disposition and the pharmacokinetic parameters were estimated by Phoenix 
WinNonlin® 6.4 by fitting the following equation: 
 
                                                   			𝐶 𝑡 = 𝐴𝑒'() + 𝐵𝑒',)																																																					(1) 
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where, C(t) = 125I-Aβ40 or 125I-Aβ42 µCi/ml of plasma, A and B are intercepts and α and 
β are the bi-exponential rate constants. 
 
 
 
Figure 2.1 Experimental study design to predict 125I-Aβ40 and 125I-Aβ42 plasma 
pharmacokinetics. Plasma samples were collected at designated time points and the 
radioactivity associated with the intact peptide was determined by TCA precipitation. A 
two-compartment model was fitted to the data using WinNonlin® 6.4 and the parameters 
were estimated.  
  
3
Wild	Type
125I-Aβ
125I-Aβ
125I-Aβ
8	wk
24	wk
52	wk
Plasma	samples
TCA	precipitation
Measure	125I
Compartmental PK	analysis
(WNL)	and	compare	
parameters	between	Aβ40	
and	Aβ42
AD	Transgenic	
(APP,PS1)	
8	wk
24	wk
52	wk
Mild	
cognitive	
impairment
Late	
stage	AD
Early	onset
125I-Aβ
125I-Aβ
125I-Aβ
58	
	
2.3.5. Blood brain barrier permeability studies 
 After the 15th minute blood sample was obtained from the femoral artery as 
described above, 131I-BSA was injected via the femoral vein, and the final blood sample 
was withdrawn at the end of the 16th minute. Then, the animal was sacrificed, brain was 
removed from the cranial cavity; dissected into the anatomical regions: cortex, caudate 
putamen, hippocampus, thalamus, brain stem and cerebellum and assayed for 125I and 131I 
radioactivity.  
The residual brain region plasma volume (Vp, microliters per gram) and the 
permeability surface area product (PS) values were calculated as described, using: 
 																																																																															𝑉1 = 	 23	4	56789	4	: 																																																			(2)                                                   
 
where, 𝑞1	is the 131I-BSA content (cpm) of tissue, 𝐶= is the 131I-BSA concentration (cpm 
per milliliter) in plasma. W is the weight (grams) of the brain region.  
From the total of 125I-Ab content (𝑞>) (cpm) of the brain region, the amount of 
125I-Ab that enters the brain extravascular or parenchymal space (q) (cpm per gram) is 
calculated as follows: 
 																																																																	𝑞 = 	 2?: −	A38B567                                                         (3) 
where, 𝐶C is the final 125I-Ab concentration (cpm per milliliter) in plasma. The PS 
(milliliters per gram per second) at the BBB is calculated as follows: 
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                                																									𝑃𝑆 = 	 283	F)GH 																																																																	(4) 
 
where, t is the circulation time, q is the extravascular 125I activity in the brain region at 
time t and 𝐶1	𝑑𝑡)6  is the plasma concentrations time integral of 125I-Ab.  
2.3.6. Data analysis and statistics 
 Unless mentioned otherwise, the significance of difference in the mean values of 
controls and treatments were tested by Two-Way ANOVA followed by Bonferroni post 
hoc test for age and animal model (WT vs APP,PS1) as two factors in GraphPad Prism 
version 5.0 (GraphPad Software Inc, San Diego, CA).  
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2.4. RESULTS 
2.4.1. 125I-Ab40 and 125I-Ab42 exhibit bi-exponential disposition in the plasma 
(Figures 2.2 and Table 2.1) 
Like described before, (Agyare et al., 2013; Kandimalla et al., 2005), both 125I-Ab40 
and 125I-Ab42 exhibited bi-exponential disposition in the plasma. Moreover, their plasma 
pharmacokinetic parameters altered with age and between WT and APP, PS1 mice. 
Age dependent changes in predicted plasma pharmacokinetic parameters: 
Ab40 (Figure 2.2 (A-B) and Table 2.1): In WT as well as in APP,PS1 mice, AUC 
increased and clearance decreased with age. A corresponding increase in the terminal 
half-life, (t1/2,b) with age in both WT and APP,PS1 mice was also noted. In addition, the 
Cmax values decreased with age in both WT and APP,PS1 animals.  
Ab42: (Figure 2.2 (C-D) and Table 2.1): Unlike Ab40, Cmax decreased with age in WT 
animals. On the other hand, AUC and clearance trends demonstrated a decrease and an 
increase, respectively with age. Terminal half-life (t1/2,b) also trended to decrease with age 
in WT mice. But there was no change in these parameters with age in APP,PS1 animals.  
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Figure 2.2 Plasma pharmacokinetics of 
125
I-Aβ40 and 
125
I-Aβ42 in WT and APP,PS1 
mice at 8, 24, 52 weeks. Plasma pharmacokinetic profiles of 
125
I-Aβ40 in (A) WT and 
(B) APP,PS1 animals. Plasma pharmacokinetic profiles of 
125
I-Aβ42 in (C) WT and (D) 
APP,PS1 animals. Data are mean ± S.D. (n = 3-6); lines indicate the fit of two-
compartment pharmacokinetic model to the plasma concentration time data.  
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Differences in plasma pharmacokinetic parameters between WT and APP,PS1 mice: 
Ab40: (Figure 2.2 (A-B) and Table 2.1): In 52-week old APP,PS1 mice, AUC and 
terminal half-life values (t1/2,b) were lower than it was in WT animals; no such difference 
in clearance was observed in WT and APP,PS1 mice. Cmax in APP,PS1 animal was lower 
than that of WT in an 8 and 24-week old animal, but the trend was lost by 52-weeks.  
Ab42: (Figure 2.2 (C-D) and Table 2.1) There was a decrease in both AUC and Cmax 
values in 8-week-old APP,PS1 mice compared to age-matched WT mice. However, no 
such differences were observed at later ages. Clearance and t1/2,b were not different 
between WT and APP,PS1 mice. 
Interaction between the age and genotype factors (WT and APP,PS1) 
Ab40: Significant interaction was found between age and genotype factor in AUC***, 
clearance**, Cmax *** and t1/2,b**. 
Ab42: Similar to Ab40, significant interaction was found between age and genotype 
factor in AUC* and Cmax***; but not in t1/2,b and clearance.  
2.4.2. Changes in the L-A BBB permeability of  125I-Ab40 and 125I-Ab42 with age 
and between WT and APP,PS1 mice (Figure 2.3)  
Age dependent changes in L-A BBB permeability: 
Ab40: (Figure 2.3 A-B) BBB permeability of Ab40 decreased with age in the cortex and 
hippocampus of WT mice. Although, similar trends were evident in APP,PS1 mice, they 
were not statistically significant. 
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Ab42: (Figure 2.3 C-D): BBB permeability increases with age in WT animals in both 
cortex and hippocampus. Again, statistically significant trends were not seen in APP,PS1 
animals with age.  
 
 
 
Figure 2.3 Blood brain barrier (BBB) permeability surface area (PS) product of 
125
I-
Aβ40 and 
125
I-Aβ42 in WT and APP,PS1 mice at 8-, 24-, 52- weeks in two brain 
regions (cortex and hippocampus) that are severely implicated in AD. Luminal to 
abluminal (L-A) PS values of 
125
I-Aβ40 in (A) cortex; (B) hippocampus. Similarly, 
luminal to abluminal (L-A) PS values of 
125
I-Aβ42 in (C) cortex; (D) hippocampus. Data 
is mean ± S.D. (n = 3-6) Significance assessed over age (** p < 0.01 and *** p < 0.001) 
and WT versus APP,PS1 (## p< 0.01) by Two-Way ANOVA followed by Bonferroni post 
hoc tests.  
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Differences in L-A BBB permeability between WT and APP,PS1 mice: 
Ab40 Figure 2.3 (A-B): Even at an early age of 8-weeks, the BBB permeability of Ab40 
in APP,PS1 mice was lower than that observed in WT mice. Similar trends were seen in 
24-week mice as well. By 52 weeks, the permeability of Ab40 in WT mice also 
decreased to the levels observed in APP.PS1 mice. 
Ab42 Figure 2.3 (C-D): No substantial difference in BBB permeability was seen 
between WT and APP,PS1 animals at any age group, not even by 52 weeks.  
Interaction between the age and genotype factors (WT and APP,PS1) 
Ab40: Significant interaction was found between age and genotype factor in BBB 
permeability in cortex**; but not in hippocampus.  
Ab42: Similar to Ab40, Significant interaction was found between age and genotype 
factor in BBB permeability in cortex*; but not in hippocampus 
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2.5. DISCUSSION 
Age is the obvious risk factor of AD. Higher concentrations of Ab isoforms and 
perturbations in Ab42:Ab40 ratios that are  associated with AD progression, are believed 
to be a consequence of BBB dysfunction. However, the manner in which these three 
factors interplay with each other and perpetrate AD pathogenesis is not clearly 
understood. The objective of this study was to investigate changes in the plasma 
pharmacokinetics and BBB permeability of Ab isoforms with age in WT and APP,PS1 
mice.  
The plasma pharmacokinetics of Ab40 and Ab42 in WT and APP,PS1 mice 
demonstrate distinct profiles (Figures 2.1 and Table 2.1). Increase in the plasma AUC 
and decrease in clearance for Ab40 shows that this isoform accumulates in the plasma 
and Ab42 does not. As significant interaction was seen between age and genotype (WT 
and APP,PS1) factors; to assess individual trends in the factors, One-Way ANOVA 
statistical analysis followed by Bonferroni’s post hoc tests was also conducted 
(Supplementary Figure S-2.2) and the increase and decrease in plasma AUC and the 
opposite trends for clearance, for Ab40 and Ab42; respectively with age, were validated. 
This decreases the plasma Ab42:Ab40 ratio, which was previously shown to be 
associated with AD pathology. Interestingly, these indications of age dependent changes 
in Ab profiles that are lost in AD model have been suggested earlier as well (Giedraitis et 
al., 2007; Sundelöf et al., 2008), where the normal equilibrium (correlation) between CSF 
and plasma Ab levels was not seen in AD or MCI cases (Giedraitis et al., 2007). In 
Tg2576 AD transgenic mice model, there are age dependent changes in plasma, brain and 
CSF of both Aβ40 and Aβ42. Brain levels of Aβ40 and Aβ42 increase to that observed in 
67	
	
AD by 12-24 months, that is proportional to a decrease in CSF Aβ and a highly 
significant decrease in plasma Aβ levels (Kawarabayashi et al., 2001). Also, human 
plasma Aβ40 and Aβ42 have been shown to increase with age over 65 years and in late 
onset AD (Ertekin-Taner et al., 2008) and early onset AD. APP,PS1 is an animal model 
that overexpresses amyloid beta proteins. The kinetic changes observed in APP,PS1 mice 
might not be entirely due to the saturation of receptors Ab by proteins, because the 
changes are evident at a very early age of 8-weeks, when the Ab protein concentration is 
barely detectable in the plasma (Poduslo et al., 1999). This finding of accumulation of 
Aβ40 and not Aβ42 with age, also meant that over time, the luminal exposure of BBB 
endothelium to Aβ40 increases with age. Now instinctively, one would think that as the 
Ab concentrations in the brain are almost 10 fold higher in normal as well as AD 
conditions, will this increased plasma (or luminal) exposure directly contribute to Ab 
accumulation in the brain? 
Surprisingly, our BBB permeability data (Figure 2.2) revealed that the increased 
exposure of Ab40 does not translate to increase in its permeability. In fact, the 
permeability of Ab40 decreases at an early age of 8 weeks in APP,PS1 mice compared to 
WT mice. However, no significant change in the permeability of Ab42 was seen even by 
52 weeks. Also, we could clearly see that over age, while the BBB permeability of Ab40 
decreases with age the permeability of Ab42 increases with age in WT and APP,PS1 
mice. This finding reemphasizes that BBB is far more than just a layer of tightly packed 
endothelial cell surrounding the cerebral blood vessels. It has an active signaling and 
trafficking apparatus and is directly and independently capable of modulating the brain 
homeostasis. Further, these results suggest that the increase in Ab42 permeability is not 
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due to mere breakdown of the paracellular integrity of the BBB, but most likely due to 
the BBB dysfunction triggered by age. 
In summary, the key finding from this chapter is as follows: a relatively early 
change in the course of disease progression; the decrease in Ab40 uptake and increase in 
Ab42 uptake at the BBB endothelium from the luminal to abluminal (L-A) direction 
could increase and decrease the Ab42:Ab40 ratios in the brain and plasma, respectively; 
that are associated with AD progression. In the subsequent chapters, we provide evidence 
that this BBB dysfunction is triggered by disrupted vesicular trafficking by Ab isoforms.  
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CHAPTER THREE  
3 DISTINCT UPTAKE MECHANISMS OF AMYLOID BETA ISOFORMS AT 
THE BLOOD BRAIN BARRIER ENDOTHELIUM IN ALZHEIMER’S 
DISEASE 
 
3.1.SUMMARY 
Blood brain barrier (BBB) is one of the primary clearance portals of Aβ proteins 
from the brain; and also is known to maintain the dynamic equilibrium between plasma 
and brain Aβ pools. It is widely known that Aβ42:Aβ40 ratios in plasma and brain are 
perturbed during AD progression. However, the mechanistic details on how these ratios 
are altered have not been clearly elucidated. In this chapter, using molecular interventions 
and kinetic assessments of Aβ proteins in two in-vitro BBB models, we demonstrate that 
the BBB endothelium handles Aβ40 and Aβ42, distinctly. While, Aβ40 is endocytosed 
via the clathrin-dependent endocytosis, Aβ42 is endocytosed by the lipid raft-mediated 
endocytosis. Our findings also suggest that the rate of uptake and permeability of Aβ 
isoforms are distinct, only in the luminal to abluminal or L-A direction. These 
mechanistic and kinetic differences provide the first direct evidence supporting the 
hypothesis that BBB dysfunction implicated in AD could differentially affect the 
trafficking of Aβ40 and Aβ42 between plasma and brain; and engender shifts in the 
Aβ42:Aβ40 ratios observed during AD progression. Further, Aβ isoforms utilizing the 
two canonically employed endocytosis machineries to varying extents, and probably 
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interfering with their function, also provide a mechanistic rationale to the impaired 
transport of other macromolecules such as insulin, transferrin, among others, that is seen 
in AD pathology.   
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3.2. INTRODUCTION 
Most of the investigations on neurodegenerative disorders including Alzheimer’s 
disease (AD) have been neurocentric. The involvement of the neurovascular unit (NVU) 
in neurodegenerative diseases has been relatively underexplored (Bell et al., 2007; Deane 
et al., 2009). The NVU comprises of BBB endothelium, astrocytes, pericytes, 
oligodendrocytes, and neurons, which work together as a cohesive communication and 
functional unit (Erickson and Banks, 2013; Zlokovic, 2010). This NVU is believed to be 
disrupted in AD (Zlokovic, 2010). The BBB endothelium, which is a critical component 
of the NVU, and is present at the interface of plasma and brain, is believed to maintain 
the dynamic equilibrium of Aβ in periphery and brain. 
Recently, Mauwyenga et al (Kwasi G Mawuenyega et al., 2010) clearly 
demonstrated that it is the impaired clearance, and not overproduction of Aβ proteins that 
leads to their over accumulation and subsequent plaque formation in sporadic AD brain. 
Further, the BBB endothelium plays a critical role in Aβ clearance from the brain. In 
addition to degradation by proteolytic enzymes and removal by perivascular drainage, the 
BBB endothelium is suggested as one of the primary clearance pathways of Aβ (Bowman 
and Quinn, 2008; Deane et al., 2009). Hence, BBB dysfunction could impair Aβ 
clearance from the brain, and augment cerebral Aβ burden.  
In non-demented individuals, the concentration of Aβ40 is about 10- fold and 1.5- 
fold higher than Aβ42 in cerebrospinal fluid (CSF) and plasma, respectively (Deane et 
al., 2009). These Aβ42:Aβ40 ratios were shown to increase in brain and decrease in 
plasma during AD progression (Toledo et al., 2013) Although not entirely clear, 
peripheral Aβ levels have been demonstrated to contribute to brain Aβ burden; directly 
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via the bi-directional transport of Aβ across BBB endothelium (DeMattos et al., 2001; 
Eisele et al., 2014; Marchi et al., 2004); or indirectly due to the dysfunction triggered by 
oxidative stress (Ascolani et al., 2012)  or other mechanisms (Schupf et al., 2008; 
Sutcliffe et al., 2011). Although, dynamic equilibrium of plasma and brain Aβ levels are 
expected to be maintained by the BBB endothelium, the precise molecular mechanisms at 
the BBB endothelium that could discriminate Aβ40 and Aβ42 have not been deciphered.  
Further, receptor for advanced glycation end products (RAGE) and low-density-
lipoprotein receptor related protein (LRP) have been demonstrated to be involved in the 
influx and trafficking of Aβ proteins at the BBB endothelium. Interestingly, these 
receptors are proposed to be internalized by different mechanisms: LRP uses lipid rafts-
mediated transport processes (Yoon et al., 2007) and RAGE may use clathrin-dependent 
or independent endocytotic processes (Ott et al., 2014). In addition, there may be other 
receptors involved in Aβ trafficking at the BBB (Roy and Rauk, 2005). Therefore, instead 
of focusing on the receptor identity and the associated mechanisms, in this study we 
focused on the global endocytosis mechanisms and kinetics that could differentially 
regulate Aβ trafficking at the BBB endothelium.  
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3.3. MATERIALS AND METHODS 
3.3.1. Synthesis of native and fluorescein-labeled Aβ proteins 
Aβ40, fluorescein labeled Aβ40 (F-Aβ40), Aβ42, and F-Aβ42 were synthesized 
as described in our earlier publications (Agyare et al., 2013; Kandimalla et al., 2005; 
Omtri et al., 2012) and Aβ monomers were prepared according to the procedure 
described by Klein (Klein et al., 2004) and characterized as soluble oligomers 
(Supplementary figure S-3.1). Fluorescein is attached to Aβ at the N-terminus, which 
does not participate in the secondary structure of the protein. Moreover, being a small 
molecule with a molecular weight of 332.32 g/mol; fluorescein is not expected to 
substantially alter the inherent biophysical properties and physiological interactions of 
Aβ40 and Aβ42 (molecular weight 4329.86 g/mol and 4514.04 g/mol, respectively). 
3.3.2. Chemicals and materials 
  The Na125I was obtained from Perkin-Elmer Life and Analytical Sciences 
(Boston, MA). Plasticware was obtained from Corning Life Sciences (Tewksbury, MA), 
USA Scientific (Ocala, FL) or Denville Scientific Inc. (South Plainfield, NJ). 
Chlorpromazine was obtained from MP Biomedicals (Solon, OH) and methyl-β-
cyclodextrin was purchased from Acros Organics (Morris, New Jersey). The K44-
Dynamin plasmid was a kind gift from McNiven laboratory (Mayo Clinic, Rochester, 
MN) (Cao et al., 2007). The siRNA-clathrin was obtained from Dharmacon (Lafayette, 
CO). All other reagents were purchased from Sigma Aldrich (St. Louis, MO), unless 
stated otherwise. 
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3.3.3. Cell cultures 
  Human brain endothelial (hCMEC/D3) cells were a gift from Dr. Pierre-Oliver 
Couraud, INSERM U1016, Institut Cochin, Paris, France. The hCMEC/D3 cells were 
grown in EBM-2 medium (Lonza, NJ) supplemented with 1 ng/mL human basic 
fibroblast growth factor (PeproTech, NJ), 10 mM HEPES, 1 % chemically defined lipid 
concentrate (Gibco, NY), 5 µg/mL ascorbic acid, 1.4 µM hydrocortisone, 1 % penicillin-
streptomycin (MP Biomaterials, OH) and 5 % of fetal bovine serum. Polarized 
hCMEC/D3 cell monolayers were cultured on collagen (Corning, MA) coated cover slip 
bottomed dishes (Mattek, MA), on 6 well plates, or on Transwell® filters (Corning 
CostarTM, MA) at 5 % CO2 and 37 °C. Bovine brain microvascular endothelial (BBME) 
cells were obtained from Cell Applications Inc., (San Diego, CA). The BBME cellular 
monolayers were grown as reported previously (Agyare et al., 2013). Formation of 
monolayers on Transwell® filters with good tight junctional integrity was confirmed by 
measuring the trans-endothelial electrical resistance (TEER) across the monolayers. All 
the monolayers were moved to low-serum (1 % serum) medium, one hour before the 
experiment.  
3.3.4. Microscopy and cellular imaging 
  The hCMEC/D3 or BBME monolayers were treated with 3.1 µM of F-Aβ40, F-
Aβ42, Sulforhodamine101 (SR101) labeled Aβ40, or SR101-Aβ42 for 60 min followed 
by 20 µg/mL of AlexaFluorâ633 labeled transferrin (AF633-TRF) treatment for 30 min. 
In case of inhibitor experiments, the cells were pretreated with inhibitor for the 
designated time and then incubated with F-Aβ. Then the cells were washed with PBS and 
the nuclei were stained by incubating with Hoechst dye (0.5 µg/mL in PBS) for 5 min. At 
75	
	
the end, the dishes were fixed in 4 % para-formaldehyde (PFA) at 4 °C for 60 min; 
mounted with ProLong® gold antifade reagent (Life technologies, OR); and dried 
overnight before imaging by laser confocal microscopy.   
3.3.5. Clathrin knockdowns and K44-negative dominant dynamin transfections 
 GFP and non-GFP K44-negative-dominant dynamin transfections of hCMEC/D3 
cell monolayers were performed using Lipofectamine reagent (Invitrogen, CA) as per 
manufacturer’s protocol. The cells were allowed to recover for 24 h in hCMEC/D3 
medium (1 % FBS) and the experiment was performed the next day. Clathrin knockdown 
was performed on polarized hCMEC/D3 cell monolayers using siRNA kit containing 
RNAi mix (Invitrogen, CA) and reduced serum medium, Opti-MEMÒ (Gibco, NY). The 
cells were allowed to recover for 48 h in hCMEC/D3 medium (1 % FBS) before the 
uptake experiment were performed.  
3.3.6. Flow cytometry 
Following the treatment with various fluorophores, hCMEC/D3 cells were washed 
thoroughly with PBS and gently trypsinized with trypsin-EDTA for 30 sec and 
neutralized with FBS. The dislodged cells were washed twice using ice cold PBS, fixed 
with 4 % PFA solution and analyzed for intracellular fluorescence using BD 
FACSCaliburTM flow cytometer. The F-Aβ40 and F-Aβ42 intracellular fluorescence 
intensities were measured using 488 nm laser fitted with 530/30 filter. Data was acquired 
with BD CellQuestTM Pro and analyzed using FlowJo software. The F-Aβ uptake was 
represented as histograms of intracellular fluorescence intensities. All sample analyses 
were performed within one hour from the completion of the experiment.  
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3.3.7. Permeability across the BBB endothelium 
  Polarized BBME cell monolayers were incubated with 125I-Aβ42 in tracer 
amounts on either luminal or on the abluminal side. Multiple samples were taken from 
the contralateral chamber (receiver compartment containing the blank medium) till 90 
min to assay the radioactivity that transcytosed across the BBME endothelium. Flux of 
125I-Aβ42 across the BBME endothelium was calculated as the slope of cumulative 
amount of 125I-Aβ42 accumulating in the receiver chamber versus time. The apparent 
permeability coefficients were calculated by normalizing the flux with the initial 
concentration of 125I-Aβ42 protein added to the donor chamber and the surface area of the 
Transwell® filter used. The resultant value is the permeability coefficient with units of 
cm/min.  
3.3.8. Uptake kinetics of F-Aβ40 and F-Aβ42 at BBB endothelium  
Following experiments were conducted to elucidate the kinetics of F-Aβ40 and F-
Aβ42 uptake at the BBB endothelium: 
3.3.8.1.Total, specific, and non-specific uptake of F-Aβ as a function of donor 
concentration 
Polarized hCMEC/D3 cells monolayers were incubated with various 
concentrations of F-Aβ40 or F-Aβ42 (0.19 µM to 3.1 µM) on the luminal side for 30 min 
and analyzed using flow cytometry as per the procedure previously described. The 
geometric means of intracellular fluorescence were obtained from the cytometer. The 
experiment was performed at both, 37 °C (total uptake: specific + non-specific uptake) 
and 4 °C (non-specific uptake). Intracellular fluorescence (geometric mean ± S.D.) was 
plotted against F-Aβ concentrations (µM).  
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Since the intracellular fluorescence was measured as geometric means, the 
specific uptake of F-Aβ was calculated as described below: 
𝑈𝑝𝑡𝑎𝑘𝑒O1PQRSRQ	 = 	𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐	𝑚𝑒𝑎𝑛[\°8𝐺𝑒𝑜𝑚𝑒𝑡𝑟𝑖𝑐	𝑚𝑒𝑎𝑛^°8 																																																																		 1  
The ratio thus obtained was plotted over donor concentration and fitted to a Michaelis-
Menten model (Equation 2) as described below using GraphPad Prism® software and the 
parameters were predicted. 
															𝑈𝑝𝑡𝑎𝑘𝑒	𝑅𝑎𝑡𝑒	𝑜𝑟	𝑉 = 	 𝑉 Ca𝐶𝐾` + 𝐶																																																																																(2) 
where,	𝑉	= velocity or rate of uptake (unit less as ratio),	𝑉 Ca=	maximum uptake rate 
(unit less),	𝐶	=	concentration (µM),	𝐾`= Michaelis-Menten constant (µM). 	
3.3.8.2.Total uptake of F-Aβ as a function of time 
Polarized hCMEC/D3 monolayer was incubated with 3.1 µM of F-Aβ40 or F-
Aβ42 in either luminal (L) or abluminal (A) chambers for various lengths of time (15-60 
min). Intracellular uptake from the luminal to abluminal (L-A) or abluminal to luminal 
(A-L) was assessed by flow cytometry as described above. The geometric means, thus 
obtained were then plotted over time and the rates of uptake were estimated by fitting the 
data to a linear regression model using GraphPad Prism® software. 
3.3.9. Mechanism of F-Aβ40 and F-Aβ42 endocytosis at the BBB endothelium 
  Following studies were conducted to investigate the uptake mechanisms of F-
Aβ40 and F-Aβ42 at the BBB endothelium: 
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3.3.9.1.Energy dependence of F-Aβ40 and F-Aβ42 uptake 
The polarized hCMEC/D3 cell monolayers grown on Transwell® filters and 6-
well culture plates were pre-incubated with glucose free DMEM supplemented with 50 
mM 2-deoxy glucose and 0.1 % sodium azide (ATP depletion medium) for 30 min before 
start of the experiment. The control cells were incubated with regular DMEM medium 
containing glucose. Then, 3.1 µM of either F-Aβ40 or F-Aβ42 was added to the luminal 
side of the Transwell® filter and incubated for 30 min. The resultant intracellular 
fluorescence was assessed by flow cytometry.  
3.3.9.2.Temperature dependence of F-Aβ40 and F-Aβ42 uptake  
The hCMEC/D3 monolayers on Transwell® filters (and 6 well culture plates) were 
acclimatized to 37 °C or 4 °C for 60 min. Then the monolayers were treated with various 
concentrations (0.19 µM to 3.1 µM) of either F-Aβ40 or F-Aβ42 (luminal side for 
Transwell® filters) for 30 min at 37 °C or 4 °C. The cells were harvested and the 
intracellular fluorescence was assessed by flow cytometry. The geometric means 
obtained were analyzed as described in section 3.3.8.1. 
3.3.9.3.Dynamin, clathrin and lipid raft mediated endocytosis of F-Aβ40 and F-Aβ42 
Small molecule inhibitors (specific and non-specific) were used to inhibit the 
dynamin dependent vesicle pinch-off, clathrin dependent endocytosis, or lipid raft-
mediated uptake to assess the contribution of these processes to the internalization of F-
Aβ40 and F-Aβ42 by the BBB endothelium. In these experiments, polarized hCMEC/D3 
monolayers were pre-incubated with medium containing 1 % serum for at least one hour 
before the addition of inhibitors, to trigger endocytosis machinery (Conner and Schmid, 
2003). The hCMEC/D3 cells grown on 6-well culture plates or on Transwell® filters were 
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pre-incubated with 80 µM Dynasore (Tocris bioscience, MO), a small molecule inhibitor 
of dynamin, for 30 min. Then, 3.1 µM of F-Aβ40 or F-Aβ42 was added and the 
monolayers were incubated for 60 min. The uptake of F-Aβ peptides was determined 
using flow cytometry. The polarized hCMEC/D3 monolayers were pre-incubated with 
200 µM monodansylcadaverine (MDC, specific clathrin inhibitor) (Schlegel et al., 1982), 
10 mM chlorpromazine (MP Biomaterials, OH) (CPZ, non-specific clathrin inhibitor) 
(Ogiso et al., 1981), 2.5 µM nystatin (specific lipid raft inhibitor) (Chen et al., 2011) or 5 
mM methyl-β-cyclodextrin (Acros Organics, NJ) (mβCD, non- specific cholesterol 
chelator) (Zidovetzki and Levitan, 2007) for 30 min followed by incubation with 3.1 µM 
of either F-Aβ40 or F-Aβ42 for 60 min (Ivanov, 2008). All the control experiments were 
performed in a similar fashion without the addition of inhibitors and the intracellular 
fluorescence was assessed by flow cytometry. 
In a separate experiment, polarized BBME cell monolayers were also pre-
incubated with 10 mM mβCD for 30 min, followed by incubation with 3.1 µM of F-Aβ40 
or F-Aβ42, and 20 µg/mL Alexafluor® labeled Transferrin (AF633-TRF) for 60 min. The 
z-series confocal micrographs were obtained after washing the filters with PBS and fixing 
with 4 % PFA for 1 h at 4 °C. Then Transwells® were mounted with Vectashield Antifade 
mounting medium with DAPI (Vector Laboratories, CA).  
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3.4.RESULTS 
To investigate the kinetics and mechanism of Aβ40 and Aβ42 transcytosis across the 
BBB endothelium, we employed transcellular trafficking studies in-vitro in polarized 
human cerebral microvascular endothelial (hCMEC/D3) cells and primary bovine brain 
microvascular endothelial (BBME) cell monolayers. 
3.4.1. Energy and temperature dependent internalization of F-Aβ40 and F-Aβ42 at 
the BBB endothelium (Figure 3.1 and 3.2.1)   
It is known that receptor mediated endocytotic processes require energy (ATP) 
and are impaired at 4 °C. The uptake of F-Aβ40 and F-Aβ42 in hCMEC/D3 cells, as 
determined by flow cytometry (Figure 3.1), decreased in ATP depleted cells (red 
histogram) compared to the normal cells (green histogram). Also, there was a substantial 
decrease in the uptake of F-Aβ40 and F-Aβ42 in hCMEC/D3 cells (Figure 3.2.1) at 4 °C 
compared to that at 37 °C. Further, saturable uptake kinetics were seen at 37 °C, in 
comparison to the linear, but significantly lower uptake at 4 °C. 
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Figure 3.1. Energy dependence of F-Aβ40 and F-Aβ42 uptake in hCMEC/D3 cells as 
determined by flow cytometry analysis. Intracellular fluorescence histograms of 
hCMEC/D3 cells treated with 3.1 µM of (A) F-Aβ40 or (B) F-Aβ42 for 30 min without 
(green) and with (red) ATP depletion. Intracellular fluorescence of untreated control cells 
is shown in grey. Fold change in intracellular fluorescence of (C) F-Aβ40 and (D) F-
Aβ42 expressed as mean ± S.D. Statistical significance was determined by Student’s T 
test (*p< 0.05). 
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Figure 3.2.1 Total and non-specific uptake of F-Aβ40 and F-Aβ42 with increasing 
donor concentrations in hCMEC/D3 cells. Intracellular fluorescence of hCMEC/D3 
cells incubated with various concentrations of F-Aβ40 (circle) or F-Aβ42 (square) for 30 
min was assessed at either 37 oC (filled) or 4 oC (open) by flow cytometry. Extent of total 
uptake (37 oC) and non-specific uptake (4 °C) has been plotted as geometric mean ± S.D.  
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3.4.2. Saturable and polarized uptake kinetics of F-Aβ40 and F-Aβ42 in 
hCMEC/D3 cellular monolayers (Figure 3.2.2 and 3.3). 
The specific receptor-mediated uptake of F-Aβ proteins at 37 oC was found to be 
saturable in hCMEC/D3 cells (Figure 3.2.2). The Michaelis-Menten parameters 
describing F-Aβ uptake ratio showed a greater Vmax (23.38 ± 3.5) for F-Aβ40 than for F-
Aβ42 (9.28 ± 0.7) (Table 3.1). No statistically significant differences in Km values 
between F-Aβ40 (0.22 ± 0.14 µM) and F-Aβ42 (0.04 ± 0.04 µM) were observed. Uptake 
kinetics measured over time (Figure 3.3) indicated that luminal to abluminal (L-A) 
uptake of both F-Aβ40 and F-Aβ42 was greater than the abluminal-luminal (A-L) uptake. 
Further, in the L-A direction, F-Aβ42 uptake (1.79 ± 0.12 random units/minute or 
RU/min) against time was found to be higher than that of F-Aβ40 (0.55 ± 0.04 RU/min). 
However, in A-L direction, no significant differences in F-Aβ40 (0.11 ± 0.003 RU/min) 
and F-Aβ42 (0.11 ± 0.01 RU/min) uptake were observed (Table 3.2). 
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Figure 3.2.2. Distinct uptake kinetics of F-Aβ40 and F-Aβ42 in polarized 
hCMEC/D3 cell monolayers. Intracellular fluorescence in hCMEC/D3 cells incubated 
with various concentrations of F-Aβ40 (circle) or F-Aβ42 (square) for 30 min was 
assessed by flow cytometry. (A) Extent of specific uptake at each concentration was 
determined by dividing the geometric means of the intracellular fluorescence at 37 °C by 
that observed at 4 °C. Table 3.1 shows the kinetic parameters predicted by fitting the 
observed data to Michaelis-Menten expression (Equation 2). F-Test was used to assess 
the statistical significance: F (DFn,DFd) = 15.56 (2,8), where DFn and DFd refer to 
degree of freedom of numerator and denominator, respectively.  
 
 
 
Parameter F-Aβ40 F-Aβ42 Significance 
Vmax 23.38 ± 3.5 9.28 ± 0.7 * 
Km 0.22 ± 0.14 0.04 ± 0.04 N.S. 
Table 3.1 Michaelis-Menten model fit 
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Parameter F-Aβ40 (L-A) F-Aβ40 (A-L) F-Aβ42 (L-A) F-Aβ42 (A-L) 
SLOPE 0.55 ± 0.04 0.11 ± 0.003 1.79 ± 0.12 0.11 ± 0.01 
 
 
Figure 3.3. Differential uptake of F-Aβ40 and F-Aβ42 in hCMEC/D3 cell 
monolayers. Polarized hCMEC/D3 monolayer were treated with 3.1 µM of F-Aβ40 
(circle) or F-Aβ42 (square) on the (A) luminal (L-A) or on the (B) abluminal (A-L) side. 
Cellular fluorescence due to accumulation of F-Aβ proteins in the hCMEC/D3 cells was 
analyzed by flow cytometry and plotted against the incubation time. Linear regression 
analysis was conducted (Table 3.2) and statistical significance was determined by F Test. 
L-A slopes of F-Aβ40 and F-Aβ42 were found to be different. F (DFn, DFd) = 116.9 
(2,2) where DFn and DFd refer to degree of freedom of numerator and denominator, 
respectively. 
 
 
 
 
 
 
Table 3.2 Linear regression fit
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3.4.3. Dynamin dependent uptake of F-Aβ40 and F-Aβ42 in polarized hCMEC/D3 
monolayers (Figure 3.4)  
To determine if Aβ endocytosis at the BBB endothelium involves dynamin, which 
aids in pinching off the endocytotic vesicles, the hCMEC/D3 cells were transfected with 
a negative dominant mutant of K44-dynamin. (Figure 3.4.1 A-G). A significant decrease 
in green puncta of F-Aβ40 (Figure 3.4.1 A-B) or F-Aβ42 (Figure 3.4.1 F-G), and red 
puncta of AF633-TRF was seen in cells transfected with negative dominant mutant K44-
dynamin compared to control cells. In the cells transfected with GFP-K44-dynamin 
(Figure 3.4.1 C-E), the uptake of SR101-Aβ40 (orange puncta, Figure 3.4.1 D) and 
AF633-TRF (red puncta, Figure 3.4.1 E) into the cytosol was inhibited. Most of the 
SR101-Aβ40 and AF633-TRF signals were limited to the cell circumference. However, 
non-transfected cells without the green fluorescence of GFP-K44-dynamin internalized 
SR101-Aβ40 as well as AF633-TRF. Also, in the flow cytometry studies, the uptake of 
F-Aβ40 and F-Aβ42 in hCMEC/D3 cells (Figure 3.4.2) decreased in cells pretreated with 
dynasore, a dynamin inhibitor (red histogram) compared to the untreated normal cells 
(green histogram).  
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Figure 3.4.1. Dynamin dependent endocytosis of F-Aβ40 and F-Aβ42 in polarized 
hCMEC/D3 monolayers. A-G: Representative images of cells incubated with AF633-
TRF (red), F-Aβ40 (green), F-Aβ42 (green), or SR101-Aβ40 (orange) and stained with 
Hoechst dye (blue) are presented. A-B: Decreased intracellular uptake of F-Aβ40 and 
AF633-TRF in (B) the cells transfected with K44-dynamin mutant relative to (A) control 
cells demonstrating the inability of F-Aβ40 and AF633-TRF to get into the cell without 
functional dynamin. Similarly, C-E: cells expressing (C) GFP/K44-Dynamin (marked by 
dashed white line) demonstrated a reduced uptake of (D) SR101-Aβ40, or (E) AF633-
TRF. F-G: Uptake of F-Aβ42 and AF633-TRF was also inhibited in hCMEC/D3 cells 
expressing (G) negative dominant K44-dynamin compared to (F) control cells 
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Figure 3.4.2. Effect of dynamin inhibitor on internalization of F-Aβ40 and F-Aβ42 in 
polarized hCMEC/D3 cells. Dynasore, a small molecule inhibitor of the vesicle 
pinching off protein dynamin inhibits intracellular accumulation of F-Aβ40 and F-Aβ42 
as seen in flow cytometry analysis of cells incubated with 80 µM dynasore for 60 min, 
followed by F-Aβ incubation for 60 min. A-B: Intracellular fluorescence histogram of 
(A) F-Aβ40 and (B) F-Aβ42 pretreated with (red) and without (green) dynasore. 
Intracellular fluorescence of untreated control cells is shown in grey.  C-D Fold Change 
of intracellular fluorescence of (C) F-Aβ40 and (D) F-Aβ42 in geometric mean ± S.D. 
Statistical significance was determined by Student’s T test. (*p < 0.05). 
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3.4.4. F-Aβ40 endocytosis at the BBB endothelium is predominantly clathrin-
mediated (Figure 3.5) 
The role of clathrin-mediated endocytosis, which is a constitutive endocytotic 
pathway, in Aβ internalization was assessed using specific clathrin knock down studies 
(Figure 3.5.1). In cells transfected with si-RNA clathrin, the green puncta due to F-Aβ40 
uptake was significantly reduced (Figure 3.5.1 A-B), whereas the prevalence of F-Aβ42 
puncta did not change substantially, as compared to the un-transfected control cells 
(Figure 3.5.1 C-D). AF633-TRF, which is a well-accepted ligand for the clathrin-
mediated endocytosis, was used as the control (Figure 3.5.1 A-D). Also, clathrin 
inhibitors- specific, monodancyl cadaverin (MDC) and non-specific, chlorpromazine 
(CPZ) (Figure 3.5.2) decreased the uptake of F-Aβ40 significantly whereas F-Aβ42 was 
only slightly affected.  
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Figure 3.5.1 Clathrin mediated endocytosis of F-Aβ40, but not of F-Aβ42 in 
polarized hCMEC/D3 monolayers. Endocytosis of F-Aβ40 (green) and AF633-TRF 
(red) is reduced in (B) the cells knocked-out of clathrin compared to (A) the control cells. 
C-D: Although there is a decrease in AF633-TRF (red) uptake, no change in F-Aβ42 
(green) uptake was observed in (D) clathrin knocked-out cells compared to (C) the 
control cells.  
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Figure 3.5.2. Endocytosis of F-Aβ40, but not of F-Aβ42, is clathrin-dependent in 
polarized hCMEC/D3 monolayers. A-C: Effect of clathrin inhibitors on the uptake of 
F-Aβ40. A&B: Flow cytometry histograms of hCMEC/D3 cells incubated with 3.1 µM 
of F-Aβ40 for 60 min pretreated with (red) and without (green) (A) monodancyl 
cadaverin (MDC), a specific inhibitor and (B) chlorpromazine (CPZ), a non-specific 
inhibitor. (C). Fold change in the intracellular fluorescence of F-Aβ40 with and without 
inhibitor treatment D-E: Only a slight reduction in F-Aβ42 uptake was observed after 
pretreatment with (D) MDC and (E) CPZ. In addition, (F) the fold change in the 
intracellular fluorescence due to Aβ42 uptake was not significantly affected by the 
inhibitors. Significance was determined by One-Way ANOVA followed by Dunnett’s 
posttest. (*p<0.05)   
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3.4.5. F-Aβ42 uptake at BBB endothelium is lipid raft-mediated (Figure 3.6) 
Red histogram representing the intracellular fluorescence of F-Aβ42 in 
hCMEC/D3 cells treated with lipid raft inhibitors, nystatin (NYS) and methyl-β-
cyclodextrin (mβCD), demonstrated a left shift compared to the controls. This 
demonstrates a decrease in F-Aβ42 uptake compared to the control cells (green 
histogram) (Figure 3.6 D-F). However, the uptake of F-Aβ40 in hCMEC/D3 cells 
(Figure 3.6 A-C) decreased following the pre-treatment of mβCD, a non-specific 
cholesterol chelator (Zidovetzki and Levitan, 2007) but not following the pre-treatment of 
nystatin, a specific lipid-raft inhibitor (Parton and Richards, 2003).  
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Figure 3.6. Endocytosis of F-Aβ42, but not F-Aβ40 in polarized hCMEC/D3 
monolayers is mediated by lipid rafts. A-B: Flow cytometry histograms of hCMEC/D3 
cells incubated with 3.1 µM of F-Aβ40 for 60 min pretreated with (red) and without 
(green) inhibitors. Although reduced uptake of F-Aβ40 was observed after pretreatment 
with the non-specific cholesterol chelator (B) mβCD, no change was observed after 
pretreatment with the specific cholesterol inhibitor (A) NYS. In comparison, D-E: 
Uptake of F-Aβ42 is substantially decreased after pretreatment with both (D) NYS and 
(E) mβCD. Untreated control cells are shown in grey. C&F: Fold change in the 
intracellular fluorescence of (C) F-Aβ40 and (F) F-Aβ42 demonstrated the lipid raft 
mediated uptake of F-Aβ42, but not F-Aβ40. Significance was determined by One-Way 
ANOVA followed by Dunnett’s posttest (*p< 0.05). 
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3.4.6. F-Aβ uptake in primary bovine brain microvascular endothelial (BBME) cell 
monolayer (Figure 3.7)  
Primary BBME cell monolayers was used to confirm the distinct uptake 
mechanisms of Aβ isoforms observed in polarized hCMEC/D3 cell monolayers. The 125I-
Aβ42 demonstrated polarized uptake in luminal to abluminal (L-A) and abluminal to 
luminal (A-L) directions (Figure 3.7 A); L-A permeability is higher than that of A-L 
permeability. Confocal z-stack images (Figure 3.7 B) indicated a reduced intracellular 
accumulation of F-Aβ42 (green puncta) and AF633-TRF (red puncta) after (D) lipid raft 
disruption by mβCD; in comparison to (C) control cell monolayers. In addition, the 
uptake of F-Aβ40 (green puncta) was unaffected by (B) mβCD pre-treatment when 
compared to (A) control cells.  
 
 
 
 
 
 
 
 
 
 
 
95	
	
 
Figure 3.7 Uptake of F-Aβ42 and F-Aβ40 in bovine brain microvascular endothelial 
(BBME) cell monolayer treated with methyl beta cyclodextrin. A: Distinct 
permeability of 
125
I-Aβ42 in the luminal to abluminal (L-A) and abluminal to luminal (A-
L) direction (Mean ± SEM). Further, relative to the permeability of 
125
I-Aβ40 that was 
published by our group earlier (Agyare et al., 2013); permeability of 
125
I-Aβ42 was 
greater than 
125
I-Aβ40, only in L-A direction, but not in A-L direction. Confocal images: 
Intracellular accumulation of F-Aβ42 and not F-Aβ40 is lipid raft mediated in BBME 
cells: A-B No change in the uptake of F-Aβ40 (green) was found in cells pretreated with 
(B) mβCD compared to (A) control cells. C-D Intracellular uptake of F-Aβ42 is reduced 
following (D) mβCD treatment compared to (C) control cells. Images shown in all three 
planes: x-y (square box), x-z (top horizontal panel) and y-z (right vertical panel).  
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3.5. DISCUSSION  
Prolonged exposure of BBB endothelium to toxic Aβ peptides, could trigger 
intracellular alterations that may precipitate into BBB dysfunction in AD pathogenesis 
(Carrano et al., 2011; Erickson and Banks, 2013). The BBB dysfunction is typically 
assessed by evaluating vascular reactivity and loss in BBB integrity, which is verified by 
increase in the brain permeability of plasma proteins like albumin. As reviewed by Skoog 
et al. (Skoog, 1998), multiple studies showed an increase in the CSF/serum albumin ratio 
in the AD patients group with vascular defects, such as hypertension, non-insulin 
dependent diabetes mellitus and non-ischemic heart disease, than in control group 
(Blennow et al., 1990; Frölich et al., 1991; Skoog et al., 1998). Interestingly, no 
significant BBB dysfunction was noted in AD patients without any vascular defects 
(Blennow et al., 1990). While this approach may show alterations in the paracellular 
integrity of the BBB endothelium, but, it may not reveal the early pathophysiological 
changes such as the intracellular trafficking or the signaling component of the BBB 
endothelium; that are severely understudied.  
In addition to maintaining the brain homeostasis and restricting the exposure of 
xenobiotics circulating in the plasma, the BBB modulates the Aβ42:Aβ40 ratios in brain 
and plasma (Hawkins and Davis, 2005), which were shown to be altered during AD 
progression such that the Aβ42:Aβ40 ratio increases in the brain parenchyma, but 
decreases in the plasma (Toledo et al., 2013). However, the mechanistic rationale that 
drives this perturbation is not known yet. Therefore, we hypothesize that the BBB 
endothelium may have the ability to discriminate these Aβ isoforms and traffic them 
independently by maintaining distinct transcytosis mechanisms and kinetics. To test this 
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hypothesis, we investigated the differences in the transcytosis of Aβ40 and Aβ42 at the 
BBB endothelium in-vitro. In this chapter, although we also assessed the permeability 
profiles encompassing the complete transcytosis process, our focus was the first step of 
transcytosis: uptake or endocytosis.  
The receptor mediated endocytosis of Aβ at the BBB endothelium is long known. 
(Poduslo et al., 1999; Skoog, 1998). Multiple receptors such as RAGE and LRP have 
been proposed to be involved in influx and efflux of Aβ, respectively (Deane et al., 2004, 
2004, 2012; Shibata et al., 2000). However, the intracellular trafficking of Aβ has so far 
been an unknown territory. There is evidence that LRP most likely involves lipid rafts 
(Yoon et al., 2007) and endocytosis of RAGE receptor could be via clathrin dependent or 
independent pathways (Ott et al., 2014). Understanding the intracellular trafficking at 
BBB endothelium is essential to comprehend the pathogenesis of several neurological 
ailments including AD. Further, bioinformatics analysis conducted by our collaborators 
has shown that the genes that code for various proteins in the intracellular cargo sorting 
and trafficking are down regulated in AD patient brain (Supplementary Figure 5.8). 
Hence, the variations in Aβ42:Aβ40 could be caused by the selective disruption of 
transcytotic pathways that predominantly handle Aβ40 or Aβ42. In addition, an increased 
expression of LRP at blood-cerebral spinal fluid barrier (BCSFB), the other barrier or 
portal for Aβ to clear from the brain, further asserts that receptors alone would not suffice 
to tackle the issue of impaired Aβ clearance (Marques et al., 2013).  
In this chapter, we investigated both luminal to abluminal (L-A) and abluminal to 
luminal (A-L) trafficking of Aβ40 and Aβ42 and demonstrated that BBB handles the Aβ 
isoforms differently. We used polarized monolayers of hCMEC/D3 cells in-vitro, which 
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is a widely studied human BBB model. Although, this cell line is known to have leakier 
tight junctions, its human origin is of significant importance (Poller et al., 2008; Weksler, 
2005). Moreover, as we employed these cells to investigate the uptake of a protein and 
not a small molecule, we expect this model to provide crucial information on the 
mechanisms of Aβ endocytosis. Earlier studies have demonstrated that the uptake of both 
Aβ40 and Aβ42 is energy dependent and is inhibited at the sub-physiological temperature 
of 4 °C, where the endocytotic mechanisms are inhibited due to the arrest of cellular 
physiological processes (Kandimalla et al., 2009). Our findings suggest that the uptake of 
Aβ proteins at the BBB endothelium is energy dependent and saturable, which are the 
primary characteristics of receptor-mediated uptake, and verifies the assertion that Aβ 
isoforms utilize receptor mediated endocytosis at the BBB endothelium. Next, we have 
shown that Aβ internalization is dynamin dependent. Dynamin is needed by cells to pinch 
the vesicles and be released into the cytosol once they are formed at the plasma 
membrane. We show that in the cells expressing a dominant mutant and a non-functional 
form of dynamin, the uptake of both Aβ40 and Aβ42 is significantly reduced, thereby, 
suggesting that dynamin is involved in the endocytosis of Aβ40 and Aβ42 at the BBB 
endothelium. Similar role of dynamin in the endocytosis of Aβ (Omtri et al., 2012) and 
APP (Carey et al., 2005; Ehehalt et al., 2003) has been demonstrated in neurons. 
Moreover, the results obtained in hCMEC/D3 model verifies the results obtained in a 
primary bovine endothelial cell model. Similar revelations were made from another study 
that demonstrated that L-A uptake of Aβ isoforms is mediated by RAGE, is inhibited at 4 
°C, and is sensitive to fillipin, a cholesterol or lipid raft chelating agent (Candela et al., 
2010).  
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Clathrin- and lipid-rafts (mediated primarily by caveolin) are the two well-studied 
endocytotic mechanisms that facilitate the receptor-mediated endocytosis of several 
macromolecules. As elegantly reviewed in (Preston et al., 2014), clathrin mediated 
endocytosis of transferrin (Roberts et al., 1993); or lipid rafts mediated endocytosis of 
insulin (Schnitzer et al., 1994) among others such as TNF-a, alpha2-macroglobulin, 
platelet-derived growth factor-B; would be affected if BBB endothelium becomes 
dysfunctional in AD. Interestingly, most of these observations have been noted in AD 
patients (Craft, 2007; Kovacs, 2000; Licastro et al., 2000; Namekata et al., 1997; 
Simpson et al., 1994; Tesseur et al., 2006). 
 Further, it has been shown that clathrin-mediated endocytotic processes are 
compromised in AD. An adaptor protein associated with clathrin coated vesicles (CCV), 
AP180, have been shown to be altered in superior frontal gyrus and hippocampus (Yao 
and Coleman, 1998). Another CCV associated protein, AP-2, has also been shown to be 
dysfunctional in AD (Yao et al., 2000). Moreover, there is evidence that in AD, impaired 
synaptic vesicular trafficking, typically involving clathrin-mediated trafficking processes 
is impaired way before the structural deterioration in synapses (Yao, 2004). Lipid raft 
machinery was also noted to be sub-optimal in AD. It was proposed that the abnormal 
lipid raft composition can affect the transport of substrates and modify enzymes that 
cleave APP (Ferrer, 2009; Rushworth and Hooper, 2010). For example, high cholesterol 
has been demonstrated to increase the partitioning of APP, along with BACE1 and γ-
secretase components, into lipid rafts (Kosicek et al., 2010). In their excellent review 
Rushworth et al. (Rushworth and Hooper, 2010) describe the implication of lipid rafts in 
AD pathogenesis as they: (1) mediate APP processing (2) provide havens for Aβ 
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aggregation in the neuronal membranes; and (3) host specific neuronal receptors for 
toxicity (such as cellular prion protein) and signal transduction (such as glutamate 
receptor). Similar revelations for clathrin mediated endocytosis that is affected in the 
hippocampal neurons of AD brain (Granseth et al., 2006) have also been made.  
Therefore, we investigated the role of both clathrin and lipid-raft endocytic 
mechanisms in Aβ uptake. Using specific gene knockdowns with siRNAs, we 
demonstrated that the endocytosis of Aβ40 and not of Aβ42 is clathrin-mediated in 
hCMEC/D3 monolayers. With the perturbations in clathrin-mediated endocytosis 
observed in AD brain, the trafficking of Aβ40 could be impaired at the BBB. On the 
other hand, our studies demonstrate that Aβ42 most likely uses lipid rafts-mediated 
uptake at the BBB endothelium. This is intriguing that the two Aβ isoforms do not utilize 
the canonical clathrin-mediated machinery to the same extent. Pathophysiologically, this 
makes sense as Aβ42, which is regarded as a pathological isoform, accesses lipid raft-
mediated pathway; that is typically exploited by neurological toxins such as tetanus 
neurotoxin (Herreros et al., 2001) and botulinum neurotoxin (Petro et al., 2006). But 
Aβ40, which is considered as a physiologically relevant isoform, prefers the canonical 
clathrin-mediated pathway.  
These distinct uptake mechanisms of Aβ40 and Aβ42 preferentially utilizing clathrin 
and lipid-raft mediated endocytosis processes have been hypothetically depicted in 
Figure 3.8. Aβ binds to a canonical receptor (Step 1. Binding) and gets ready to 
internalize (Step 2. Budding). At the same time, depending on whether it is Aβ40 or 
Aβ42; the respective coat protein of clathrin or caveolin (in lipid-raft) is recruited at the 
membrane. Once the vesicle is fully formed, it is pinched off by dynamin (Step 3. 
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Scission). This is followed by multiple steps involving the revelation of the targeting 
peptide (such as SNARE, discussed in Chapter 5), that essentially decides the fate or 
target of the vesicle (Steps 4-6). Briefly, it includes exposing the vesicle in cytosol (Step 
4 Uncoating) so that it attaches to the cytoskeletal element (Step 5 Translocation) and 
finally tethers (Step 6 Tethering), docks (Step 7. Docking) to the target membrane to 
trigger exocytosis or fusion (Step 8 Fusion). These steps leading to exocytosis of the Aβ 
filled vesicles are going to be discussed in detail Chapter 5. Also, Rab proteins (family of 
small GTPases) assist in almost all of these cellular transcytosis steps.  
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Figure 3.8 Proposed vesicular transcytosis process of Aβ at the BBB endothelium 
Ab40 or Ab42 (1) binds to the receptor at the luminal side. The Ab40 is internalized 
predominantly via clathrin-mediated endocytosis. On the other hand, Ab42 is 
endocytosed via lipid-raft mediated endocytosis by recruiting caveolin. The membrane 
around the cargo-receptor complex then (2) begins to bud, form a vesicle, and recruit coat 
proteins as well as targeting peptides (SNAREs). (3) Then the vesicle is cleaved from the 
membrane by dynamin protein by scission process (4). The free vesicle in the cytosol is 
then uncoated to expose the targeting peptide. (5) The uncoated vesicle is then 
translocated onto the other side of the cell or the acceptor organelle by microtubular 
cytoskeletal elements. (6) The vesicle is attached or tethered to the abluminal membrane, 
by a tethering factor. This process usually employs Rab GTPases. (7) The tethered 
vesicle then docks at the abluminal side of the membrane and the v-SNARE or VAMP-2 
(targeting peptide on the vesicle) come close to the t-SNARE or SNAP-25 (targeting 
peptide on the target membrane) by a process called as docking. (8) Finally, VAMP-2 
and SNAP-25, along with another SNARE peptide, syntaxin (STX-1), coil around each 
other to form the SNARE complex and bring the two membranes close to each other, and 
eventually fuse to release the transported cargo. As shown, this entire vesicular transport 
apparatus is divided into endocytosis or uptake, cellular transit and exocytosis. Steps 6-8 
have been described in detail in Chapter 5.  
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In addition to the molecular evidence, we have also provided evidence that the 
kinetics of Aβ40 and Aβ42 uptake at the BBB endothelium are substantially different. 
The extent of L-A uptake is more than that of the A-L uptake for both Aβ isoforms, but 
the rate of Aβ40 uptake is greater than that of Aβ42 uptake, only in L-A direction. 
Although, there is no direct evidence that implicate L-A uptake in AD pathogenesis, it is 
interesting to note that the Aβ isoforms have different rates only in this direction. Further, 
the same trend was also seen in the BBME cellular monolayers, where the L-A 
permeability of Aβ42 was more than that in the A-L direction. In addition, on comparing 
with our previously published data of Aβ40 in the same cell model (Agyare et al., 2013); 
permeability of Aβ42 was found to be more than that of Aβ40, again, only in the L-A 
direction. The A-L permeability was similar. These findings further indicate that 
understanding the transcytosis of Aβ in the L-A direction or the plasma-to-brain direction 
may provide some revelations about BBB dysfunction that eventually leads to AD 
pathology.  
In summary, this is the first evidence that demonstrated the independent uptake of 
Aβ isoforms at the BBB. Earlier studies have claimed that Aβ40 and Aβ42 are 
internalized at the BBB via common transport system (Martel et al., 1996). However, our 
data suggests that although both Aβ40 and Aβ42 isoforms use receptor-mediated 
endocytosis, the endocytotic machineries they engage vary. The Aβ40 primarily uses 
clathrin, whereas Aβ42 uses lipid raft machinery to transcytose the BBB endothelium 
from the L-A side. Based on the extent to which these pathways are disrupted in AD, the 
dynamic equilibrium between plasma and brain Aβ42 and Aβ40 levels could be 
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differentially impacted, and this may be reflected as changes in Aβ42:Aβ40 ratios; as 
observed in AD patients.  
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CHAPTER FOUR 
 
4. ASSESSMENT OF AMYLOID BETA UPTAKE KINETICS AT THE BLOOD 
BRAIN BARRIER ENDOTHELIUM USING QUANTITATIVE MODELING 
4.1. SUMMARY 
Elucidation of amyloid beta (Aβ) interactions with the BBB endothelium is 
expected to provide clues to understand the role of BBB in maintaining the dynamic 
equilibrium between plasma and brain Aβ levels, and the trafficking perturbations leading 
to their accumulation as plaques in the brain in Alzheimer’s disease (AD). Traditional 
tissue uptake measurements for the brain may not offer detailed information on the binding 
and uptake of the Aβ at the BBB endothelium. However, dynamic brain imaging of 125I-Aβ 
tracer injected into the plasma by dynamic single photon emission computed tomography 
(SPECT-CT) enables quantitative estimation of initial binding as well as total uptake of Aβ 
into the BBB and subsequently into the brain parenchyma. In this work, brain (and BBB 
tissue) uptake observations from SPECT-CT and plasma from traditional PK measurements 
were used to employ pharmacokinetic modeling and graphical model plot approaches 
(Patlak and Logan plot) as tools to dissect the differential kinetics of Aβ isoforms at the 
BBB endothelium. Using these two independent approaches of (1) PK model with 
designated number of compartments, and (2) graphical model assuming no fixed number of 
compartments; we demonstrate that the rate of uptake of Aβ42 was more than that of Aβ40 
at the BBB endothelium as well as into the brain parenchyma. However, the extent of 
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uptake of Aβ40 into the BBB endothelium was more than that of Aβ42 that distributes 
relatively quickly into the brain parenchyma.   
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4.2. INTRODUCTION 
In Chapter Three, Aβ isoforms were shown to utilize distinct uptake mechanisms 
at the BBB endothelium. Aβ40 is primarily clathrin mediated, whereas Aβ42 employs 
lipid rafts to get into the endothelial cell. In this chapter, we elucidated differential 
kinetics of Aβ40 and Aβ42 uptake at the BBB endothelium. To accomplish such a task 
in-vivo via conventional methods could be fraught with artifacts associated with the 
quantification of protein of interest in the brain tissue. Therefore, we employed imaging 
techniques and quantitative modeling approaches to investigate the interactions of Aβ 
radiotracers with the BBB endothelium. 
Quantitative analysis of the initial uptake of Aβ in the brain is expected to 
delineate the differential interactions of Aβ isoforms with the BBB endothelium. 
Quantifying the radioactivity associated with brain as imaged by dynamic single photon 
emission computed tomography-computed tomography (SPECT-CT) provides an 
opportunity to capture the initial interactions of Aβ proteins with the BBB, which could 
be missed in steady state brain uptake measurements. Kinetic information of Aβ in the 
plasma pool is determined by measuring the radioactivity in plasma samples collected 
over time by gamma counter. In addition, to elucidate the trends in both plasma and brain 
(or BBB) pools simultaneously and predict the blood-to-brain transfer constants; two 
approaches: (1) pharmacokinetic compartment modeling; and (2) Patlak and Logan 
graphical-plot methods were employed. 
In the first approach, a three-compartment model was constructed using 
PhoenixWinNonlin® 6.4. The model equations were fitted to brain (SPECT-CT) and 
plasma (Gamma counter) observations simultaneously, and parameters were estimated.  
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In the second approach, theoretical models: (1) Patlak plot; and (2) Logan plot; 
were employed and the linear slopes, referred to as influx clearance (𝐾R) in Patlak plot 
and distribution volume (𝑉>) in Logan plot, were estimated. These commonly employed 
graphical methods to describe radiotracer kinetics allowed us to linearize the brain and 
plasma observations without making any assumptions about the number of 
compartments. The Patlak and Logan plots describe the kinetics of an irreversible or a 
reversible tracer, respectively. As explained in subsequent sections, initial interactions of 
Aβ with the BBB endothelium are reversible and then become irreversible as the probe 
enters the brain parenchyma.  
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4.3. MATERIALS AND METHODS 
4.3.1. DATA COLLECTION 
4.3.1.1. Aβ proteins synthesis, radioiodination and plasma pharmacokinetics 
The Aβ40 and Aβ42 were synthesized as described earlier (Kandimalla et al., 
2005) and monomers were prepared according to the procedure described by Klein (Klein 
et al., 2004). The Aβ proteins were radioiodinated and the plasma pharmacokinetic 
studies were conducted on 24-week old C57B6/SJL (WT) as described in the earlier 
chapters.  
4.3.1.2. Brain uptake studies using dynamic Single Photon Emission Computed 
Tomography- Computed Tomography (SPECT-CT) 
A 500 µCi dose of 125I-Aβ40 and 125I-Aβ42 was administered to 24-week-old WT 
mice. Brain uptake of 125I-Aβ was determined by dynamic planar imaging (Gamma Medica 
Ideas Pre-Clinical Imaging, Northridge, CA) using the low energy and high resolution 
parallel-hole collimator with 12.5 cm FOV; 13:36 min acquisition time; 64 projections (10 
sec per projection); and reported resolution of 1 to 2 µm. The CT acquisition was a 
continuous circular orbit with a 50 µm slice thickness; 256 images at 80 kVp with a 0.28 
mA current; and a reported resolution of 43 µm. Dynamic SPECT-CT images were 
processed and analyzed using Biomedical Image Quantification and Kinetic Modeling 
Software version 2.85 (PMOD Technologies, Switzerland).  
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4.3.2. DATA ANALYSIS 
4.3.2.1. Mathematical model for circulating Aβ-BBB interactions 
To evaluate the uptake of Aβ40 and Aβ42 at the BBB endothelium and subsequently 
into the brain, a quantitative mathematical model with three compartments was constructed. 
Compartment 1: Plasma or Central compartment; Compartment 2: Tissue compartment and 
Compartment 3: Blood brain barrier and brain compartment. The model (shown in Figure 
4.1) was based on the following assumptions: 
1. Uniform mixing in all the three compartments.  
2. Tissue compartment comprises of all the peripheral tissues and organs except the 
brain and BBB endothelium.  
3. Compartment 3 is a combination of BBB endothelium and brain. However, 
assuming that Aβ protein takes more than five minutes to enter the brain via the 
BBB endothelium, the brain radioactivity obtained from dynamic SPECT-CT 
imaging in the first five minutes was assumed to be associated with the BBB 
endothelium. This assumption is reasonable as (1) Aβ, a protein, primarily relies 
on transcytosis to get into the brain. Further, transcellular pathways or 
transcytosis processes usually require energy; and mostly, are relatively slower 
than passive diffusion (Alberts et al., 2002). Also, (2) initial linearity of Logan 
plot (Figure 4.7) (validated until 5 minutes) is lost at later times indicating that 
Ab is in the reversible compartment (BBB endothelium) initially, beyond which it 
most likely enters the irreversible compartment (brain). Based on this assumption, 
to elucidate the initial kinetics, the third compartment could be assumed as the 
BBB endothelium, thus, simplifying the model presented in Figure 4.1 B. 
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4. Elimination is strictly from the central compartment. In other words, the 
elimination from BBB and the tissue compartment is negligible when compared 
to the elimination from the central compartment.  
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A. 
 
 
 
 
B.  
 
 
 
 
 
Figure 4.1 Pharmacokinetic models describing amyloid beta interactions with brain 
at the BBB interface. (A) Model comprising of plasma, tissue, BBB and brain 
compartments along with their corresponding rate constants. The k40 is the elimination 
rate constant from the brain compartment, which describes the clearance processes other 
than the BBB clearance. As our assay was unable to resolve BBB and brain 
compartments separately, they are combined as one compartment (dashed box), thus 
reducing the model to a simpler model (B). The inherent assumption made in the data 
interpretation was that the first five minute kinetics describes the interactions of Ab 
proteins with solely the BBB endothelium.  
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4.3.2.1.1. Model description. 
Compartment 1: plasma and highly perfused tissues or central compartment; 
compartment 2: other peripheral organs and tissues; compartment 3: BBB endothelium; 
and compartment 4: brain. The rate constants describe: transfer from plasma to peripheral 
tissues (𝑘5c) and vice versa (𝑘c5); transfer between plasma and BBB endothelium (𝑘5[), 
and in the reverse direction (𝑘[5); and 𝑘[^ and 𝑘^[, are BBB endothelium-brain and 
brain-BBB endothelium transfer rate constants, respectively. The 𝑘56 denotes the 
elimination rate constant from the central compartment, whereas the 𝑘^6 describes Aβ 
elimination directly from the brain, which includes enzymatic degradation by proteases, 
phagocytosis by microglia and astrocytes, and/or perivascular clearance. It is assumed 
that the short time exposure (< 5 min) to the BBB endothelium is insufficient to attain 
detectable levels in the brain compartment. Hence, this model has been reduced to a 
simpler model depicted in Figure 4.1 B and compiled on PhoenixWinNonlin® 6.4. 
Finally, the model was run as a population using a naïve pooled method with an additive 
error model. Although, no additional information about the between subject variabillity 
(BSV) was obtained using this method, the degree of freedom allowed by the model, 
greater confidence in the predicted parameters. Such a compromise on BSV has been 
reported earlier to obtain accurate predictions for small sample sizes (Mahmood, 2012). 
Also, this approach allowed us to individually define doses administered to animals. The 
initial estimates for the fixed effect parameters (listed below) were provided for both 
Aβ40 and Aβ42; either based on the in-vitro uptake studies (𝑘5[ and 𝑘[5), or the 
pharmacokinetic parameters (𝑘5c, 𝑘c5, 𝑘56, 𝑉) predicted by curve-fitting the in-vivo 
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plasma data. Lastly, the model was allowed to converge based on the equations described 
below and the defined parameters were predicted. 
The 125I-Aβ was administered to the plasma compartment via intravenous (femoral) bolus 
injection. The initial conditions in various compartments were: 
 
																																									𝐶1dCO`C 					= 	𝐷𝑜𝑠𝑒𝑉 																																																																									(2) 																																							𝐶)ROOgP = 𝐶hhh = 0																																																																												(3) 
 
where, Dose refers to the total dose administered in mass or radioactivity µCi units, V 
stands for apparent volume of distribution in milliliters (mL), 𝐶1dCO`C, 𝐶)ROOgP and 𝐶hhh 
stand for concentration in plasma, tissue and BBB, respectively. After equilibration, there 
is dynamic transport of Aβ between the compartments as defined by the model. Thus, rate 
of change of Aβ concentration in the particular compartment becomes: 
 
																													𝑑𝐶1dCO`C	𝑑𝑡 = 	− 	𝑘56 + 	𝑘5[ + 	𝑘5c	 . 𝐶1dCO`C + 	𝑘c5	. 𝐶)ROOgP + 	𝑘[5. 𝐶hhh								(4) 
																																																		𝑑𝐶)ROOgP𝑑𝑡 = 	 𝑘5c	. 𝐶1dCO`C − 	𝑘c5. 𝐶)ROOgP																																															 5  
																																										𝑑𝐶hhh𝑑𝑡 = 	 𝑘5[	. 𝐶1dCO`C − 	𝑘[5. 𝐶hhh																																																														(6) 
 
Where,		F83nBopBF) , F8GqoorsF) , F8tttF)   depicts the rate of change of Aβ tracer concentration in 
plasma, tissue and BBB compartment, respectively.  
Various kinetic parameters were predicted by simultaneously fitting the model to 
plasma radioactivity (obtained from gamma counter and simulated to dose match 
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SPECT-CT) and brain tissue radioactivity (obtained from SPECT-CT imaging after 
removing the counts in the cerebral vasculature). To obtain the vascular contribution or 
counts in the cerebral vasculature, simulated plasma concentrations (SPECT-CT dose 
matched) were multiplied with average vascular volume obtained from 10 animals. 
Finally, the model fit was assessed by various goodness-of-fit criteria. (Appendix).  
4.3.2.2. Patlak and Logan Plots: Theoretical graphical methods to evaluate 
circulating Aβ transport into the brain via the BBB endothelium  
Graphical plot approaches such as Patlak and Logan take a rather simplistic 
approach to commonly employed linear models, such as the one described above. The 
idea is to linearize and convert the model equations into one equation evaluated at time 
points corresponding to the scanning times to provide fewer parameters- mostly a slope 
and an intercept. Specifically, these approaches describe a way to linearize the blood-to-
brain tissue distribution so that the slope of the line, influx clearance or 𝐾R  in Patlak plot 
(Patlak et al., 1983), and distribution volume or 𝑉> in Logan plot (Logan et al., 1990), can 
be compared between Ab isoforms. Mostly, blood-to-brain transfer is described by the 
following three parameters: (1) extraction fraction; (2) washout (efflux) parameter; and 
(3) 𝐾R  or influx clearance. It has been demonstrated that for solutes that cross the BBB 
slowly, 𝐾R is the only parameter that can be determined accurately. (Patlak et al., 1983; 
Patlak and Blasberg, 1985). Logan plot (Logan, 2003; Logan et al., 1990) also describes 
the same mechanism (entry into the tissue), but the ligand is expected to follow reversible 
kinetics for the duration of the experiment. 
4.3.2.2.1. Theory and assumptions of graphical model plots 
4.3.2.2.1.1.General blood-to-brain exchange model and Patlak plot 
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The Figure 4.2, describes the general, blood-to-brain exchange model. No 
assumption has been made about the time course of arterial concentrations or the 
particular arrangement and the number of compartments involved. However, it describes 
a set of compartments, probably in series, between the plasma and brain parenchyma. 
This final transfer is assumed to be at the BBB, which is unidirectional or irreversible, 
and the flux dominates the blood-to-brain distribution of the protein during the 
experiment. This assumption essentially means that for the time course of the experiment, 
there is greater influx than efflux of the substance into the brain. Although, it may not be 
entirely true physiologically, during the experiment, when there is a greater influx, the 
assumption is deemed to be valid. Moreover, this approach eliminates the need for a 
vascular marker or an intravascular distribution correction.  
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Figure 4.2 Blood- brain exchange model for theoretical graphical plot approaches. 
Reversible region of n compartments freely exchanges with plasma. Solute can enter the 
irreversible (brain) region but cannot leave. Patlak Plot describes the entry into the 
irreversible compartment (brain). Logan plot is used to describe the entry into the 
reversible compartment (BBB endothelium) Adapted from (Patlak et al., 1983).  
	
	
In this work, the theoretical model approach is used to assess: (1) brain uptake (obtained 
from dynamic SPECT-CT imaging), and (2) plasma pharmacokinetics (obtained after 
administered intravenous bolus injections of 125I-Ab). The following assumptions of the 
theoretical model have been considered: 
1. Plasma is the only source of the radiolabeled Ab (125I-Ab).  
2. The concentration of 125I-Ab in the plasma varies with time. 
3. The reversible compartment is the BBB endothelium, where a rapid exchange of 
125I-Ab between plasma and its receptors at the BBB is expected. However, once 
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125I-Ab enters the endothelial cell and subsequently the brain parenchyma, it is 
deemed irreversible.   
4. Brain parenchymal region is the irreversible compartment; once 125I-Ab enters the 
irreversible compartment, it does not come back into the plasma or BBB intact 
during the course of the experiment..  
5. The transfer within all these compartments obeys first order kinetics.  
6. There are no significant structural alterations or metabolism within the 
physiological compartments during the course of the experiment. If at all there is 
metabolism, the metabolites carrying 125I label predominantly gets trapped within 
the brain or the irreversible tissue only. 
7. There is no pre-existent radiolabeled 125I-Ab in the brain or BBB. And if there is, 
it follows the same tracer kinetics as the freshly injected tracer.  
The Patlak plot is generated by plotting 𝐴` 𝐶1 vs. 	 𝐶1𝑑𝜏)6 𝐶1. Slope becomes linear 
after time t > 𝑡v∗ . The 𝑡v∗  refers to the time after which the Patlak slope becomes linear, 
which is indicative of the time to attain pseudo equilibrium between the plasma and 
reversible (BBB) compartments. In our studies, as described below, this 𝑡v∗  is assumed to 
£ 5 minutes. The parameter of interest is the slope or 𝐾R,	also called as influx clearance or 
Patlak constant. The Patlak equation is represented as: 
																																			𝐴`GyG∗ = 	𝐾R 𝐶1𝑑𝜏)6 + 𝑉6 +	𝑉1 	𝐶1																																															 7  
where, 𝐴` = 𝑡𝑜𝑡𝑎𝑙	𝑎𝑚𝑜𝑢𝑛𝑡	𝑜𝑓	125I-Ab in the brain tissue, until time t 𝐶1 = 𝑝𝑙𝑎𝑠𝑚𝑎	𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛	𝑎𝑡	𝑡𝑖𝑚𝑒	𝑡 
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𝐶1𝑑𝜏)6 = 𝑝𝑙𝑎𝑠𝑚𝑎	𝐴𝑈𝐶	𝑢𝑛𝑡𝑖𝑙	𝑡𝑖𝑚𝑒	𝑡 𝐾R = 𝑖𝑛𝑓𝑙𝑢𝑥	𝑐𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒	 𝑉6 +	𝑉1 = 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡	 = 𝑡𝑜𝑡𝑎𝑙	𝑑𝑖𝑠𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛	𝑣𝑜𝑙𝑢𝑚𝑒	(VD) 
The 𝑉 is also called as, rapidly reversible volume (vascular volume + BBB complex + 
any other extravascular compartment in parallel with the BBB and rapidly exchanges 
with plasma), It should be noted that this distribution volume or rapidly reversible 
volume, theoretically defines the same distribution volume or 𝑉>, which is estimated by 
the slope of Logan plot. However, in theory, this 𝑉6, represents the ‘lower limit’ of the 
rapidly reversible volume (vascular compartment, BBB). In fact, V0 or the ordinate 
intercept obtained by extrapolating the linear portion of the Patlak slope is equal to or less 
than the apparent steady state distribution volume of Ab in all the reversible and 
exchangeable compartments, including blood space of the tissue. Therefore, the absolute 
value of 𝑉6 may be lower than that of 𝑉>, as is seen in our findings as well. However, this 
means that in these graphical method approaches, it is possible to predict the volume of 
distribution of vascular space without using a vascular marker. Another advantage is that 
there is no restriction on the number of compartments; hence, it is a compartment 
independent approach  
It was further elaborated in the earlier publications that expounded the theory of 
Patlak plots that this approach is not valid if the (1) biological state of the analyte is 
changed during the experiment, and (2) the animal model used is not reproducible from 
one subject to another. Also, non-specific binding is expected to influence the slope but 
not the intercept of the graphical plot.  
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Moreover, adhering to the model, the following conditions were ensured while 
calculating the slope parameter: 
1. Unidirectionality: The assumption of unidirectional transfer is satisfied by estimating 
the slope from the linear portion of the Patlak plot.  
2. Insignificant efflux: In the Patlak plot, if a concave trend is seen at t > 𝑡v∗ , then a 
significant back flux is suspected. However, Patlak made amendments to this notion 
by affirming that as long as the tracer, 125I-Ab in this case, is ‘nearly’ irreversibly 
bound, and the net influx is positive for an appreciable duration of time, the Patlak 
plot could still describe the uptake kinetics into the irreversible compartment (brain) 
Although, we did not see concavity indicating significant back flux in our Patlak 
plots, our compartmental model has shown that there could be some reversibility of 125I-
Ab interactions with the BBB, at least during the early phase. Therefore, we employed 
Patlak plots to determine the uptake rate constant into the irreversible compartment (brain 
parenchyma) after the distribution equilibrium has been reached and the Logan plots to 
capture the reversible interactions of 125I-Ab proteins with its receptors at the BBB 
endothelium. Accordingly, the initial kinetics (0-5 min) were considered as reversible 
(described the Logan Plot) and the 5-40 min data is assumed to describe irreversible 
uptake into the brain compartment (described by the Patlak Plot). This transition where 
Ab moves from reversible to irreversible compartment (BBB-brain) was quite evident in 
our results from longer time SPECT-CT measurements as the plot loses its linearity. In 
other words, Patlak and Logan plots describe different stages of the process; interactions 
of Ab proteins with receptors at the BBB endothelium is assumed to be reversible, 
whereas the uptake of Ab into brain was assumed to be irreversible. Hence, the slope of 
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the Logan plot provides an estimate of the distribution volume (𝑉>) of Ab proteins into 
the BBB endothelium. On the other hand, the slope of the Patlak plot provides an 
estimate of uptake (influx clearance, 𝐾R) into the brain parenchyma via the BBB 
endothelium.  
 
4.3.2.2.1.2.Logan plot theory 
Logan extended the theoretical foundation laid by Gjedde and Patlak to the 
reversible binding systems. Unlike the Patlak plot, the Logan plot does not assume 
irreversible trapping and assumes that the radiotracers injected have a rapid dissociation 
constant and a rapid efflux from tissue. Like with the Patlak plot, no particular model 
structure is assumed with the Logan plot.  The Logan equation is depicted below:  
                               
 ) F)GH ()) = 𝑉> .		 83F)GH()) +	b                                                    (8) 
and the Logan plot is generated by plotting 
																																																			  ) F)GH ()) 	𝑣𝑠.		 83F)GH()) 																																																																				(9) 
where,  𝑅𝑂𝐼(𝑡) = amount of 125I-Ab associated with the brain as measured by PET/SPECT in the 
region of interest or ROI until time t 𝑅𝑂𝐼	 𝑡 𝑑𝑡)6  = Brain AUC until time t 𝐶1= the concentration of tracer in the plasma until time t 𝐶1𝑑𝑡)6   = 𝑝𝑙𝑎𝑠𝑚𝑎	𝐴𝑈𝐶	𝑢𝑛𝑡𝑖𝑙	𝑡𝑖𝑚𝑒	𝑡 
VT = Slope of the linear equation, referred to as the distribution volume 
b = Intercept of the linear equation 
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The slope and intercept can be further elaborated mechanistically as per the model. This 
is discussed in the application section. (4.3.2.2.2.1.) 
It should be noted that, in Patlak plot (equation 7), normalizing term is the plasma 
concentration (Cp) in the denominator, whereas in Logan Plot, (equation 8), it is the brain 
(BBB tissue) amount or ROI(t). This also means that ‘linearity’ in the two plots hold 
different meanings. The linearity (constant slope) in the Logan plot is reached when the 
equilibrium (or pseudo equilibrium) between the plasma and BBB endothelium is 
attained (𝑡∗ or Lag time), and remains linear until the ligand is associated with BBB 
endothelium displaying reversible kinetics. When this linearity is lost, the reversibility 
assumption is no longer valid, and the ligand is assumed to enter the irreversible 
compartment or brain. The linear slope in the Patlak plot, reached at time 𝑡v∗ , refers to the 
equilibrium (or pseudo equilibrium) between the plasma and reversible compartment or 
BBB endothelium. However, depending upon several factors, including the ligand, 
measurement times and interval, it may be difficult to identify 𝑡v∗  and 𝑡∗ individually. 
Also, these times indicate the exposure time of the tissue that may not be the same as the 
measurement times, that is the time at which the measurement is taken.  
4.3.2.2.2. Application strategy for Logan and Patlak plots 
Dynamic SPECT-CT data from brain was assumed to follow reversible kinetics at 
the surface of the BBB, initially and then reach the irreversible compartment, brain 
parenchyma. Therefore, first five minutes (0-5 minutes) SPECT-CT data was used to 
construct the Logan plot and 5-40 minutes data was used to construct the Patlak plot. 
Plasma observations were simulated for individual animals and doses from the PK 
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profiles obtained earlier. The slope and intercept for both Logan and Patlak plots were 
obtained and assessed.  
4.3.2.2.2.1. Logan plot application  
Like previously described (Logan, 2003; Logan et al., 1990; Meyer and Ichise, 
2001), we assume two separate functional compartments (Figure 4.3), 125I-Ab is injected 
into the plasma compartment (concentration	𝐶1) and enters the BBB endothelium 
compartment via reversible interactions with the receptors at the luminal surface 
(amount	𝐶5).  
 
 
Figure 4.3. Logan model describing the reversible receptor-binding kinetics of Aβ at 
BBB endothelium.	Logan Plot analysis of two compartment model system describing the 
blood to BBB distribution of 125I-Aβ injected into the plasma compartment (	𝐶1) and 
enters the BBB endothelium (	𝐶5) (via receptors following reversible kinetics as per the 
transfer rate constants mentioned. 
	
	
Further, the 125I-Ab transfer between the compartments is described as follows: 𝐾5 = clearance (volume / time), representing 125 I-Ab entry into the tissue or BBB 
endothelium.  
!"#$ %$Plasma	 Tissue
(BBB	endothelium)(Plasma)
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 𝑘c = rate constant describing the efflux (time-1) of 125 I-Ab from the tissue or BBB 
endothelium.  𝜆 = partition coefficient between the plasma and tissue or BBB endothelium 
compartment. It is the ratio of 125 I-Ab in the tissue compartment to the plasma 
compartment at equilibrium, which is the ratio of 𝐾5/ 𝑘c. Units in volume.  
The use of radiolabeled tracers, 125 I-Ab, may help elucidating the kinetics without 
saturating the receptors. The linear slope and intercept from Logan Plot is then described 
as:   
 																																				𝑆𝑙𝑜𝑝𝑒	𝑜𝑟	𝑉> 		= 	𝜆 +	𝑉1																																																																		 10  																																	𝐼𝑛𝑡𝑒𝑟𝑐𝑒𝑝𝑡 = 	 '5(	5	3 	)                                                                (11) 
where, 𝑉1		 refers to the plasma volume in ROI (BBB endothelium). 
The Logan slope refers to the total distribution volume VT, which is the sum of partition 
coefficient and plasma volume. On the other hand, the x-intercept has units of time. 
Further, it should be noted that, 𝐾5/ 𝑘c.in Logan plot and k13/ k31 in the mathematical 
model refer to the same process, but they are not the same; 𝐾5/ 𝑘c.is the Logan slope, 
which has units of volume (VT), whereas k13/ k31 has no units. 
4.3.2.2.2.1. Patlak Plot application  
As described in one application of Patlak plot, Figure 4.4 (Logan, 2003; Logan et 
al., 1990; Meyer and Ichise, 2001), which is relevant for Ab kinetics, we assume two 
tissue compartments- BBB endothelium (reversible compartment,	𝐶5) and brain 
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(irreversible compartment, 𝐶c) and the plasma compartment (	𝐶1). The 125I-Ab was 
injected into the plasma compartment. 
	
 
Figure 4.4. Model for the application of Patlak plot describing irreversible uptake 
kinetics of 125I-Ab into the brain tissue via the BBB endothelium.	Patlak plot analysis 
of a three compartment model describing 125I-Ab distribution from blood (plasma) to 
brain tissue (via the BBB endothelium). The 125I-Ab is injected into the plasma 
compartment (𝐶1), enters the tissue compartment, which comprises of brain (𝐶c) and 
BBB endothelium(	𝐶5), as per the transfer rate constants outlined. 
 
The slope is thus described as: 
 																																															𝑆𝑙𝑜𝑝𝑒	𝑜𝑟	𝐾R = 7	7 = 	 7	7 																																															(10)  
Where, 𝐾5, 𝑘c	𝑎𝑛𝑑	𝑘[	are respective clearance, and transfer rate constants and 𝜆 = 	. 
However, Patlak plot can provide an estimate of slope or 𝐾R, which is a function of 𝜆. 
Direct estimation of 𝜆 is obtained as the slope in Logan plot (VT). Further 𝐾5is a function 
of blood flow. Although 𝜆 is not a function of blood flow, 𝐾R still depends upon blood 
flow and capillary permeability. Therefore, an increase or change in 𝐾R could be due to a 
change in binding or just the blood flow. While, 𝐾R by itself is unable to provide 
information about the receptor dynamics or ligand binding (𝜆), the Logan slope (VT) 
!"#$ !%&$ &"Plasma	 Tissue
(Brain	parenchyma)(BBB	endothelium)(Plasma)
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could provide the magnitude of ligand binding and interaction with receptors at the BBB 
interface. Hence, the distribution volumes (VT) obtained as the slopes of Logan plot were 
employed to assess differential interactions of 125I-Ab40 and 125I-Ab42 with the receptors 
at the BBB interface. On the other hand, their influx clearances (Ki) into brain, which 
were estimated by determining the slopes of Patlak plots, were also compared. 
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4.4.  RESULTS 
4.4.1. Mathematical model predicts a greater affinity of Aβ40 than Aβ42 at the 
BBB endothelium (Figure 4.5) 
 The quantitative model described in Figure 4.1 was simultaneously fitted to the 
plasma and dynamic-SPECT brain data of 125I-Aβ obtained in WT mice. The model 
equations adequately fitted the observed data points for brain and plasma profiles of 125I-
Aβ40 and 125I-Aβ42 (Figure 4.5). Comparison of the parameter estimates (Table 4.1) 
revealed statistically significant differences of plasma-tissue parameter estimates (k12, k21 
and k10) between in 125I-Aβ40 and 125I-Aβ42. Volume of distribution or V was predicted 
to be 3.1-fold greater for 125I-Aβ42 (16.47 ± 1.28 mL) than for 125I-Aβ40 (5.15 ± 0.37 
mL). The plasma PK profiles of 125I-Aβ40 and 125I-Aβ42 were also shown to be 
statistically significant. Also, parameter estimates describing the early plasma-brain 
interactions (k13 and k31) between 125I-Aβ40 and 125I-Aβ42 were found to be significantly 
different. As 125I-Aβ peptides are associated with the BBB endothelium for the first five 
minutes, the model predicts a lower value estimate of ‘on’ k13 rate constant, ‘off’ k31 rate 
constant and correspondingly, dissociation constant or ratio of k31 to k13, (i.e. k31/k13 or kd) 
for 125I-Aβ40 (k13 = 0.004 ± 0.0006 min-1, k31 = 0.43 ± 0.05 min-1 and k31/k13 = 107.5) 
than 125I-Aβ42 (k13 = 0.009 ± 0.001min-1, k31 = 3.2 ± 0.35 min-1 and k31/k13 = 355.5). 
Finally, the plasma-to-brain clearance (CL13), estimated as the product of k13 and V, for 
125I-Aβ42 (0.148 mL/min) was 7.4-fold greater than that of 125I-Aβ40 (0.02 mL/min). 
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Figure 4.5 Plasma and brain pharmacokinetics of 
125
I-Aβ40 and 
125
I-Aβ42 in 24-
week-old WT mice. Pharmacokinetic profile of (A) 
125
I-Aβ40 and (B) 
125
I-Aβ42 in 
plasma (open circles- observed values and dashed lines: predicted data) and brain (dark 
circles- observed values and solid lines: predicted data). Compartmental pharmacokinetic 
model depicted in Figure 4.1 was simultaneously fitted to plasma and brain data using 
PhoenixWinNonlin® 6.4.  
 
Table 4.1 The pharmacokinetic parameters predicted by the model for 
125
I-Aβ40 and 
125
I-
Aβ42 were presented as estimated value ± standard error. The statistical significance of 
the difference between 
125
I-Aβ40 and 
125
I-Aβ42 for each parameter was assessed by 
Student’s t-test (*p < 0.05, **p<0.01, ***p<0.001). 
  
 
 
  
130	
	
4.4.2. Logan plots predict a greater slope parameter for Aβ42 than Aβ40 at the 
BBB endothelium (Figure 4.6 and 4.7) 
The slope describing the distribution volume (VT) of 125I-Ab42 (55.78 ± 1.25 µL) 
is 1.4-fold greater than that of 25I-Ab40 (39.73 ± 0.07 µL) (Figure 4.6). The lag time (x-
intercept) of Ab40 (26.1 min) is more than that of Ab42 (9.15 min). Further, it is evident 
from the plot that the slope deviates from linearity at later times, which suggests that the 
assumption of reversible kinetics is no longer valid (Figure 4.7).  
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Figure 4.6 Logan plot describing the distribution volume of 
125
I-Aβ into the brain 
(BBB) from plasma in 24-week WT mice. Logan plots of 
125
I-Aβ40 (circle) and 
125
I-
Aβ42 (square). Estimates of distribution volume for 
125
I-Aβ40 and 
125
I-Aβ42 were 
obtained from the slopes (estimate ± standard error). Statistical significance was assessed 
by Student’s t-test (*p<0.05) 
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Figure 4.7 Logan plot describing the distribution volume of 
125
I-Aβ into the brain 
(BBB) from plasma in 24-week WT mice. (A) Logan plots of 
125
I-Aβ40 from 
measurements obtained until 5 minutes (filled circle) and separately, till 40 minutes (open 
circles). Slope parameter estimates (red: 5 minutes and green: 40 minutes) demonstrate 
the loss in linearity beyond 5 minutes such that Logan plot assumption is no longer valid. 
(estimate ± standard error).  
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4.4.3. Patlak plot predicts greater plasma-brain influx rate constant for Aβ42 than 
for Aβ40 (Figure 4.8) 
The Patlak plot estimated a 1.8-fold greater influx clearance (Ki or slope) into the 
brain for Aβ42 (3.3 ± 0.07 X 10-5 mL/min) than for Aβ40 (1.75 ± 0.03 X 10-5 mL/min) 
(***p<0.0001). Also, y-intercept, which is an estimate of the distribution volume of 
reversible compartment, was 5.3-fold larger for Aβ42 (29.92 ± 5.24 X 10-5 mL) than for 
Aβ40 (5.59 ± 3.4 X 10-5 mL). (**p<0.001) 
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Figure 4.8 Patlak plot describing the Aβ influx clearance into brain via the BBB in 
24-week WT mice. Solid circles represent
125
I-Aβ40, whereas solid squares represent 
125
I-
Aβ42. Slope parameter or Influx clearance (Ki) is presented as estimate ± standard error. 
Difference in the parameter estimates between 
125
I-Aβ40 and 
125
I-Aβ42 is statistically 
significant. Student’s t-test (**p<0.01 and ***p<0.0001). 
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4.5. DISCUSSION 
Imbalance in plasma and brain Ab levels could be due to perturbations in Ab 
trafficking at the BBB endothelium in AD brain (Erickson and Banks, 2013; Marques et 
al., 2013). These trafficking disturbances could be due to incompetency of the molecular 
players involved in Ab transcytosis at the BBB, which are reflected in aberrant Ab 
trafficking kinetics at the BBB, and the disposition of Ab proteins in plasma and brain 
compartments. Owing to the differential trafficking mechanisms shared by Ab40 and 
Ab42 at the BBB, the BBB trafficking perturbations could disproportionately affect 
Ab40 and Ab42, differentially alter their kinetics in plasma and brain compartments, and 
bring changes in Ab42:Ab40 ratios in AD progression.  
Bi-exponential disposition of Ab proteins in plasma have been previously described 
(Ghiso et al., 2004; Kandimalla et al., 2005; Qosa et al., 2014). In addition, a biphasic 
decline in brain Ab levels has been documented in APP,PS1 animals (Yuede et al., 2016) 
and humans (Cirrito et al., 2003). However, no direct comparison between the kinetics of 
the two main Ab isoforms, Ab40 and Ab42, has been made. This information will be 
critical to comprehend the physiological processes behind Ab42:Ab40 ratio that increases 
in brain and decreases in plasma during AD progression. Therefore, it is imperative to 
elucidate the distribution kinetics of these two isoforms separately.  
Impaired clearance and not overproduction was claimed to be primarily responsible 
for Ab accumulation in the brain (Mawuenyega et al., 2010). The clearances of Ab40 and 
Ab42 in AD patients compared to non-demented individuals of similar age were found to 
be respectively 0.72- and 0.69- fold lower (Mawuenyega et al., 2010). However, to our 
understanding, no investigations on the plasma-to-brain influx kinetics of Ab40 and 
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Ab42 have been conducted so far. As the transport of Ab isoforms at the BBB 
endothelium is bidirectional and interdependent (Eisele et al., 2014; Hamaguchi et al., 
2012), it is critical to investigate the contributions of both these processes to brain 
amyloid burden and AD progression.  
The objective of the work presented in this chapter was to compare the kinetics of 
Aβ40 and Aβ42 uptake at the BBB endothelium, and subsequently into the brain 
parenchyma. The plasma-to-brain uptake kinetics was expected to resolve the association 
between plasma Ab levels (luminal exposure) and AD progression. Owing to the lower 
concentrations compared to the brain, plasma Ab may not directly enhance the brain 
amyloid burden. However, chronic exposure of BBB to luminal Ab could disrupt the 
critical signaling/trafficking pathways at the BBB, and diminish the ability of the BBB to 
efflux brain Ab proteins. We believe that Ab40 and Ab42 differentially affect the BBB 
function; hence, their kinetics at the BBB, which could affect their luminal and abluminal 
prevalence, should be carefully elucidated.  
Furthermore, conventional methodologies of measuring radiolabeled Ab post 
intravenous or intracerebral injections using steady state measurements (Shibata et al., 
2000) or microdialysis (Cirrito et al., 2003) would not be able to dissect the immediate 
changes at BBB endothelium. Hence, dynamic SPECT-CT imaging techniques were 
employed to resolve differential interactions of Ab proteins with the BBB endothelium 
and their subsequent transcytosis into the brain. However, SPECT-CT brain imaging does 
not distinguish the uptake of 125I-Aβ peptides into the BBB endothelium versus the brain 
parenchyma. Therefore, initial interactions of 125I-Aβ peptides with the BBB endothelium 
were elucidated by investigating kinetic changes in the brain-associated radioactivity 
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during the first five minutes following intravenous administration. The Logan plots for 0-
5 minutes assumes that up to 5 minutes, Aβ interactions with the BBB endothelium are 
still reversible. This assumption is reasonable as Aβ peptides have low permeability at the 
BBB. Moreover, the linearity of the Logan plot is lost at later time points, which is likely 
due to the entry of the tracer into the irreversible compartment, mostly the brain 
parenchyma. Hence, we employed Patlak plots to predict influx clearance into the 
irreversible compartment, beyond 5 minutes.  
Further, to eliminate the radioactivity dose differences between the PK 
experiments and SPECT-CT imaging, plasma observations were individually simulated 
for the corresponding SPECT-CT dose. This enabled us to curve-fit plasma and brain 
observations simultaneously to predict and compare 125I-Aβ40 and 125I-Aβ42 kinetics in 
plasma and brain compartments. Also, to eliminate the contribution of radioactivity in the 
circulation to the total brain activity, the radioactivity counts in the plasma were 
subtracted from the total brain SPECT-CT counts. This enabled us to fit the precise brain 
‘tissue’ (parenchyma) observations in the model. As explained earlier, graphical model 
approaches, Patlak and Logan plot did not need any such adjustment. Finally, although 
two different instruments (gamma counter and SPECT-CT) were used to measure 
radioactivity in plasma and brain respectively, no conversion factor was employed. This 
was justified as the instrument conversion factor, a constant scaling factor, is expected to 
have equal contribution to both 125I-Aβ40 and 125I-Aβ42 kinetics, and hence would not 
alter relative differences in kinetic parameters of the peptides.  
The proposed PK model predicted significant differences in the kinetics of 125I-
Aβ40 and 125I-Aβ42 in plasma and brain compartments. The differences in predicted 
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transfer rate constants between the plasma and tissue (peripheral tissue and brain) verified 
the possibility of different plasma PK profiles of 125I-Aβ40 and 125I-Aβ42 presented in 
Chapter Two. The greater k13 for 125I-Aβ42 than for 125I-Aβ40 indicated the possibility 
that the rate of influx of 125I-Aβ42 is more than that of 125I-Aβ40. Also, CL13 (influx 
clearance, that was assessed as a product of k13 and V), was greater for 125I-Aβ42 than 
125I-Aβ40. This is also confirmed by the higher Patlak influx rate (Ki) for 125I-Aβ42 than 
for 125I-Aβ40. While the Patlak plot describes the net clearance into the BBB endothelium 
and beyond, into the brain parenchyma, no distinctions could be drawn between influx 
and efflux rate constants from the Patlak plot.  The PK model predicted higher k31 for 
125I-Aβ42 than for 125I-Aβ40. Also, the ratio of k31 to k13 (k31/k13), more commonly 
designated as the dissociation constant or kd, was greater for 125I-Aβ42 than 125I-Aβ40. 
These results indicate that the affinity of 125I-Aβ40 to the receptors at the BBB 
endothelium could be higher than that of 125I-Aβ42. This result is not surprising as Ab40 
was demonstrated to have greater affinity for the putative Aβ receptors, LRP1 and 
possibly for RAGE (Deane et al., 2009, 2004, 2012), than Aβ42. However, the luminal 
uptake of F-Aβ42 was significantly greater than that of F-Aβ40.These model predictions 
are also confirmed by the studies conducted in hCMEC/D3 cell monolayers in-vitro 
(Chapter Three, Figure 3.3). It is important to note that the greater endothelial uptake of 
125I-Aβ40 over 125I-Aβ42, does not translate into higher rates of transcytosis. We 
postulate that the following factors may contribute towards this finding: (1) affinity: 
macromolecules with only optimal affinities could be transcytosed and translate to higher 
permeability across the cellular barriers. (Thomas, 2000). That is, macromolecules with 
considerably high affinity to the endothelium may get bound or stuck onto the 
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endothelium and do not enter the parenchyma altogether, or experience a significant 
delay in their internalization. Therefore, it is possible that the higher affinity of Ab40 
may indeed reduce its ability to trancytose across the BBB. (2) ineffective exocytosis: Our 
earlier publication had demonstrated that a vasculotropic mutant form of Ab40, Dutch-
Ab40, accumulates more in the cerebral vasculature than Ab40 by inhibiting its own 
exocytosis (Agyare et al., 2013). Therefore it is possible that Ab40, which is more 
vasculotropic than Ab42 accumulates in the BBB endothelium by inhibiting its own 
exocytosis, and demonstrate lower translocation into the brain parenchyma.  
The slope of the Logan plot, which represents distribution volume (VT), was 
greater for Ab42 than for Ab40. This may indicate the greater receptor occupancy of 
Ab42 on the BBB endothelium compared to that of Ab40. These results, support the PK 
model predictions of greater affinity, but lower extent of uptake of Ab40 than Ab42 at 
the BBB endothelium. Further, this is also supported by 𝑡∗, (x-intercept) values from 
Logan plot, where, Ab42, equilibrates faster (shorter lag time) and begins to distribute 
quickly, whereas Ab40, with its greater affinity, takes longer (longer lag time) to 
equilibrate. Higher distribution volume for Ab42 compared to Ab40 has also been 
predicted by the Patlak Plot. As can be deduced from the Equation 7, y-intercept of the 
Patlak plot refers to the distribution volume within the reversible compartments, 
including the BBB endothelial surface.  
The Patlak plot predicts greater slope, which represents greater influx clearance 
(or transcytosis) into the irreversible compartment (brain), for Ab42 than for Ab40. This 
is in line with the Logan plot trends as well. The Logan slope (VT) and Patlak slope (Ki), 
represent two distinct parameters. Greater VT of Aβ42 than Aβ40 suggests more 
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distribution into the BBB endothelium and beyond, whereas, greater Ki of Aβ42 than 
Aβ40 suggests greater rate of transcytosis (clearance) into the brain of Aβ42 compared to 
Aβ40. Moreover, CL13, plasma-to-BBB influx clearance calculated using the predictions 
from the PK model, was higher for Ab42 than Ab40. These observations indicate the 
clearance of Ab42 into the BBB endothelium, as well as into the brain parenchyma, is 
greater than that of Ab40. These observations contradict the earlier findings of BBB 
permeability measurements in 24-week old WT animals presented in Chapter Two, 
Figure 2.3 that demonstrated that permeability surface area product or PS value of Ab42 
is 0.78-fold lower than that of Ab40. The PS values measured in those studies estimated 
the steady state brain permeability 15 minutes after 125I-Ab injection in plasma, followed 
by harvesting the total brain tissue and measuring the radioactivity counts in gamma 
counter. Therefore, it may be possible that these PS values primarily measure endothelial 
cell accumulation and not the brain parenchyma. In such a case, PS value of Ab40 could 
be more than that of Ab42, due to its greater tendency to accumulate at the endothelium, 
as observed in this Chapter by multiple approaches.  
In summary, the quantitative models predict that Ab40 has greater affinity (lower 
kd) to the BBB endothelium than Ab42. However, Ab42 exhibits higher permeability 
across the BBB endothelium based on the higher slope value in Patlak Plot. This is also 
supported by the larger volume of distribution of Ab42 than Ab40 predicted by Logan 
plot. On the other hand, Ab40 tends to stay into the BBB endothelium longer. These 
model predictions help us to infer that Aβ40 may accumulate in the BBB endothelium 
and is unable to transcytose as efficiently as Aβ42. This prolonged stay, probably, 
enables it to interfere with the intra-endothelial trafficking apparatus; and subsequently, 
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result in disrupted trafficking or the impaired Aβ clearance at the BBB endothelium, 
which is observed during AD progression. One such interference with the SNARE 
exocytosis assembly, which could possibly explain the lower transcytosis and greater 
BBB accumulation of Ab40 than Ab42, will be elaborated in the subsequent chapter 
(Chapter Five). 	
	  
142	
	
CHAPTER FIVE 
 
5. AMYLOID BETA INTERFERES WITH SNARE MEDIATED VESICULAR 
FUSION PROCESSES 
5.1. SUMMARY 
SNARE (Soluble NSF Attachment protein Receptor, where NSF stands for N-ethyl–
maleimide-sensitive fusion protein) mediated vesicular fusion processes have been 
implicated in Alzheimer’s disease (AD). However, the causal association between 
SNARE dysfunction and AD pathogenesis has not been clearly elucidated. Amyloid beta 
(Aβ) proteins accumulate as amyloid plaques in the brain, which is most likely due to 
impaired clearance of Aβ peptides. Earlier studies have claimed that vesicular exocytosis 
perturbations could be responsible for the impaired exocytosis of Aβ proteins at the BBB, 
which is one of the primary portals that clear Aβ from brain. Further, synaptic function 
has also been known to be disrupted in AD, which eventually triggers cognitive 
disabilities. In this chapter, using sophisticated microscopic techniques of fluorescence 
resonance energy transfer (FRET) followed by fluorescence lifetime imaging microscopy 
(FLIM), we demonstrate that Aβ directly interferes with the interactions between two 
SNARE proteins: vesicle associated membrane protein (VAMP-2) and synaptosomal 
associated protein of 25 kDa (SNAP-25). Moreover, we also provide preliminary 
evidence that VAMP-2 is also involved in Aβ exocytosis. Hence, our findings suggest 
that Aβ may interfere with its own exocytosis as well as the exocytosis of several 
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biomolecules, including transferrin and insulin at the BBB endothelium, in addition to 
causing synaptic dysfunction in neurons.   
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5.2. INTRODUCTION 
Synaptic vesicle recycling- the process of neurotransmitter exocytosis from small 
round vesicles into the synaptic cleft and retrieval of the components involved in the 
process- is one of the best controlled processes in cell biology (Rizzoli, 2014). Therefore, 
interference at any step of this process could lead to deleterious pathophysiological 
consequences. Similarly, vesicular transcytosis involving the intracellular delivery of 
cargo molecules from the donor organelle or cell to the specific receiver compartment- is 
a highly monitored event, critical for cell survival. Although the precise mechanisms 
involved in intracellular trafficking are still an enigma to biologists, all vesicular 
transport processes can be described by these four steps: (1) budding or formation of the 
vesicle from the plasma membrane; (2) movement of vesicles towards the acceptor 
compartment by diffusion or propelled by microtubular motors along the cytoskeletal 
tracks; (3) tethering, or attachment of the vesicle to the acceptor plasma membrane; and 
lastly (4) fusion or exocytosis.  
The exocytosis, an integral step in transcytosis as well as in synaptic fusion, shares 
similar cellular organization involving SNARE exocytosis assembly that brings the 
vesicular membrane closer to the plasma membrane, and facilitate their fusion to release 
the vesicular cargo to the extracellular space (Cai et al., 2007). This process is 
accomplished by two sister SNARE assembly proteins- the vesicular SNARE (v-
SNARE) and the target SNARE (t-SNARE). The v-SNARE is located on the vesicular 
membrane, and the t-SNARE is located on the plasma membrane or on the membrane of 
a target organelle. During exocytosis, the v- and t-SNAREs interact and facilitate the 
fusion of both membranes by utilizing the energy that is released during the formation of 
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a four-helix bundle of corresponding SNARE proteins, right before exocytosis. The 
formation of this bundle leads to a tight connection at the fusion site. After the exocytosis 
is accomplished, the helical SNARE complex is uncoiled, and the dissociated SNAREs 
are recycled. The energy required for this complex operation is supplied by the ATPase 
activity of NSF. Strategic subcellular localization that imparts specificity to membrane 
fusion events and the ability to form stable complex to facilitate membrane fusion, make 
SNAREs, the fundamental fusion factors (Duman and Forte, 2003). 
For vesicular docking and fusion events with the plasma membrane, a vesicle protein 
such as, synaptobrevin or vesicle-associated membrane protein (VAMP-2), and two 
plasma membrane proteins- syntaxin and synaptosomal associated protein of 25 kDa 
(SNAP-25)- come close together and are tightly assembled into a complex. Then, SNAP 
and NSF are involved in the disassembly process, which involves the recovery of VAMP-
2 with the vesicular membrane and retaining of syntaxin as well as SNAP-25 on the 
plasma membrane. These will then be available for fusion with newly docked vesicles 
(Chen et al., 2001; Degtyar et al., 2013). Although SNARE proteins have been 
demonstrated to carry out the fusion process themselves, the sudden fusion events after 
an action potential requires calcium, that binds to C2 domain of synaptotagmin, which 
eventually interacts with SNARE proteins to accelerate the fusion process (Tucker et al., 
2004). Though, the precise events in this membrane fusion process are not fully known, it 
is believed that the N terminals of VAMP-2, syntaxin and SNAP-25, come together to 
form a tight coiled helical SNARE complex, whereas the C terminals are embedded in 
their respective membranes (Degtyar et al., 2013) (Figure 5.1). 
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Figure 5.1 Synaptic vesicular exocytosis process by SNAREs assembly and 
disassembly. Synaptobrevin (VAMP-2) interacts with SNAP-25 and Syntaxin to zip the 
two membranes together by forming a SNARE complex to trigger exocytosis or fusion. 
After fusion, N-ethylmaleimide-sensitive fusion protein (NSF) and soluble NSF-
attachment proteins (SNAPs) disassemble the core complexes that remain on the same 
membrane to recycle them for another round of fusion. Reused after permission.(Rizo 
and Südhof, 2002)  
 
We hypothesize that disruptions in SNARE machinery at the BBB endothelium 
affect Ab transcytosis, and consequently Ab clearance at the BBB in AD brain. 
Moreover, synaptic neurotransmission has been known to be disrupted in AD. However, 
the precise mechanistic understanding of these disrupted processes has not been 
elucidated. In addition, several links between SNAREs and AD pathology have been 
proposed in the literature. Recently, the formation of SNARE complexes was shown to 
be substantially reduced in postmortem brains of AD patients (Sharma et al., 2012). Also, 
aberration in SNARE complex formation could lead to cognitive defects (Corradini et al., 
2009; Honer et al., 2002), that might be triggered by misfolded proteins (Choi et al., 
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2015, 2013). It was also shown that a reduction in presynaptic SNARE protein 
interactions, between SNAP-25 and syntaxin, were directly associated with AD 
pathology (Honer et al., 2012)  as well as in the Lewy-Body Variant of AD (Mukaetova-
Ladinska et al., 2009). Moreover, the expression of snyaptobrevin (VAMP-2) is 
significantly decreased in all AD brain regions (Sze et al., 2000). The VAMP-2 interacts 
with calmodulin and regulates calcium dependent exocytosis (Quetglas et al., 2002). It is 
further known that calcium signaling is affected in AD. However, the role of SNARE 
machinery in Ab transcytosis at the BBB and the mechanistic link between impaired 
SNARE assemblies and amyloid accumulation in AD brain in not clearly established.  
The amyloidogenic and toxic Ab42 was shown to affect neurotransmitter release by 
disrupting the interaction between synaptophysin and VAMP-2 (Russell et al., 2012). 
Synaptophysin (p 38) is another SNARE protein that directly binds to (Calakos and 
Scheller, 1994) and assists in targeting (Pennuto et al., 2003) of VAMP-2. Their 
interaction is known to be upregrulated during neuronal development, and Ab has been 
shown to interfere with it (Russell et al., 2012). Moreover, Ab, along with a-synuclein, 
the protein that accumulates in Parkinson’s brain, have been demonstrated to block 
SNARE dependent vesicular fusion (Choi et al., 2015). Furthermore, it was shown that 
Ab is capable of directly binding to Syntaxin1a and impairing SNARE mediated 
exocytosis (Yang et al., 2015). While, interference with any of these processes may affect 
the exocytosis of vesicular contents, the experimental evidence is lacking.  
In this work, we provide direct evidence that Ab inhibits the functional interactions 
between VAMP-2 and SNAP-25 at neuronal membranes using sophisticated microscopy 
tools of fluorescent resonance imaging microscopy (FRET), followed by fluorescent 
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lifetime imaging microscopy (FLIM). Moreover, we also demonstrate that Ab may use 
this machinery to exocytose itself from the cell; and consequently inhibits its own 
exocytosis. Finally, we also provide preliminary evidence that this mechanism is 
common to vesicular exocytosis in neurons as well as the transcytosis at the BBB. This 
commonality provides mechanistic link between the impaired clearance of Ab, due to 
perturbation of vesicular transcytosis at BBB endothelium, and synaptic dysfunction in 
AD.  
5.2.1. Theory of Fluorescence resonance energy transfer (FRET) fluorescence 
lifetime imaging microscopy (FLIM) 
Foster Resonance Energy Transfer, is a process by which a fluorophore (donor) in 
its excited state transfers some of its energy to a neighboring molecule (acceptor) by non-
radiative dipole-dipole interaction (Berney and Danuser, 2003; Förster, 2012; Piston and 
Kremers, 2007). If the acceptor is also a fluorophore, the process is also referred to as 
Fluorescence Resonance Energy Transfer (FRET). During the steady state intensity based 
FRET microscopy, two different approaches could be used to capture the energy transfer: 
(1) Emission measurement: Donor is excited and the decrease in donor emission or the 
increase in acceptor emission is measured. (2) Acceptor photobleaching: Donor is excited 
and its emission is captured before and after the photobleaching of the acceptor. To better 
understand the theoretical concept of FRET-FLIM measurements; the simplified version 
of the Jablonski diagram has been reviewed below.  
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Figure 5.2 Simplified version of Jablonski diagram illustrating the concept of 
fluorescence and the two decay processes for the decaying fluorophore from the lowest 
vibrational state of the excited state. Modified from Chang et al., 2007. 
 
The S0 represents the ground state and S1 represents the first excited state. 
Horizontal lines depict the different vibrational states of the fluorophore (Becker, 2010; 
Becker et al., 2006; Chang et al., 2007). After exposure to the designated wavelength 
light, the fluorophore is excited and then rapidly relaxes to the lowest vibrational state 
within the excited state. From that point, the fluorophore could return to the ground state 
via one of the two decay processes: non radiative decay (k) or radiative decay (G). 
Radiative decay is responsible for the fluorescence emission, which is dependent on the 
electronic properties of the isolated fluorophore. On the other hand, non-radiative decay 
is expected to be dependent on the local dynamic environment of the fluorophore, such 
as, its interactions with other fluorophores or quenchers in the FRET system. Hence, 
either of the two processes- radiative decay (or changes in fluorescence intensity) or non-
radiative decay (or changes in fluorescence lifetime) are capable of depopulating or 
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decreasing the number of fluorophores in the lowest vibrational excited state (Lakowicz, 
2006). 
This situation can be described mathematically by the following equation: 
 
																																									𝑑𝑁(𝑡)𝑑𝑡 = − 𝛤 + 𝑘 𝑁 𝑡 																																																									(1 
 
where,  
F())F) = decay rate of the fluorescence emission intensity 𝛤 = non-radiative decay rate 𝑘 =	radiative decay rate 𝑁 𝑡 	= total decaying population of the fluorphores 
The decay rate of the fluorescence emission intensity is proportional to the total decaying 
population of the fluorophores and is attributed to both decay processes. It can be re-
written in its exponential form: 
 																																													𝑁 𝑡 = 𝑁𝑒'()) = 𝑁𝑒')/																																																(2)  
                                                                𝜏 = 	 5 																																																																(3) 
where,  𝑁 = initial number of fluorescent molecules in first excited state 𝜏 = fluorescence lifetime, where 𝜏	is the inverse of the sum of two decay rates. 
The 𝜏 is refered to as the fluorescence lifetime, and is defined as the average time 
a molecule spends in the excited state prior to returning to the ground state. This lifetime 
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(𝜏) is determined in the FLIM studies. Expectedly, FRET leads to a change in the 
fluorescence emission of the donor by changing the radiative decay rate. This brings 
changes in the lifetime of the donor, which are captured in fluorescent lifetime imaging 
microscopy or FLIM.  
In the microscopy field, fluorescence property can be assessed by either of the 
two ways described in equation 2: (i) steady state fluorescence microscopy (SSFM) also 
called as intensity based measurements, which measures 𝑁 𝑡 ; and (ii) fluorescence 
lifetime imaging microscopy that measures the lifetime property 𝜏. Interestingly, these 
two analytical measurements differ in their sensitivities and the information provided. 
Intensity based measurements, that are more commonly employed, measure the total 
intensity of the fluorophore. It provides information about the cell morphology, 
intracellular content, but is sensitive to a variety of things such as the source intensity, 
detector gain settings, optical loss sample, variation in sample fluorophore concentration, 
photobleaching, microscope focusing, and spectral overlap. On the other hand, FLIM 
measures the lifetime property of the fluorophore. This essentially tells how rapidly the 
fluorophore decays, which is an intrinsic property of the fluorophore, and unlike 
intensity, does not change with the amount of fluorophore. The FLIM provides spatially 
resolved images of fluorophore lifetimes that are actually sensitive to the local 
environment of the fluorophore, and is totally independent of all the factors described 
earlier that influence the intensity.  
In FRET, there is a pair of fluorophores, the donor (cyan fluorescent protein or 
CFP) and the acceptor (yellow fluorescent protein or YFP). The emission of the donor 
overlaps with the excitation of the acceptor. As a result, there is transfer of energy from 
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the donor to the acceptor. Before FRET, the two fluorophores are separate; on exciting 
CFP, only CFP will emit. However, when the CFP-YFP are close to each other and CFP 
is excited, some energy gets transferred from CFP to YFP, thereby exciting YFP. 
Consequently, YFP can also emit now. However, this is a very sensitive phenomenon that 
can happen only if all the three FRET conditions are met: (1) spectral overlap- emission 
of donor overlaps with the excitation of acceptor; (2) distance between donor and 
acceptor is less than 10 nm- this property is exploited in several FRET experiments to 
image interacting organelles in live cells; and (3) orientation of the two fluorophores 
should be optimal to facilitate the transfer (Broussard et al., 2013)..  
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5.3. MATERIALS AND METHODS 
5.3.1. Vectors, cell culture and transfections 
The plasmid mCer-4aa-VAMP2 (Addgene plasmid #53233) and its corresponding 
FRET partner mCit-4aa-SNAP25B (Addgene plasmid # 53235) were obtained as a gift 
from Robert Zucker (Department of Molecular and Cellular Biology, University of 
California at Berkeley). Neuroblastoma 2a (N2A) cells were cultured in Dulbecco’s 
modified Eagle’s medium supplemented with 10 % fetal bovine serum (FBS) and 1 % 
penicillin-streptomycin, and maintained at 37 °C in 5 % (v/v) CO2 and 95% (v/v) air. The 
hCMEC/D3 cells were cultured in supplemented EBM-3 medium, as described earlier in 
Chapter 3. Either cells were grown on coverslip-bottom culture dishes (MatTek 
Corporation, MA). After 3 days, cells were transfected overnight with mCer-4aa-VAMP2 
or Cer-VAMP2 (donor only), mCit-4aa-SNAP25B or Cit-SNAP25 (acceptor only), or 
both (mCer-4aa-VAMP2:mCit-4aa-SNAP25B in the ratio of 1:1) using Effectene 
transfection reagent (Qiagen) as per the manufacturer’s protocol. The total DNA amount 
used was 1 µg and was kept the same for all dishes. Following day, the culture medium 
was replaced and the cells were allowed to recover from the transfection. While the 
hCMEC/D3 cells were imaged directly, the N2A cells were differentiated by incubating 
them with differentiating medium (DMEM supplemented with 1 % FBS and 0.2 mM 
retinoic acid), 24 hours before the experiment. The differentiation was confirmed by 
visual examination of cells and formation of dendrites and neurites.  
Fifteen minutes before the experiment, the cells were replaced with Krebs-Ringer 
bicarbonate buffer (115 mM NaCl, 5 mM KCl, 24 mM NaHCO3, 2.5 mM CaCl2, 1 mM 
MgCl2, 10 mM HEPES pH 7.4 and 0.1% BSA). All FRET-FLIM imaging experiments 
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were conducted at normal (unstimulated exocytosis) and high potassium (stimulated 
exocytosis) conditions. After image acquisition under normal potassium levels, the KCl 
concentration was raised to 55 mM by spiking the medium with 100 µL of concentrated 
KCl solution. Cells were imaged immediately following the high potassium stimulation. 
The FM dye (FMÒ 4-64, Invitrogen) was used to track the exocytosis.  
5.3.2. Confocal laser scanning microscopy and image analysis 
All FRET and FLIM experiments were performed at the University of Minnesota 
imaging center (Minneapolis, MN). The constructs mCer-4aa-VAMP2 and mCit-4aa-
SNAP25B served as FRET donor and acceptor, respectively. The donor lifetime of mCer-
4aa-VAMP2 was measured in FLIM studies. FRET intensity experiments were 
performed on transfected live cells an Olympus FluoView FV1000 IX2 Inverted 
Confocal microscope with FLIM detector, and the image acquisition settings are 
described below. Data acquisition was performed using a 512 X 512-pixel image size, 
using a PLAPON 60X O NA1:42 objective lens. Separate fluorescence emission channels 
were collected simultaneously in three different sequential phases at 2.5X zoom.  
Table 5.1 Image acquisition settings in FRET intensity experiments 
Sequential 
phases Simultaneous channels 
PMT 
Voltage Excitation Emission 
Instrument 
settings 
Phase 1 Channel 1 
(CFP/YFP/FRET, exciting 
CerVAMP2 and capturing 
CerVAMP2) 
600V 405 nm 475 nm 
BF position 
(460 nm) and 
BF range  
(40 nm) 
Channel 2 
(CFP/YFP/FRET, exciting 
CerVAMP2 and capturing 
FRET or CitSNAP25) 
360 V 405 nm 0 nm, mirror 
BF position 
(515 nm) and 
BF range  
(100 nm) 
Phase 2 Channel 3 (FM 4-64, 
exciting FM Dye and 
capturing FM Dye) 660 V 488 nm 
0 nm, 
mirror 
BF position 
(610 nm), and 
BF range  
(100 nm). 
Phase 3 Channel 4 (ECFP, exciting 600 V 405 nm 475 nm BF position 
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CerVAMP2 and capturing 
CerVAMP2) 
(460 nm) and 
BF range  
(40 nm) 
Channel 5 (EYFP, exciting 
CitSNAP25 and capturing 
CitSNAP25) 360 V 515 nm 
0 nm, 
mirror 
BF position 
(530 nm) and 
BF range  
(100 nm). 
 
Spectrum separation was kept ‘on’ throughout the image acquisition. Acquired 
images were viewed and were processed using FIJI ImageJ 1.50i software (Wayne 
Rasband, National Institutes of Health, USA).  
5.3.2.1. Intensity image processing 
 The confocal intensity images were obtained in all different channels as described 
above and were processed individually to account for the following: (1) the bleed over 
from the Channel 1 (Cerulean) into Channel 2 (FRET channel); (2) original donor 
intensity in Channel 1 (Cerulean), that will indirectly impact the intensity in Channel 2 
(FRET channel). The functional FRET interactions between the Cer-VAMP2 and Cit-
SNAP25 are expected to happen at the site of exocytosis on the plasma membrane, 
Hence, using the band and mask tool, the region of interest (ROI) was defined to measure 
the intensity of just the membrane, and not the complete cell. This was done as follows.  
Step I: Estimation of channel bleed-over using Cer-VAMP2 only. In the cells transfected 
with Cer-VAMP2, intensity in Channel 1 ( 𝐼5) and FRET Channel or Channel 2 ( 𝐼c) were 
measured. Since, there was no acceptor or Cit-SNAP25 in this system, the intensity in the 
FRET channel (Channel 2) was considered as the bleed over. Quantitatively, the bleed 
over factor is defined as,  
 																																																				𝐵𝑙𝑒𝑒𝑑	𝑜𝑣𝑒𝑟	𝑓𝑎𝑐𝑡𝑜𝑟 = 	 𝐼c 𝐼5																																												(4)	 
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where, 𝐼c	= intensity of Channel 2 (FRET channel) in donor only (Cer-VAMP2) system.  𝐼5= intensity of Channel 1 (Cerulean channel) in donor only (Cer-VAMP2) system.  
Step 2: FRET channel intensity correction using dual transfection or Cer-VAMP2 and 
Cit-SNAP25 or FRET systems. In the dual transfection systems, Corrected FRET after 
removing the bleed over is calculated as follows. Intensity in Channel 1 ( 𝐼[) and FRET 
Channel or Channel 2 ( 𝐼 ) is measured. Corrected FRET is then calculated as, 
 
																																				𝐶𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑	𝐹𝑅𝐸𝑇 = 	 𝐼 −		 𝐼c𝐼5 ∗ 	 𝐼[ 																			 5  
 
where, 𝐼  = intensity of Channel 2 (FRET channel) in double transfected FRET control 
system 𝐼[ = intensity of Channel 1 (Cerulean channel) in double transfected FRET control 
system.  
Thus, corrected FRET image was constructed by the software and its intensity 𝐼 was 
measured.  
Step 3: Calculate the effective transfer ratio (ETR) in treated and untreated FRET 
systems. As the magnitude of FRET is inherently dependent on the original intensity in 
Channel 1 (Cerulean channel), the ETR was calculated as, 
 
																																															𝐸𝑇𝑅 = 	 𝐼𝐼[ 																										(6) 
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The final ETR image was software-constructed and color-coded as shown. Finally, the 
intensity 𝐼	 of the constructed ETR image was measured and plotted as mean intensity.  
 
Schematically, these steps are explained by the following pictographic:  
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5.3.3. TCSPC-FLIM acquisition and analysis 
 Time-correlated single-photon counting (TCSPC) measurements were made 
under 800-820 nm two photon excitation (TPE), which efficiently excited cerulean, 
without any detectable direct excitation or emission from citrine. We used a time domain 
system that pulsed lasers at 405 nm with a Hybrid GaAsP cathode detector with emission 
filter setups of 480/30nm band pass for CFP emission.  
Off-line FLIM data analysis was performed using SPCImage software (Becker & 
Hickl). The fluorescence was assumed to be a multiexponential (monoexponential decay 
for Cer-VAMP2 only systems and biexponential for dual transfected FRET systems). In 
addition, binning and threshold was kept constant at 3 and 5 respectively. The ROI was 
adjusted to limit the analysis of the functional interactions occurring at the membrane 
from the intensity window and subsequent color-coded spatial lifetime image 
(distribution of life time in space) and frequency histogram was obtained after calculating 
the decay matrix. The mean lifetime in the ROI at the membrane, 𝜏`	was estimated from 
the software (± SD). Also, as vesicle fusion reactions do not happen at all places on the 
membrane, n=30 distinct fusion processes (pixels) on the membrane were compared in a 
total of five independent cells (n=5) (image acquisitions) and precise 𝜏`at that pixel was 
measured. The fusion processes were selected using the FM dye exocytosis as the 
reference. Finally, the median lifetimes of control (Cer-VAMP2 and FRET) and 
treatments were compared in the scatter plot. Every point of interest was selected from 
the intensity (and not lifetime) window to avoid bias. Further, mean photon counts of 102-
103 and c2 values less than 2.5 was maintained as a selection criteria for every fusion 
process (point of interest). Model was confirmed to fit the data well by checking for the 
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random distribution of weighted residuals around zero. Finally, the FRET efficiency is 
calculated as: 																																																												𝐸 = 	1 −	 𝜏` ?	𝜏`¡¢£¢¤		 																													(7) 
 
Where,		𝐸 = FRET efficiency, 𝜏` ?	= mean lifetime of Cer-VAMP2 in a FRET 
system (N2A cells transfected with Cer-VAMP2 and Cit-SNAP25), and 𝜏`¡¢£¢¤		= mean 
lifetime of Cer-VAMP2 in a donor only system (N2A cells transfected with Cer-VAMP2 
only).  
5.3.4. Fixed cell microscopy and cellular imaging 
  Normal (untransfected) or transfected N2A cells or primary cultured neurons were 
grown on cover slip bottom dishes and were treated with 3.1 µM of F-Aβ40, F-Aβ42 or 
F-Dutch Aβ40 for 60 min followed by 20 µg/mL of AF633-TRF for 30 min. In TeNT 
experiments, the cells were pretreated with TeNT for 60 min followed by F-Aβ treatment. 
Cells were then washed with PBS and nuclei were stained with Hoechst Dye (0.5 µg/mL 
in PBS) for 5 min. Lastly, the dishes were fixed in 4 % para-formaldehyde (PFA) at 4 °C 
for 60 min, mounted with ProLong® gold antifade reagent (Life technologies, OR) and 
dried overnight before imaging by laser confocal microscopy.  
5.3.5. Permeability across the BBB endothelium 
  Polarized hCMEC/D3 cellular monolayer was incubated with 125I-Aβ40 or 125I-
Aβ42 in tracer amounts on either luminal or on the abluminal side. Multiple samples 
were taken from the contralateral chamber (receiver compartment containing the blank 
medium) till 90 min to assess radioactivity transcytosed across the BBB endothelium. 
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Flux of 125I-Aβ across the BBB endothelium was calculated as the slope of cumulative 
amount of 125I-Aβ accumulating in the receiver chamber versus time. The apparent 
permeability coefficients were calculated by normalizing the flux with the initial 
concentration of 125I-Aβ protein added to the donor chamber and the surface area of the 
Transwell® filter used. This permeability coefficient, expressed as cm/min was compared 
in L-A and A-L directions. In the TeNT treatments, the monolayers were pretreated with 
TeNT for 60 min prior to adding 125I-Aβ.  
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5.4. RESULTS 
5.4.1. Ab decreases the effective FRET transfer between Cer-VAMP2 and Cit-
SNAP25 in differentiated N2A cells (Figure 5.3)  
Representative images from the confocal microscopy demonstrate decrease in 
functional FRET interactions between Cer-VAMP2 and Cit-SNAP25 in N2A cells 
pretreated with Ab40 (Figure 5.3.1-3.2 C), Ab42 (Figure 5.3.1-3.2 D) for 24 h, and 
TeNT (Figure 5.3.1-3.2 E) for 1 h in comparison to the FRET control system (Figure 
5.3.1-3.2 B). The measured FRET intensity (yellow) in control cells after bleed-over 
correction (Figure 5.3.1 B) is greater than that of the negative control- Cer-VAMP2 only 
system (Figure 5.3.1 A), and when cells are pretreated with Ab40 (Figure 5.3.1 C), 
Ab42 (Figure 5.3.1 D) and TeNT (Figure 5.3.1 E). This is more evident in the software 
constructed effective transfer ratio images, where the membranes in dual transfected cells 
pretreated with Ab40 (Figure 5.3.2 C), Ab42 (Figure 5.3.2 D) and TeNT (Figure 5.3.1 
E) are mostly blue, which represents low effective FRET or ETR, and closer to the donor 
Cer-VAMP2 system (Figure 5.3.2 A), than that of dual transfected control cells (Figure 
5.3.2 B). Further, this decrease is demonstrated semi-quantitatively (Figure 5.3.3) by 
comparing the mean values of the membrane intensity or effective FRET transfer in 
images from Figure 5.3.2.  
Further, the cerulean and the uncorrected FRET channel are presented in 
Supplementary figure S-5.1 without LUT adjustment. Moreover, the red fluorescence 
intensity due to FM dye exocytosis (Supplementary figure S-5.2) confirms the presence 
of active exocytosis within these cells. Also, images from Phase 3: independent cerulean 
and citrine channel, validate the transfection of Cer-VAMP2 and Cit-SNAP25 
166	
	
(Supplementary figure S-5.2) in all the treated system; confirm that decrease in FRET is 
not due to poor transfection but due to the interference with the FRET interaction. The 
same trend is also seen when exocytosis is stimulated at high potassium condition 
(Supplementary figure S-5.3)  
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Figure 5.3.1 Representative corrected intensity images capturing FRET in 
transfected N2A cells A-E Images obtained by exciting cerulean and capturing citrine 
(FRET) in cells transfected with either (A) Cer-VAMP2 only or (B-E) Cer-VAMP2 and 
Cit-SNAP25. Demonstrated FRET intensity is corrected for cerulean channel bleed over 
by software. A-B Considerable FRET is seen at the membrane in (B) dual transfected 
cells or FRET (positive control), in comparison to (A) negative control cerulean-only 
transfected cell. C-E FRET intensity images in dual transfected cells pretreated with (C) 
Aβ40; (D) Aβ42; and (E) TeNT.  
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Figure 5.3.2 Representative effective FRET transfer ratio images in transfected N2A 
cells A-E Software constructed images of corrected FRET (Fig 5.3.1) normalized to the 
donor intensity (Cerulean channel, Supplementary S-5.1) in cells transfected with either 
(A) Cer-VAMP2 only or (B-E) Cer-VAMP2 and Cit-SNAP25. Images demonstrate the 
effective FRET transfer per donor intensity; color coded from dark blue (least FRET 
transfer per donor intensity) to white (maximum FRET transfer per donor intensity). A-B 
At the plasma membrane, considerable effective FRET transfer per donor intensity is 
seen in (B) dual transfected cells [FRET (positive control)], in comparison to (A) 
negative control (cerulean-only transfected cell). C-E Effective FRET transfer ratio 
images in dual transfected cells pretreated with (C) Aβ40; (D) Aβ42; and (E) TeNT.  
169	
	
 
 
Figure 5.3.3 Quantitative plot of effective FRET transfer ratios of membrane 
intensities represented in Figure 5.3.2 Data demonstrates effective FRET transfer ratio 
or corrected FRET normalized to the donor (cerulean channel) intensity measured only at 
membrane using mask tool in Fiji software. Bars represent mean effective transfer ratio 
(ETR) intensity at the membrane.  
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5.4.2. Ab isoforms increase donor lifetime and decrease functional FRET efficiency 
between Cer-VAMP2 and Cit-SNAP25 in differentiated N2A cells (Figure 5.4) 
Spatial lifetime images and spectral frequency histograms demonstrate an increase 
in donor lifetime and a decrease in the FRET efficiency between Cer-VAMP2 and Cit-
SNAP25 in N2A cells pretreated with Ab40 (Figure 5.4.1 C), Ab42 (Figure 5.4.1 D) for 
24 h, or with TeNT (Figure 5.4.1 E) for 1 h, compared to the FRET controls (Figure 
5.4.1 B). Lifetime increased with rightwards shift into blue range in cells treated with 
Ab40, as observed in spatial image and frequency histogram (Figure 5.4.1 C). Similar 
effects were also observed with treatments with Ab42 (Figure 5.4.1 D), and TeNT 
(Figure 5.4.1 E). The goodness of multi-exponential model fit is verified by the random 
distribution of residuals (Supplementary figure S.5.4). Significant increase in the tm of 
FRET system (~2000 ps), pretreated with Ab40 (~2600 ps), Ab42 (~2600 ps) and TeNT 
(~2400 ps) showed the decrease in the corresponding FRET and the FRET efficiency 
from ~ 20% to 2-10%. This is demonstrated in the cumulative table of software projected 
tm values, and their ranges (Table 5.2, Figure 5.4), as well as tm lifetime and FRET 
efficiency measurements from the actual 30 vesicular fusion events (Figure 5.4.2). As 
can be seen, the increase in tm lifetime and the decrease in FRET efficiency is 
irrespective of mono-exponential (Figure 5.4.2) or bi-exponential model fit 
(Supplementary figure 5.4.6) The same trend is also seen when exocytosis is stimulated 
by exposing N2A cells to high potassium condition (Supplementary figure S-5.5).  
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Figure 5.4.1 Spatial lifetime images of donor (cerulean) lifetime and corresponding 
frequency histograms in transfected N2A cells. A-E Spatial lifetime images and 
frequency histograms obtained by measuring lifetime of cerulean (donor) by Time 
Correlated Single Photon Counting (TSCPC) in cells transfected with either (A) Cer-
VAMP2 only or (B-E) Cer-VAMP2 and Cit-SNAP25. Histogram represents lifetime 
frequency at the plasma membrane. A-B Lifetime decreases from the blue range in (A) 
negative control cerulean-only transfected cell to yellow range in (B) dual transfected 
cells or FRET (positive control).C-E In the presence of (C) Aβ40; (D) Aβ42; and (E) 
TeNT; donor lifetime increases back from yellow to blue range . Color code represents 
lifetime from 2000 (red) to 2700 (blue) picoseconds. Table 5-2 shows changes in donor 
(cerulean) lifetime as estimated by B&H software for the membrane ROI in picoseconds 
(range) 
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Figure 5.4.2 Lifetime measurements and corresponding FRET efficiency of 
functional vesicular fusion events in N2A cells. Changes in (A) 𝜏`PC¥	or mean lifetime 
of donor (cerulean) and (B) FRET efficiency in cells transfected with cer-VAMP2 only 
(Cer-VAMP2 control) or both Cer-VAMP2 and Cit-SNAP25 (FRET) that are pretreated 
with Aβ40, Aβ42 or TeNT. Over 30-40 functional vesicular fusion processes at the 
plasma membrane are estimated using FM dye image as the reference. Data represented 
as scatter dot plot of individual measurements as well as the median. Significance 
determined using One-Way ANOVA followed by Dunnett’s Post Test (*** p<0.001).  
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5.4.3. Ab isoforms increase donor lifetime and decrease FRET between Cer-
VAMP2 and Cit-SNAP25 in polarized hCMEC/D3 cells (Figure 5.5) 
Similar to N2A cells, spatial lifetime images and spectral frequency histograms 
demonstrate an increase in donor lifetime and a decrease in the FRET efficiency between 
Cer-VAMP2 and Cit-SNAP25 in hCMEC/D3 cells pretreated with Ab40 (Figure 5.5.1 
C), Ab42 (Figure 5.5.1 D) for 24 h, or with TeNT (Figure 5.5.1 E) for 1 h, compared to 
the FRET controls (Figure 5.5.1 B). Lifetime increased with rightwards shift into blue 
range in cells treated with Ab40, as observed in spatial image and frequency histogram 
(Figure 5.5.1 C). Similar effects were also observed with treatments with Ab42 (Figure 
5.5.1 D), and TeNT (Figure 5.5.1 E). The goodness of multi-exponential model fit is 
verified by the random distribution of residuals (Supplementary figure S-5.6). This 
increase in lifetime and corresponding decrease in FRET is demonstrated in the 
cumulative table of software projected tm values, and its range (Table 5-3, Figure 5.5). 
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Figure 5.5 Spatial lifetime images of donor (cerulean) lifetime and corresponding 
frequency histograms in transfected hCMEC/D3 Cells. A-E Spatial lifetime images 
and frequency histograms obtained by measuring lifetime of cerulean (donor) by TCSPC 
in cells transfected with either (A) Cer-VAMP2 only or (B-E) Cer-VAMP2 and cit-
SNAP25. Histogram represents lifetime frequency at the plasma membrane surface. A-B 
Lifetime decreases from the blue (low donor life time) in (A) negative control cerulean-
only transfected cell to yellow (higher donor life time) in (B) dual transfected cells or 
FRET (positive control). C-E In the presence of (C) Aβ40; (D) Aβ42; and (E) TeNT; 
donor lifetime increases from yellow to blue range. Color code represents lifetime from 
2000 (red) to 2700 (blue) picoseconds. Table 5.3. shows changes in donor (cerulean) 
lifetime as estimated by B&H software for the membrane ROI. 
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5.4.4. Ab isoforms directly inhibit endogenous VAMP2 in differentiated N2A Cells 
(Figure 5.6) 
Western-blots demonstrated a time dependent decrease of VAMP2 in differentiated 
N2A cells after treatment with Ab40, Ab42 and mutant DutchAb40. Quantitative 
estimation with the loading control (GAPDH) demonstrated a 50 % decrease in VAMP2 
expression by 24 h.  
 
 
Figure 5.6 Western blots of endogenous VAMP-2 expression in treated N2A cells. A-
B. Aβ isoforms (Aβ40 and Aβ42) and mutant Dutch-Aβ40 cleave endogenous VAMP-2 
in a time dependent manner. TeNT is used as a control to cleave VAMP-2 at shorter time 
points. The quantification of (A) VAMP-2 band intensity and endogenous loading control 
GAPDH is represented as (B) fold changes in various treatments. 
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5.4.5. Ab isoforms colocalize with VAMP2 in differentiated N2A Cells (Figure 5.7) 
Representative images of fixed N2A cells that were transfected with Cer-VAMP2 
and treated with F-Ab (green) demonstrated colocalizion of Cer-VAMP2 (red) with F-
Ab40 (Figure 5.7 (a)) and F-Ab42 (Figure 5.7 (b)). Moreover, this colocalization 
increases, which appears as more yellow puncta, when the cells are pretreated with 
TeNT, in case of F-Ab40 (Figure 5.7 (c)) as well as F-Ab42 (Fig 5.7 (d)).  
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Figure 5.7 Colocalization of Cer-VAMP2 and Aβ isoforms in N2A cells. A-B. Increase 
in the co-localization (denoted by the yellow color) of F-Aβ40 (green), with Cer-VAMP2 
(red) when cells are pretreated with (B) tetanus toxin (TeNT) in comparison to (A) 
control cells. C-D. Increase in the co-localization of F-Aβ42 (green), with Cer-VAMP2 
(red) when cells are pretreated with (D) tetanus toxin (TeNT) in comparison to (C) 
control. The box area is zoomed in the inset.  
 
  
178	
	
5.4.6. TeNT pretreatment increases the accumulation of Ab proteins in primary 
neurons (Figure 5.8). 
 Representative images of primary neurons pretreated with TeNT followed by F-Ab 
(green) and AF633-TRF (red). The accumulation of F-Ab40 and AF633-TRF increased 
after pretreatment with TeNT (Figure 5.8 (b)) in comparison to the control (Figure 5.8 
(a)). Also, the uptake of F-DutchAb40, a vasculotropic mutant form of Ab40, and 
AF633-TRF increased after pretreatment with TeNT (Figure 5.8 (d)) in comparison to 
the control (Figure 5.8 (c)). 
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Figure 5.8 Representative images of primary neuronal cultures treated with Aβ 
proteins following VAMP-2 disruption by TeNT. A-B. Accumulation of F-Aβ40 
(green) and AF633-TRF (red) increases when cells are pretreated with (B) TeNT in 
comparison to (A) control cells. C-D Accumulation of a mutant form, F-DutchAβ40 
(green), and AF633-TRF (red) increases when cells are pretreated with (D) TeNT in 
comparison to (C) control cells The box area is zoomed in the inlet.  
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5.4.7. TeNT pretreatment reduces the luminal to abluminal (L-A) permeability of 
Ab proteins across BBB endothelium  (Figure 5.9) 
 The permeability of 125I-Ab across the polarized monolayer of hCMEC/D3 cells 
grown on TranswellÒ filters, decreased significantly if the cells were pretreated with 
TeNT in the luminal to abluminal (L-A direction). No change was seen in the abluminal 
to luminal (A-L) direction.  
 
 
 
Figure 5.9 Permeability of Aβ isoforms across the polarized hCMEC/D3 cell 
monolayers after inhibiting VAMP-2 by TeNT. The hCMEC/D3 cells grown on 
Transwell® filter were treated with 125I-Aβ proteins on either luminal or abluminal side. 
Permeability is measured as described in either luminal to abluminal (L-A) or abluminal 
to luminal (A-L) direction. A-B Impairing VAMP-2 by TeNT decreases the permeability 
of (A) Aβ40 and (B) Aβ42 only from L-A direction. Significance is determined by 
Student’s t-test (*p<0.05) 
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5.5. DISCUSSION 
Cognitive decline in AD patients has been linked to the synaptic dysfunction in 
hippocampus and cortex (Huang and Mucke, 2012; Sheng et al., 2012), two brain regions 
that are known to be affected in AD. Bioinformatics analysis from our lab that compared 
gene expression of 161 AD patient brains with age matched non-demented individuals 
demonstrated downregulation of SNARE assembly and VAMP-2. (Supplementary figure 
S-5.8). The clinical manifestations of these deficits are temporarily alleviated by 
acetylcholine esterase inhibitors. However, this indirect way of stimulating the neuronal 
synapses is just a symptomatic relief, and does not intervene with the disease progression.  
Involvement of toxic Ab proteins in AD pathogenesis has been reasonably well 
established. Previous publications from our lab have shown that Ab protein is transported 
in ‘vesicles’ across the BBB endothelium, and the vesicular transcytosis is most likely 
disrupted in AD (Agyare et al., 2013). Obviously, this constitutive vesicular transcytotic 
process, which includes endocytosis, cellular transit and exocytosis is not unique for Ab, 
but could also affect the trafficking of other biomolecules.  
It has been shown that that the molecular mediators in SNARE exocytosis overlap 
between neurons and epithelial cells (Coco et al., 1999; Hong, 2005; Proux-Gillardeaux 
et al., 2005; Steegmaier et al., 2000), the same could be true between neurons and BBB 
endothelial cells. . For example, VAMP-2 is involved in L-A transport and VAMP-7 and 
VAMP-8 are involved in A-L transport (Fields et al., 2007; Proux-Gillardeaux et al., 
2005). Although, in epithelial cells, VAMP-2 was shown to interact with SNAP-23 
instead of SNAP-25, the two are supposed to be quite similar in structure and 
function(Low et al., 1998; Russell J. Diefenbach et al., 2002) 
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Based on these evidences that suggest direct or indirect links between SNARE 
assembly and AD pathology, two questions have been addressed in the study outlined in 
this chapter. (1) what is the effect of Ab on the fusion between VAMP-2 and SNAP-25 in 
neurons? (2) does Ab employ similar apparatus (VAMP-2 and SNAP-25) to exocytose 
from neurons and BBB endothelial cells?  
To address the first question, established FRET-pair constructs of Cer-VAMP2 and 
Cit-SNAP25 have been employed. The effect of Ab isoforms on the FRET between Cer-
VAMP2 and Cit-SNAP25 was investigated using: (1) simple intensity based confocal 
microscopy, and (2) fluorescence lifetime based microscopy (FLIM). These two 
sequential measurements on the same sample provided a powerful tool to not only detect 
the changes in FRET interactions qualitatively, but also quantitatively. Further, several 
controls such as: multichannel-simultaneous followed by multiphase-sequential 
measurements; bleed over correction in intensity measurements and binning; threshold 
correction; multicomponent analysis and model-fit validation in lifetime measurements 
were employed to avoid artifacts. Moreover, the studies were conducted in both 
hCMEC/D3 cells (BBB model), and in differentiated mouse neuroblastoma (N2A) cells 
that have been used earlier to study SNARE interactions. (Medine et al., 2007). 
The FRET-FLIM studies outlined in this chapter have clearly indicated that Ab 
could directly interfere with the fusion of VAMP-2 and SNAP-25. We demonstrated 
FRET interaction between Cer-VAMP2 and Cit-SNAP25, using both intensity and 
lifetime approaches, decreased in the presence of Ab40 and Ab40. The N2A cells, a 
neuronal cell line, was expected to demonstrate exocytosis process more profoundly than 
hCMEC/D3 cells, a BBB endothelium model, simply because of their developmental 
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biology and functioning at synapses. Therefore, the relatively lower intensities in 
hCMEC/D3 cells in comparison to N2A cells was not surprising. Further, as changes in 
lifetime are sensitive to the environment and not affected by the intensity of the 
fluorophore, only spectral lifetime measurements were employed in hCMEC/D3 cells to 
avoid artifact due to weaker intensity signals. Due to its established ability to cleave 
VAMP-2 (Chen et al., 2008), tetanus neurotoxin (TeNT) was used as a positive control in 
our experiments. Further, to make sure that only functional fusion events were considered 
for analysis, only the FRET on the plasma membrane was evaluated, and the FMÒ 4-64 
dye was used to specifically locate these exocytosis events. The same trend was seen with 
the exocytosis stimulated with high potassium. (Supplementary section, Figure S-5.5). 
Apart from the functional FRET interactions at the membrane, we also observed the 
substantial presence of orphan SNARE complexes (FRET interactions) in the cytosol, 
which were also reported by several other investigators (Degtyar et al., 2013; Gaffield 
and Betz, 2006). Although we did not employ syntaxin-1 (the third SNARE peptide in the 
helical complex) in our measurements as our goal was to investigate the final fusion step 
between VAMP-2 and SNAP-25, the syntaxin-1a normally expressed in the cell was 
assumed to participate in the formation of the SNARE complex. Our study could not 
resolve if change in the FRET intensity was due to Ab binding to syntaxin (Yang et al., 
2015), SNAP-25 (Honer et al., 2012), VAMP-2 (Choi et al., 2015) or synaptophysin 
(Russell et al., 2012). But, our data certainly shows that the final event of exocytosis 
where the SNARE complex formed among VAMP-2, SNAP-25 and the constitutive 
syntaxin is inhibited. This finding explains the lower number of functional SNARE 
complexes as observed in the AD brain (Sharma et al., 2012).  
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Next, to address the second question, we used fixed-cell confocal microscopy, 
western blot experiments and BBB permeability studies. Tetanus neurotoxin (TeNT) that 
cleaves VAMP-2 was employed as a positive control. The colocalization studies in N2A 
cells clearly demonstrated that Ab isoforms colocalize with VAMP-2 and therefore are 
capable of perturbing VAMP-2 function. This might also suggest that Ab utilizes VAMP-
2 for its own exocytosis. Therefore, when VAMP-2 is made unavailable, by cleaving with 
TeNT, the Ab colocalization with VAMP-2 increases. Further, as VAMP-2 was 
externally transfected in these experiments, rather than the substantial differences in the 
expression of VAMP-2, changes in its function was observed. To confirm this trend, we 
used a different model, primary neurons as well. As expected, a significant increase in the 
accumulation of Ab40 and Dutch-Ab40 (cerebrovascular mutant of Ab40) was seen after 
TeNT treatment was used to inhibit VAMP-2 function. Further, our western blot study 
clearly demonstrated that Ab was capable of cleaving VAMP-2 in a time dependent 
manner. This difference was not very apparent in the cells that overexpress VAMP-2.  
Finally, the permeability studies conducted using polarized hCMEC/D3 cell 
monolayer grown on TranswellÒ filters clearly demonstrated a decrease in Ab 
permeability upon TeNT exposure; but only in the luminal to abluminal (L-A) direction. 
VAMP-2 has been known to be involved in just L-A transport, whereas VAMP-7 and 
VAMP-8 are involved in A-L transport. (Chen et al., 2001; Fields et al., 2007; Proux-
Gillardeaux et al., 2005; Steegmaier et al., 2000). Moreover, TeNT specifically cleaves 
VAMP-2. It could be suggested from these results that, L-A transport of Ab is most 
likely disrupted due to VAMP-2 perturbations in AD. This idea was further supported by 
a separate pharmacokinetic simulation model as well. Moreover, VAMP-2 and SNAP-25 
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have been recently shown to be involved in not just exocytosis but also clathrin 
dependent endocytosis (Zhang et al., 2013)- a process- that Ab40 uses to get internalized 
by the BBB endothelium. Since, permeability quantifies the entire transcytosis process 
involving endocytosis, cellular transit, and exocytosis, our study would not be able to 
dissect the perturbations caused to VAMP-2 mediated exocytosis or endocytosis that 
decrease Ab permeability. However, as in N2A cells, we saw an increase and not a 
decrease in Ab accumulation; most likely it is the exocytosis of Ab, that is mediated by 
VAMP-2.In neurons, VAMP-2 is essential for fast exocytosis of neurotransmitters release 
and rapid endocytosis (Deák et al., 2004). This idea that AD is a disease of vesicular 
transport system is not new (Suzuki, 2006), but instead of just impaired trafficking of 
APP (Groemer et al., 2011), that will indirectly affect the production of Ab, there might 
be issues with the transcytosis of Ab itself.  
In summary, our work demonstrates that Ab interferes with the vesicular fusion step 
between two SNARE proteins,VAMP-2 and SNAP-25, in neurons, and most likely at the 
BBB endothelium. Further, Ab uses this apparatus for vesicular exocytosis in neurons 
and transcytosis at the BBB endothelium. This finding provides a mechanistic 
understanding towards impaired Ab clearance, which involves transcytosis at the BBB 
endothelium, and disrupted synaptic transmission in AD. Furthermore, impairment in 
these processes may also explain the dysregulated trafficking of other biomolecules such 
as insulin and transferrin in an AD brain.  
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CHAPTER SIX 
 
6. CONCLUDING REMARKS AND FUTURE DIRECTIONS 
6.1. Concluding remarks 
Unlike diseases where the therapeutic challenge is to make the drug available in right 
concentrations to the right location, AD field is still struggling with deciphering the basic 
pathogenesis of the disease, to be able to identify drug targets to eventually design 
effective therapies. Sporadic AD, which accounts for more than 90 % of AD cases, is 
believed primarily to be a disease of impaired clearance, where the BBB is one of the 
main portals of Ab clearance from the brain. Further, the BBB endothelium is believed to 
maintain the dynamic equilibrium of plasma and brain Ab levels, and also alter 
Ab42:Ab40 ratios in brain and plasma.  
We have demonstrated that Ab40 is internalized by clathrin-mediated endocytosis, 
whereas the endocytosis of Ab42 is via lipid rafts. These differential uptake and 
trafficking mechanisms could allow the BBB endothelium to independently modulate 
Ab42:Ab40 ratios in the brain and plasma. Further, we delved into the under-investigated 
area of BBB dysfunction in the perspective of vesicular transcytosis that may impair the 
ability of BBB to handle Ab	proteins, or for that matter the trafficking of several other 
proteins. We elucidated the manner in which Ab could impact these processes, and 
monitored the vesicular trafficking apparatus (involved with endocytosis, cellular transit 
and exocytosis) potentially harnessed by Ab isoforms, and likely by other biomolecules.  
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We have shown that Ab interferes with the SNARE exocytosis assembly, and may 
impact the trafficking of insulin and transferrin that use SNAREs for BBB transcytosis, if 
any of these steps in the vesicular transport machinery are dysfunctional. Moreover, it 
could also affect Ab clearance from the AD brain.  
The step-wise approach of the research strategy as well as the summary of results 
have been presented in Figure 6.1 
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Figure 6.1 Thesis project research strategy and conclusions.  
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6.2. Results summary 
This thesis work demonstrated an age dependent plasma PK of Ab40 and Ab42 in 
early (8-week), mild (24-week), and late stage (52-week) WT and APP,PS1 mice. The 
BBB permeability studies demonstrated a decrease in Ab40, and an increase in Ab42 
permeability, with age (Chapter 2). This suggested disproportionate luminal exposure of 
BBB endothelium to Ab40 and Ab42. Further dissecting the initial uptake kinetics by 
quantitative modeling of plasma pharmacokinetic and brain SPECT-CT imaging data 
predicted higher dissociation constant (Kd or k31/k13) for Aβ42 than Aβ40. Patlak and 
Logan plots predicted a higher input clearance into the brain for Aβ42 compared to Aβ40. 
(Chapter 3-4). 
We then conducted in-vitro trafficking studies using polarized hCMEC/D3 cell 
monolayers to elucidate BBB permeability at the cellular level. By evaluating stepwise 
endothelial Ab trafficking (endocytosis or uptake, transit, and exocytosis), we quantified 
the polarized uptake of Ab isoforms with differential kinetic profiles over time and 
concentration. Also, studies with small molecule inhibitors and genetic knockdowns of 
endocytotic processes showed distinct uptake mechanisms of Ab isoforms at the BBB 
endothelium. The uptake of Ab40 is via clathrin-mediated endocytosis, whereas the 
uptake of Ab42 is via lipid-raft mediated endocytosis. (Chapter 3-4). 
Moreover, we have shown that Ab utilizes vesicle-associated-membrane-protein 
(VAMP-2) to exocytose on the abluminal side of the endothelial cell. Fluorescent-
resonance-energy-transfer (FRET) fluorescent-lifetime-imaging microscopy (FLIM), 
revealed that Ab could inhibit the fusion of two sister SNAREs (VAMP-2 and SNAP-25) 
and impact endothelial exocytosis. By doing so, Ab may not only inhibit its own 
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exocytosis, but may affect the transcytosis of other biomolecules (insulin, transferrin) that 
use SNARE machinery for exocytosis. Therefore, Ab peptides could perturb brain 
homeostasis and neuronal synaptic transmission that rely upon SNARE exocytosis 
(Chapter 5). 
To our understanding, we are first to demonstrate that the transcytosis of Ab40 and 
Ab42 are handled differently by the BBB endothelium. This novel assertion provides a 
mechanistic vantage point to describe Aβ clearance, perturbed Aβ42:Aβ40 ratios, and 
dysregulated transport of endogenous proteins at the BBB observed in AD patients.  
We have also shown that Ab40 accumulates in the BBB endothelium more than 
Ab42. The longer stay in BBB endothelium implies that Ab40 will have more time to 
affect the vesicular transport machinery at the BBB endothelium. Further, this increased 
exposure of BBB endothelium to the toxic Ab proteins could profoundly contribute to 
BBB dysfunction that impair Ab clearance at the BBB endothelium. 
6.3.  Future directions 
Despite progress made in this thesis work in understanding cellular apparatus 
involved with Ab clearance at the BBB, there are still several unanswered questions that 
need to be further explored. Firstly, our studies demonstrated differential trafficking of 
Ab40 and Ab42 at the BBB endothelium, only in the luminal to abluminal (L-A) 
direction. It is equally important to explore how Ab proteins perturb VAMP-7 and 
VAMP-8, which mediate luminal exocytosis. Next, we specifically explored just the two 
extremes of transcytosis- endocytosis uptake and exocytosis. It would be interesting to 
see how the cellular transit apparatus (Rabs and microtubular cytoskeleton) involved in 
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this orchestrated event is affected by Ab peptides. Although our findings suggest that 
accumulation of toxic Ab would trigger BBB dysfunction, before making it leaky and 
dysfunction, a direct evidence substantiating this hypothesis would be helpful.  
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CHAPTER THREE 
 
 
 
 
Figure S-3.1. Representative blots characterizing oligomeric species of F-Aβ peptide 
solutions used in the experiments by SDS-PAGE. Silver stain (top panel) and western-
blot (bottom panel) analysis of freshly prepared F-Aβ peptide solutions used in 
experiments. Column L-R: protein ladder and corresponding molecular weight (in kDa), 
F-Aβ40 (in duplicate) and F-Aβ42 (in duplicate). IgG 4.1 primarily probes Aβ fibrils. 
Molecular weights of monomeric Aβ40 and Aβ42 are 4329.86 Da and 4514.05 Da, 
respectively.  
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CHAPTER FOUR 
Pharmacokinetic model and output from Phoenix WinNonlin® 6.4 
Aβ40: 
Model: 
Date: Jun 14, 2016 9:49:39 PM Local 
       /********************************* Begin Mappings **************************/ 
 Main : 3 Comp_edited.Data.Dat_plasma_brain_indi_5 min 
     Sort :  
          ID : Mouse_ID 
         A1 :  
          A1 Rate :  
         Time : Time 
         CObs : Cp 
         CObs_A3 : Cb 
         
           Dosing : (Internal) 
         
           Parameters : <None> 
        
           Parameters.Mapping : <None> 
        
           Random Effects : <None> 
        
           /********************************* End Mappings   ***************************/ 
 
           
           
           Phoenix Build 6.4.0.768 
        test(){ 
          deriv(A1 = - (A1 * Ke)- (A1 * K12- A2 * K21)- (A1 * K13- A3 * K31)) 
    urinecpt(A0 = (A1 * Ke)) 
        deriv(A2 = (A1 * K12- A2 * K21)) 
       deriv(A3 = (A1 * K13- A3 * K31)) 
       C = A1 / V 
         dosepoint(A1, idosevar = A1Dose, infdosevar = A1InfDose, infratevar = A1InfRate) 
   error(CEps = 0.1) 
         observe(CObs = C + CEps) 
        error(CEps_A3 = 0.001) 
        observe(CObs_A3 = A3 + CEps_A3) 
       stparm(V = tvV) 
         stparm(Ke = tvKe) 
         stparm(K12 = tvK12) 
        stparm(K21 = tvK21) 
        stparm(K13 = tvK13) 
        stparm(K31 = tvK31) 
        fixef(tvV = c(, 4.33, )) 
        fixef(tvKe = c(, 0.1, )) 
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fixef(tvK12 = c(, 0.54, )) 
        fixef(tvK21 = c(, 0.435, )) 
        fixef(tvK13 = c(, 0.011, )) 
        fixef(tvK31 = c(, 0.7, )) 
        } 
          ------------------------------------ 
        id("Mouse_ID") 
         time("Time") 
         obs(CObs<-"Cp") 
         obs(CObs_A3<-"Cb") 
         table(file="table01.csv",V,Ke,K12,K21,K13,K31,CMultStdev) 
     ------------------------------------ 
        id("Mouse_ID") 
         time("Time") 
         dose(A1<-"A1", "A1 Rate") 
        ------------------------------------ 
        Run Options 
         Method: Naive pooled 
        N Iter:1000 
         Input sorted by subject+time 
        Enabling automatic log transform (if applicable) 
      ODE solver method: matrix exponent 
       Method of computing standard errors: Central Diff 
      Sandwich standard errors 
        Confidence Level %95 
        Use FOCE Hessian 
         Simple run was performed 
        
           Table 01 
           
	
Mouse_ID time V Ke K12 K21 K13 K31 
1 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
2 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
3 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
4 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
5 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
6 0 4.76519 0.45655 0.914431 0.701386 0.000862 0.754815 
           
            
            
            
            
            
            
            
 
          Doses: 
Mouse_ID time dosepoint amt rate ss path strip 
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1 0.001 A1 100 0 0 1 
 2 0.001 A1 100 0 0 1 
 3 0.001 A1 100 0 0 1 
 4 0.001 A1 376.2 0 0 1 
 5 0.001 A1 324.5 0 0 1 
 6 0.001 A1 333.3 0 0 1 
 	
Initial estimates: 
	
Scenario parameter init low high 
 
tvV 4.33 
  
 
tvKe 0.1 
  
 
tvK12 0.54 
  
 
tvK21 0.435 
  
 
tvK13 0.011 
  
 
tvK31 0.7 
  	
Theta: 
	
Parameter Estimate Units Stderr CV% 2.5% CI 
97.5% 
CI 
tvV 4.76519 
 
0.643817 13.51083 3.481142 6.049238 347.3 
tvKe 0.45655 
 
0.058376 12.78641 0.340122 0.572978 13.654 
tvK12 0.914431 
 
0.461368 50.45406 -0.00573 1.834597 163.36 
tvK21 0.701386 
 
0.13315 18.98388 0.435827 0.966945 183.58 
tvK13 0.000862 
 
0.000176 20.44714 0.000511 0.001214 2.61E-05 
tvK31 0.754815 
 
0.109188 14.46552 0.537047 0.972583 24.311 
stdev0 0.696574 
 
0.232349 33.35595 0.23317 1.159978 
 stdev1 0.016264 
 
0.002463 15.14473 0.011351 0.021176 
 	
Overall:	
RetCode LogLik -2LL AIC BIC nParm nObs nSub EpsShrinkage Condition 
1 143 -285.92 
-
269.9 
-
251 8 78 6 0 24095.33 
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Plots: 
q-q IWRES: 
 
 
 
 
WRES vs Predicted 
 
 
 
 
 
 
 
DV versus Predicted 
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216	
	
Aβ42: 
Model: 
Date:	Jun	14,	2016	11:04:30	PM	Local	 	 	 	 	 	 	
/*********************************	Begin	Mappings	
*************************/	
Main	:	3	Comp_edited.Data.Dat_plasma_brain_indi		 	 	 	 	
Sort	:		 	 	 	 	 	 	 	 	 	
ID	:	Mouse_ID		 	 	 	 	 	 	 	
A1	:		 	 	 	 	 	 	 	 	 	
A1	Rate	:		 	 	 	 	 	 	 	 	
Time	:	Time	 	 	 	 	 	 	 	 	
CObs	:	Cp	 	 	 	 	 	 	 	 	
CObs_A3	:	Cb	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Dosing	:	(Internal)	 	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Parameters	:	<None>	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Parameters.Mapping	:	<None>	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	
Random	Effects	:	<None>	 	 	 	 	 	 	 	
/*********************************	End	Mappings			
******************************/	
	 	 	 	 	 	 	 	 	 	
Phoenix	Build	6.4.0.768	 	 	 	 	 	 	 	
test(){	 	 	 	 	 	 	 	 	 	
deriv(A1	=	-	(A1	*	Ke)-	(A1	*	K12-	A2	*	K21)-	(A1	*	K13-	A3	*	K31))	 	 	 	
urinecpt(A0	=	(A1	*	Ke))	 	 	 	 	 	 	 	
deriv(A2	=	(A1	*	K12-	A2	*	K21))	 	 	 	 	 	 	
deriv(A3	=	(A1	*	K13-	A3	*	K31))	 	 	 	 	 	 	
C	=	A1	/	V	 	 	 	 	 	 	 	 	
dosepoint(A1,	idosevar	=	A1Dose,	infdosevar	=	A1InfDose,	infratevar	=	A1InfRate)	
	 	
error(CEps	=	0.001)	 	 	 	 	 	 	 	
observe(CObs	=	C	+	CEps	*	sqrt(1	+	(C)^2	*	(CMultStdev1/sigma())^2))	 	 	
error(CEps_A3	=	0.1)	 	 	 	 	 	 	 	
observe(CObs_A3	=	A3	+	CEps_A3	)	 	 	 	 	 	 	
stparm(V	=	tvV)	 	 	 	 	 	 	 	 	
stparm(Ke	=	tvKe)	 	 	 	 	 	 	 	 	
stparm(K12	=	tvK12)	 	 	 	 	 	 	 	
stparm(K21	=	tvK21)	 	 	 	 	 	 	 	
stparm(K13	=	tvK13)	 	 	 	 	 	 	 	
stparm(K31	=	tvK31)	 	 	 	 	 	 	 	
stparm(CMultStdev1	=	tvCMultStdev1)	 	 	 	 	 	 	
217	
	
fixef(tvV	=	c(0,	5,	))	 	 	 	 	 	 	 	
fixef(tvKe	=	c(0,	0.2,	))		 	 	 	 	 	 	
fixef(tvK12	=	c(0,	1.2,	))	 	 	 	 	 	 	 	
fixef(tvK21	=	c(0,	1.2,	))	 	 	 	 	 	 	 	
fixef(tvK13	=	c(0,	0.03,	))	 	 	 	 	 	 	 	
fixef(tvK31	=	c(0,	3.5,))	 	 	 	 	 	 	 	
fixef(tvCMultStdev1	=	c(0,0.01,))	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
}	 	 	 	 	 	 	 	 	 	 	 	
	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
------------------------------------	 	 	 	 	 	 	 	
id("Mouse_ID")	 	 	 	 	 	 	 	 	
time("Time")	 	 	 	 	 	 	 	 	
obs(CObs<-"Cp")	 	 	 	 	 	 	 	 	
obs(CObs_A3<-"Cb")	 	 	 	 	 	 	 	 	
	 	 	 	 	
------------------------------------	 	 	 	 	 	 	 	
id("Mouse_ID")	 	 	 	 	 	 	 	 	
time("Time")	 	 	 	 	 	 	 	 	
dose(A1<-"A1",	"A1	Rate")	 	 	 	 	 	 	 	
------------------------------------	 	 	 	 	 	 	 	
Run	Options	 	 	 	 	 	 	 	 	
Method:	Naive	pooled	 	 	 	 	 	 	 	
N	Iter:1000	 	 	 	 	 	 	 	 	
Input	sorted	by	subject+time		 	 	 	 	 	 	
Enabling	automatic	log	transform	(if	applicable)	 	 	 	 	 	
ODE	solver	method:	matrix	exponent	 	 	 	 	 	 	
Method	of	computing	standard	errors:	Central	Diff	 	 	 	 	 	
Sandwich	standard	errors	 	 	 	 	 	 	 	
Confidence	Level	%95		 	 	 	 	 	 	
Use	FOCE	Hessian	 	 	 	 	 	 	 	 	
Simple	run	was	performed	 	 	 	 	 	 	 	
	 	 	 	 	 	 	 	 	 	
Table	01	
	
table(file="table01.csv",V,Ke,K12,K21,K13,K31,CMultStdev)	
	
Mouse_ID	 time	 V	 Ke	 K12	 K21	 K13	 K31	
1	 0	 16.0484	 0.201757	 1.32859	 1.26285	 0.001274
	 3.47595	
2	 0	 16.0484	 0.201757	 1.32859	 1.26285	 0.001274
	 3.47595	
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3	 0	 16.0484	 0.201757	 1.32859	 1.26285	 0.001274
	 3.47595	
4	 0	 16.0484	 0.201757	 1.32859	 1.26285	 0.001274
	 3.47595	
5	 0	 16.0484	 0.201757	 1.32859	 1.26285	 0.001274
	 3.47595	
	
Doses:	
	
Scenario Mouse_ID time dosepoint amt rate ss path strip 
 
1 0.001 A1 100 0 0 1 
 
 
2 0.001 A1 100 0 0 1 
 
 
3 0.001 A1 100 0 0 1 
 
 
4 0.001 A1 337.3 0 0 1 
 
 
5 0.001 A1 320.7 0 0 1 
 
         	
Initial estimates: 
	
Scenario parameter init low high 
 
tvV 5 0 
 
 
tvKe 0.2 0 
 
 
tvK12 1.2 0 
 
 
tvK21 1.2 0 
 
 
tvK13 0.03 0 
 
 
tvK31 3.5 0 
 
 
tvCMultStdev1 0.01 0 
 1. 	
Theta:	
Parameter Estimate Units Stderr CV% 2.5% CI 
97.5% 
CI 
Var. Inf. 
factor 
tvV 16.0484 
 
1.464582 9.12603 13.10522 18.99158 1169700 
 tvKe 0.201757 
 
0.018123 8.982408 0.165338 0.238176 193.98 
 
tvK12 1.32859 
 
0.388652 29.25293 0.547567 2.109613 40021 
 tvK21 1.26285 
 
0.12131 9.606012 1.01907 1.50663 2874.5 
 tvK13 0.001274 
 
0.000105 8.281049 0.001062 0.001486 0.000718 
 tvK31 3.47595 
 
0.4968 14.29249 2.477596 4.474304 68222 
 tvCMultStdev1 0.209586 
 
0.042548 20.30079 0.124084 0.295088 0 
 stdev0 0.001001 
 
0.000605 60.4498 -0.00022 0.002217 
  stdev1 0.004395 
 
0.00037 8.408294 0.003652 0.005138 
  	
 
Overall:	
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LogLik -2LL AIC BIC nParm nObs nSub EpsShrinkage Condition 
152.3629 -304.726 
-
286.726 
-
268.182 9 58 5 0 7.05E+09 
	
 
Plots: 
 
q-q IWRES: 
 
WRES vs Predicted	
 
 
DV versus Predicted 
220	
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CH APTER 5 
Intensity images  
 
Figure S-5.1. Representative intensity images in cerulean and FRET channel in 
transfected N2A cells. Images are obtained by exciting cerulean (donor) and capturing 
cerulean (top panel) and citrine or FRET (bottom panel) that gets excited due to FRET. 
The FRET channel is a combination of FRET and bleed over from cerulean channel. 
Cells are either transfected by (a-b) donor Cer-VAMP2 only (negative control); or (c-j) 
both- donor Cer-VAMP2 and acceptor Cit-SNAP25; and are subsequently pretreated with 
(e-f) Aβ40; (g-h) Aβ42 or (i-j) TeNT. (c-d) FRET only system serves as the positive 
control. FRET intensities (bottom panel) are subsequently corrected for cerulean channel 
bleed over (using negative control intensities) and normalized to donor intensities to 
obtain effective FRET transfer ratios.  
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Figure S-5.2. Representative intensity images in FM-464, cerulean and citrine 
channel in transfected N2A cells. Images are obtained by exciting and capturing FM-
464 dye (top panel), cerulean (middle panel) and  and citrine (bottom panel). Individual 
excitation and capture of donor (cerulean) and acceptor (citrine) demonstrates efficient 
mono or dual transfection. Red punctan of FM 4-64 demonstrate active exocytosis at 
membrane and enables specific vesicle fusion process analysis. Cells are either 
transfected by (a-c) donor Cer-VAMP2 only (negative control); or (d-o) both- donor Cer-
VAMP2 and acceptor Cit-SNAP25; and are subsequently pretreated with (g-i) Aβ40; (j-l) 
Aβ42 or (m-o) TeNT. (d-f) FRET only system serves as the positive control.  
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Figure S-5.3.1. Representative intensity images of N2A transfected with cerulean-
VAMP2 only (donor control). Images are taken in five channels split into three phases: 
Phase 1(a) excite and capture cerulean; (b) excite cerulean and capture citrine (FRET); 
Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and capture cerulean; (e) 
excite and capture citrine; (f) Software constructed FRET image after bleed over 
correction from (b); (g) Software constructed effective transfer ratio (ETR) image after 
bleed over and donor intensity correction. 
 
 
 
 
 
 
 
 
224	
	
 
 
 
Figure S-5.3.2. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 (FRET control). Images are taken in five channels split 
into three phases: Phase 1(a) excite and capture cerulean; (b) excite cerulean and capture 
citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and capture 
cerulean; (e) excite and capture citrine; (f) Software constructed FRET image after bleed 
over correction from (b); (g) Software constructed effective transfer ratio (ETR) image 
after bleed over and donor intensity correction. 
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Figure S-5.3.3. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with Aβ40. Images are taken in five channels 
split into three phases: Phase 1(a) excite and capture cerulean; (b) excite cerulean and 
capture citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and 
capture cerulean; (e) excite and capture citrine; (f) Software constructed FRET image 
after bleed over correction from (b); (g) Software constructed effective transfer ratio 
(ETR) image after bleed over and donor intensity correction. 
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Figure S-5.3.4. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with Aβ42. Images are taken in five channels 
split into three phases: Phase 1(a) excite and capture cerulean; (b) excite cerulean and 
capture citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and 
capture cerulean; (e) excite and capture citrine; (f) Software constructed FRET image 
after bleed over correction from (b); (g) Software constructed effective transfer ratio 
(ETR) image after bleed over and donor intensity correction. 
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Figure S-5.3.5. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with TeNT. Images are taken in five channels 
split into three phases: Phase 1(a) excite and capture cerulean; (b) excite cerulean and 
capture citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and 
capture cerulean; (e) excite and capture citrine; (f) Software constructed FRET image 
after bleed over correction from (b); (g) Software constructed effective transfer ratio 
(ETR) image after bleed over and donor intensity correction. 
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Figure S-5.4.6. Lifetime measurements and corresponding FRET efficiency of 
functional vesicular fusion processes in transfected N2A cells. A-B Changes in (A) 𝜏`PC¥	or mean lifetime of donor (cerulean) and (B) FRET efficiency in cells transfected 
with cer-VAMP2 only (Cer-VAMP2 control) or both cer-VAMP2 and Cit-SNAP25 
(FRET) that are pretreated with Aβ40, Aβ42 or TeNT.  30-40 functional vesicular fusion 
processes at membrane are estimated using FM dye channel image. Data represented as 
scatter dot plot of individual lifetime measurement from bi-exponential decay plot and 
corresponding median. Significance determined using one-way ANOVA  test. (*** 
p<0.001) 
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Figure S-5.5.1. Representative intensity images of N2A transfected with cerulean-
VAMP2 only (donor control) at high potassium. Images are taken in five channels split 
into three phases: Phase 1(a) excite and capture cerulean; (b) excite cerulean and capture 
citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: (d) excite and capture 
cerulean; (e) excite and capture citrine; (f) Software constructed FRET image after bleed 
over correction from (b); (g) Software constructed effective transfer ratio (ETR) image 
after bleed over and donor intensity correction. 
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Figure S-5.5.2. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 (FRET control) at high potassium. Images are taken in 
five channels split into three phases: Phase 1(a) excite and capture cerulean; (b) excite 
cerulean and capture citrine (FRET); Phase 2: (c) excite and capture FM-464; Phase 3: 
(d) excite and capture cerulean; (e) excite and capture citrine; (f) Software constructed 
FRET image after bleed over correction from (b); (g) Software constructed effective 
transfer ratio (ETR) image after bleed over and donor intensity correction. 
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Figure S-5.5.3. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with Aβ40 at high potassium. Images are 
taken in five channels split into three phases: Phase 1(a) excite and capture cerulean; (b) 
excite cerulean and capture citrine (FRET); Phase 2: (c) excite and capture FM-464; 
Phase 3: (d) excite and capture cerulean; (e) excite and capture citrine; (f) Software 
constructed FRET image after bleed over correction from (b); (g) Software constructed 
effective transfer ratio (ETR) image after bleed over and donor intensity correction. 
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Figure S-5.5.4. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with Aβ42 at high potassium. Images are 
taken in five channels split into three phases: Phase 1(a) excite and capture cerulean; (b) 
excite cerulean and capture citrine (FRET); Phase 2: (c) excite and capture FM-464; 
Phase 3: (d) excite and capture cerulean; (e) excite and capture citrine; (f) Software 
constructed FRET image after bleed over correction from (b); (g) Software constructed 
effective transfer ratio (ETR) image after bleed over and donor intensity correction. 
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Figure S-5.5.5. Representative intensity images of N2A transfected with cerulean-
VAMP2 and citrine-SNAP25 pretreated with TeNT at high potassium. Images are 
taken in five channels split into three phases: Phase 1(a) excite and capture cerulean; (b) 
excite cerulean and capture citrine (FRET); Phase 2: (c) excite and capture FM-464; 
Phase 3: (d) excite and capture cerulean; (e) excite and capture citrine; (f) Software 
constructed FRET image after bleed over correction from (b); (g) Software constructed 
effective transfer ratio (ETR) image after bleed over and donor intensity correction. 
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Figure S-5.5.6.  Semi quantitative plot of effective FRET transfer ratios of 
membrane intensities represented in Figures S-5.5.  Data demonstrates effective FRET 
transfer ratio or corrected FRET normalized to the donor (cerulean channel) intensity 
measured only at membrane using mask tool in Fiji software.  Bars represent mean ETR 
intensity at the membrane.  
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Figure S-5.6.6.  Spatial lifetime images of donor (cerulean) lifetime and 
corresponding frequency histograms in  transfected N2A cells at high potassium. A-
E Spatial lifetime images and frequency histograms obtained by measuring lifetime of 
cerulean (donor) by TCSPC in cells transfected with either (A) cer-VAMP2 only or (B-E) 
cerulean-VAMP2 and cit-SNAP25. Histogram represents lifetime frequency at the 
membrane. A-B Lifetime decreases from the blue range in (A) negative control cerulean-
only transfected cell to yellow range in (B) dual transfected cells or FRET (positive 
control).C-E In the presence of (C) Aβ40; (D) Aβ42; and (E) TeNT; donor lifetime 
increases back from yellow to blue range . Color code represents lifetime from 2000 (red) 
to 2700 (blue) picoseconds. Table S-5-1 shows changes in donor (cerulean) lifetime as 
estimated by B&H software for the membrane ROI in value (range) 
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Figure S-5.6.7. Lifetime measurements and corresponding FRET efficiency of 
functional vesicular fusion processes in transfected N2A cells at high potassium by 
monoexponential decay model. A-B Changes in (A) 𝜏`PC¥	or mean lifetime of donor 
(cerulean) and (B) FRET efficiency in cells transfected with cer-VAMP2 only (Cer-
VAMP2 control) or both cer-VAMP2 and Cit-SNAP25 (FRET) that are pretreated with 
Aβ40, Aβ42 or TeNT.  30-40 functional vesicular fusion processes at membrane are 
estimated using FM dye channel image. Data represented as scatter dot plot of individual 
measurement at mono-exponent decay plot and median. Significance determined using 
one-way ANOVA  test. (*** p<0.001) 
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Figure S-5.7.6  Spatial lifetime images of donor (cerulean) lifetime and 
corresponding frequency histograms in  transfected D3 Cells. A-E Spatial lifetime 
images and frequency histograms obtained by measuring lifetime of cerulean (donor) by 
TCSPC in cells transfected with either (A) cer-VAMP2 only or (B-E) cerulean-VAMP2 
and cit-SNAP25. Histogram represents lifetime frequency at the membrane. A-B 
Lifetime decreases from the blue range in (A) negative control cerulean-only transfected 
cell to yellow range in (B) dual transfected cells or FRET (positive control).C-E In the 
presence of (C) Aβ40; (D) Aβ42; and (E) TeNT; donor lifetime increases back from 
yellow to blue range . Color code represents lifetime from 2000 (red) to 2700 (blue) 
picoseconds. Table S-5-2 shows changes in donor (cerulean) lifetime as estimated by 
B&H software for the membrane ROI in value (range) 
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Figure S-5.8 KEGG Graph of synaptic vesiclular gene expression analysis in brains 
of AD patients compared to age matched normal individuals. Plot represents  
downregulation (green) of (A) SNARE assembly, in particular (B) VAMP2  SNARE 
protein.  
 
 
